AU5367496A - Reversible protease inhibitors - Google Patents
Reversible protease inhibitorsInfo
- Publication number
- AU5367496A AU5367496A AU53674/96A AU5367496A AU5367496A AU 5367496 A AU5367496 A AU 5367496A AU 53674/96 A AU53674/96 A AU 53674/96A AU 5367496 A AU5367496 A AU 5367496A AU 5367496 A AU5367496 A AU 5367496A
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- alkyl
- hydroxy
- hydrogen
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title claims description 12
- 230000002441 reversible effect Effects 0.000 title description 11
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 title description 4
- -1 dialkylammosulfonyl Chemical group 0.000 claims description 367
- 150000001875 compounds Chemical class 0.000 claims description 194
- 229910052739 hydrogen Inorganic materials 0.000 claims description 144
- 239000001257 hydrogen Substances 0.000 claims description 143
- 125000000217 alkyl group Chemical group 0.000 claims description 128
- 125000003118 aryl group Chemical group 0.000 claims description 125
- 239000000203 mixture Substances 0.000 claims description 115
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 84
- 108010005843 Cysteine Proteases Proteins 0.000 claims description 79
- 102000005927 Cysteine Proteases Human genes 0.000 claims description 78
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 76
- 150000002431 hydrogen Chemical group 0.000 claims description 70
- 150000003839 salts Chemical class 0.000 claims description 66
- 101000749287 Clitocybe nebularis Clitocypin Proteins 0.000 claims description 65
- 101000767029 Clitocybe nebularis Clitocypin-1 Proteins 0.000 claims description 65
- 229940094664 Cysteine protease inhibitor Drugs 0.000 claims description 65
- 239000003112 inhibitor Substances 0.000 claims description 65
- 238000000034 method Methods 0.000 claims description 65
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 64
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 63
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 61
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 55
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 55
- 125000005843 halogen group Chemical group 0.000 claims description 49
- 125000003545 alkoxy group Chemical group 0.000 claims description 47
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 46
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims description 46
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 44
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 41
- 125000006575 electron-withdrawing group Chemical group 0.000 claims description 40
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 39
- 239000004365 Protease Substances 0.000 claims description 34
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 33
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 32
- 125000001188 haloalkyl group Chemical group 0.000 claims description 32
- 125000001153 fluoro group Chemical group F* 0.000 claims description 30
- 102000035195 Peptidases Human genes 0.000 claims description 29
- 108091005804 Peptidases Proteins 0.000 claims description 29
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 28
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 27
- 125000001246 bromo group Chemical group Br* 0.000 claims description 26
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 25
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims description 24
- 125000005842 heteroatom Chemical group 0.000 claims description 23
- 230000005764 inhibitory process Effects 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 22
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 21
- 125000005098 aryl alkoxy carbonyl group Chemical group 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 19
- 230000027455 binding Effects 0.000 claims description 18
- 238000010494 dissociation reaction Methods 0.000 claims description 18
- 230000005593 dissociations Effects 0.000 claims description 18
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 18
- 125000003435 aroyl group Chemical group 0.000 claims description 17
- 229910052799 carbon Inorganic materials 0.000 claims description 17
- 125000001624 naphthyl group Chemical group 0.000 claims description 17
- 230000008685 targeting Effects 0.000 claims description 16
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 15
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 14
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 13
- 125000004414 alkyl thio group Chemical group 0.000 claims description 13
- 238000002360 preparation method Methods 0.000 claims description 13
- 125000003396 thiol group Chemical class [H]S* 0.000 claims description 13
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 12
- 125000001544 thienyl group Chemical group 0.000 claims description 12
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000011734 sodium Substances 0.000 claims description 11
- 229910052708 sodium Inorganic materials 0.000 claims description 11
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 10
- 125000002541 furyl group Chemical group 0.000 claims description 10
- 125000005143 heteroarylsulfonyl group Chemical group 0.000 claims description 10
- 125000002883 imidazolyl group Chemical group 0.000 claims description 10
- 125000001041 indolyl group Chemical group 0.000 claims description 10
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 125000004076 pyridyl group Chemical group 0.000 claims description 10
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 9
- 125000004981 cycloalkylmethyl group Chemical group 0.000 claims description 9
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 9
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 9
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 8
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims description 8
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 7
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 125000004472 dialkylaminosulfonyl group Chemical group 0.000 claims description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 5
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 5
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 4
- 125000005010 perfluoroalkyl group Chemical group 0.000 claims description 4
- DOUHZFSGSXMPIE-UHFFFAOYSA-N hydroxidooxidosulfur(.) Chemical compound [O]SO DOUHZFSGSXMPIE-UHFFFAOYSA-N 0.000 claims description 3
- 230000001590 oxidative effect Effects 0.000 claims description 3
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 claims description 2
- OBSIQMZKFXFYLV-QMMMGPOBSA-N L-phenylalanine amide Chemical compound NC(=O)[C@@H](N)CC1=CC=CC=C1 OBSIQMZKFXFYLV-QMMMGPOBSA-N 0.000 claims description 2
- 125000004423 acyloxy group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000005116 aryl carbamoyl group Chemical group 0.000 claims description 2
- 125000005647 linker group Chemical group 0.000 claims description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 2
- 125000000538 pentafluorophenyl group Chemical group FC1=C(F)C(F)=C(*)C(F)=C1F 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 84
- 125000001589 carboacyl group Chemical group 0.000 claims 31
- 125000006263 dimethyl aminosulfonyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])S(*)(=O)=O 0.000 claims 6
- 125000005236 alkanoylamino group Chemical group 0.000 claims 3
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 claims 2
- 125000004471 alkyl aminosulfonyl group Chemical group 0.000 claims 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 119
- 239000000243 solution Substances 0.000 description 97
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 96
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 76
- 230000015572 biosynthetic process Effects 0.000 description 71
- 238000003786 synthesis reaction Methods 0.000 description 69
- 239000002253 acid Substances 0.000 description 60
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 54
- 150000003254 radicals Chemical class 0.000 description 54
- 230000002829 reductive effect Effects 0.000 description 47
- 239000002852 cysteine proteinase inhibitor Substances 0.000 description 42
- 235000019439 ethyl acetate Nutrition 0.000 description 40
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 35
- 239000002904 solvent Substances 0.000 description 34
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 31
- 125000001424 substituent group Chemical group 0.000 description 31
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 229920006395 saturated elastomer Polymers 0.000 description 30
- 102000004190 Enzymes Human genes 0.000 description 29
- 108090000790 Enzymes Proteins 0.000 description 29
- 229940088598 enzyme Drugs 0.000 description 29
- 150000001299 aldehydes Chemical class 0.000 description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 28
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 26
- 239000000047 product Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 25
- 230000000875 corresponding effect Effects 0.000 description 25
- 239000000463 material Substances 0.000 description 25
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 21
- 201000010099 disease Diseases 0.000 description 21
- 238000004809 thin layer chromatography Methods 0.000 description 21
- 239000000758 substrate Substances 0.000 description 19
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 18
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 18
- 235000019419 proteases Nutrition 0.000 description 17
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 16
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- 239000012267 brine Substances 0.000 description 14
- 239000000816 peptidomimetic Substances 0.000 description 14
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 125000002252 acyl group Chemical group 0.000 description 13
- 235000017557 sodium bicarbonate Nutrition 0.000 description 13
- 229910000104 sodium hydride Inorganic materials 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- 229960005190 phenylalanine Drugs 0.000 description 12
- 150000003457 sulfones Chemical class 0.000 description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- 125000004429 atom Chemical group 0.000 description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 229910002092 carbon dioxide Inorganic materials 0.000 description 9
- 239000002480 mineral oil Substances 0.000 description 9
- 235000010446 mineral oil Nutrition 0.000 description 9
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 9
- 206010003246 arthritis Diseases 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 8
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 150000001450 anions Chemical class 0.000 description 7
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 7
- 208000035475 disorder Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 150000002148 esters Chemical class 0.000 description 7
- 238000005984 hydrogenation reaction Methods 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 125000004043 oxo group Chemical group O=* 0.000 description 7
- 229910052763 palladium Inorganic materials 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 241000894007 species Species 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 229910052717 sulfur Inorganic materials 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 108090000426 Caspase-1 Proteins 0.000 description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 6
- JTTHKOPSMAVJFE-VIFPVBQESA-N L-homophenylalanine Chemical compound OC(=O)[C@@H](N)CCC1=CC=CC=C1 JTTHKOPSMAVJFE-VIFPVBQESA-N 0.000 description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 6
- 150000001721 carbon Chemical group 0.000 description 6
- 239000003054 catalyst Substances 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 6
- 238000010992 reflux Methods 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 102100035904 Caspase-1 Human genes 0.000 description 5
- 102000005593 Endopeptidases Human genes 0.000 description 5
- 108010059378 Endopeptidases Proteins 0.000 description 5
- UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 229940024606 amino acid Drugs 0.000 description 5
- LGTLXDJOAJDFLR-UHFFFAOYSA-N diethyl chlorophosphate Chemical compound CCOP(Cl)(=O)OCC LGTLXDJOAJDFLR-UHFFFAOYSA-N 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 125000000524 functional group Chemical group 0.000 description 5
- 150000002576 ketones Chemical class 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 235000019198 oils Nutrition 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical class CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 4
- 102000003902 Cathepsin C Human genes 0.000 description 4
- 108090000267 Cathepsin C Proteins 0.000 description 4
- 108090000624 Cathepsin L Proteins 0.000 description 4
- 102000004172 Cathepsin L Human genes 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical group C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 4
- 241000282326 Felis catus Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- AMIMRNSIRUDHCM-UHFFFAOYSA-N Isopropylaldehyde Chemical compound CC(C)C=O AMIMRNSIRUDHCM-UHFFFAOYSA-N 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 108090000526 Papain Proteins 0.000 description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 4
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 206010064390 Tumour invasion Diseases 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 4
- JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 4
- 230000009400 cancer invasion Effects 0.000 description 4
- SKOLWUPSYHWYAM-UHFFFAOYSA-N carbonodithioic O,S-acid Chemical class SC(S)=O SKOLWUPSYHWYAM-UHFFFAOYSA-N 0.000 description 4
- 239000003610 charcoal Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000010511 deprotection reaction Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 239000012467 final product Substances 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 201000004792 malaria Diseases 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000017854 proteolysis Effects 0.000 description 4
- 125000001174 sulfone group Chemical group 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 108090000712 Cathepsin B Proteins 0.000 description 3
- 102000004225 Cathepsin B Human genes 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 239000005977 Ethylene Substances 0.000 description 3
- 206010018364 Glomerulonephritis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 3
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 3
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 3
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000007239 Wittig reaction Methods 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000013477 citrulline Nutrition 0.000 description 3
- 229960002173 citrulline Drugs 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 108090000711 cruzipain Proteins 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- MWUDRLNNAVIZGR-UHFFFAOYSA-N diethylphosphoryl methanesulfonate Chemical class CCP(=O)(CC)OS(C)(=O)=O MWUDRLNNAVIZGR-UHFFFAOYSA-N 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 239000002532 enzyme inhibitor Substances 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- 229960000310 isoleucine Drugs 0.000 description 3
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 239000012280 lithium aluminium hydride Substances 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 3
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 3
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 238000007127 saponification reaction Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- CHLCPTJLUJHDBO-UHFFFAOYSA-M sodium;benzenesulfinate Chemical compound [Na+].[O-]S(=O)C1=CC=CC=C1 CHLCPTJLUJHDBO-UHFFFAOYSA-M 0.000 description 3
- BUUPQKDIAURBJP-UHFFFAOYSA-N sulfinic acid Chemical compound OS=O BUUPQKDIAURBJP-UHFFFAOYSA-N 0.000 description 3
- 229940124530 sulfonamide Drugs 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- 150000003871 sulfonates Chemical class 0.000 description 3
- 150000003462 sulfoxides Chemical class 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 3
- MVIBYMLTZDCCAM-RSAXXLAASA-N (2s)-1-(benzenesulfonyl)-4-phenylbutan-2-amine;hydrochloride Chemical compound Cl.C([C@H](N)CS(=O)(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 MVIBYMLTZDCCAM-RSAXXLAASA-N 0.000 description 2
- MCODLPJUFHPVQP-LBPRGKRZSA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CCC1=CC=CC=C1 MCODLPJUFHPVQP-LBPRGKRZSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 2
- XCXJLWLQQPJVDR-UHFFFAOYSA-N 3-(azepan-2-yl)quinoline Chemical compound C1CCCCNC1C1=CN=C(C=CC=C2)C2=C1 XCXJLWLQQPJVDR-UHFFFAOYSA-N 0.000 description 2
- YGCZTXZTJXYWCO-UHFFFAOYSA-N 3-phenylpropanal Chemical compound O=CCCC1=CC=CC=C1 YGCZTXZTJXYWCO-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- WSNMPAVSZJSIMT-UHFFFAOYSA-N COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 Chemical compound COc1c(C)c2COC(=O)c2c(O)c1CC(O)C1(C)CCC(=O)O1 WSNMPAVSZJSIMT-UHFFFAOYSA-N 0.000 description 2
- 108010032088 Calpain Proteins 0.000 description 2
- 102000007590 Calpain Human genes 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108090000613 Cathepsin S Proteins 0.000 description 2
- 102100035654 Cathepsin S Human genes 0.000 description 2
- YASYEJJMZJALEJ-UHFFFAOYSA-N Citric acid monohydrate Chemical compound O.OC(=O)CC(O)(C(O)=O)CC(O)=O YASYEJJMZJALEJ-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical class CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000991587 Enterovirus C Species 0.000 description 2
- 101710097670 Extracellular cysteine protease Proteins 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 101001115830 Homo sapiens Prostate-associated microseminoprotein Proteins 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 208000004554 Leishmaniasis Diseases 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- GQPLMRYTRLFLPF-UHFFFAOYSA-N Nitrous Oxide Chemical compound [O-][N+]#N GQPLMRYTRLFLPF-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- KFSLWBXXFJQRDL-UHFFFAOYSA-N Peracetic acid Chemical compound CC(=O)OO KFSLWBXXFJQRDL-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100025013 Prostate-associated microseminoprotein Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 101710097834 Thiol protease Proteins 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 229910052785 arsenic Inorganic materials 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 229940077388 benzenesulfonate Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- PUJDIJCNWFYVJX-UHFFFAOYSA-N benzyl carbamate Chemical compound NC(=O)OCC1=CC=CC=C1 PUJDIJCNWFYVJX-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 150000007942 carboxylates Chemical class 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960002303 citric acid monohydrate Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 239000007859 condensation product Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940066758 endopeptidases Drugs 0.000 description 2
- 229940125532 enzyme inhibitor Drugs 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 208000007565 gingivitis Diseases 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 201000006938 muscular dystrophy Diseases 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N n-hexanoic acid Natural products CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 125000006574 non-aromatic ring group Chemical group 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 150000004965 peroxy acids Chemical class 0.000 description 2
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 125000004193 piperazinyl group Chemical group 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000006965 reversible inhibition Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 125000001010 sulfinic acid amide group Chemical group 0.000 description 2
- 125000005555 sulfoximide group Chemical group 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical class ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- JMHGMBRMIWBUPG-ZDUSSCGKSA-N tert-butyl n-[(2s)-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound CC(C)(C)OC(=O)N[C@H](C=O)CCC1=CC=CC=C1 JMHGMBRMIWBUPG-ZDUSSCGKSA-N 0.000 description 2
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- KLHLGTPNBQXSJT-QRPNPIFTSA-N (2s)-2-amino-3-phenylpropanamide;hydrochloride Chemical compound Cl.NC(=O)[C@@H](N)CC1=CC=CC=C1 KLHLGTPNBQXSJT-QRPNPIFTSA-N 0.000 description 1
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- WCUYJWSOOARVMQ-NKAFYOCUSA-N (E,2S,7S)-2,7-diamino-7-diethoxyphosphoryl-1-[4-(morpholine-4-carbonyl)phenyl]-4-(2-phenylethyl)hept-5-en-3-one Chemical compound N1(CCOCC1)C(=O)C1=CC=C(C[C@H](N)C(=O)C(/C=C/[C@H](P(OCC)(=O)OCC)N)CCC2=CC=CC=C2)C=C1 WCUYJWSOOARVMQ-NKAFYOCUSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 1
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 1
- VUDQSRFCCHQIIU-UHFFFAOYSA-N 1-(3,5-dichloro-2,6-dihydroxy-4-methoxyphenyl)hexan-1-one Chemical compound CCCCCC(=O)C1=C(O)C(Cl)=C(OC)C(Cl)=C1O VUDQSRFCCHQIIU-UHFFFAOYSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
- DFCKGLGTOXDULU-UHFFFAOYSA-N 1-[ethoxy(methylsulfonylmethyl)phosphoryl]oxyethane Chemical compound CCOP(=O)(CS(C)(=O)=O)OCC DFCKGLGTOXDULU-UHFFFAOYSA-N 0.000 description 1
- 125000004973 1-butenyl group Chemical group C(=CCC)* 0.000 description 1
- WPWHSFAFEBZWBB-UHFFFAOYSA-N 1-butyl radical Chemical compound [CH2]CCC WPWHSFAFEBZWBB-UHFFFAOYSA-N 0.000 description 1
- 125000004066 1-hydroxyethyl group Chemical group [H]OC([H])([*])C([H])([H])[H] 0.000 description 1
- 125000006017 1-propenyl group Chemical group 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- RORNWUHWEYNMLS-UHFFFAOYSA-N 2-(2-aminoethylsulfonyl)ethanamine Chemical class NCCS(=O)(=O)CCN RORNWUHWEYNMLS-UHFFFAOYSA-N 0.000 description 1
- BZCNJTRQFZCIKE-UHFFFAOYSA-N 2-(chloromethylsulfanyl)naphthalene Chemical compound C1=CC=CC2=CC(SCCl)=CC=C21 BZCNJTRQFZCIKE-UHFFFAOYSA-N 0.000 description 1
- BZXSKIOPWCSCHC-UHFFFAOYSA-N 2-(diethoxyphosphorylmethylsulfonyl)naphthalene Chemical compound C1=CC=CC2=CC(S(=O)(=O)CP(=O)(OCC)OCC)=CC=C21 BZXSKIOPWCSCHC-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- UPHOPMSGKZNELG-UHFFFAOYSA-N 2-hydroxynaphthalene-1-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=C(O)C=CC2=C1 UPHOPMSGKZNELG-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- BCOLNMGFOWHFNI-UHFFFAOYSA-N 2-trimethylsilylethanethiol Chemical compound C[Si](C)(C)CCS BCOLNMGFOWHFNI-UHFFFAOYSA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- ZYJSTSMEUKNCEV-UHFFFAOYSA-N 3-diazo-1-diazonioprop-1-en-2-olate Chemical class [N-]=[N+]=CC(=O)C=[N+]=[N-] ZYJSTSMEUKNCEV-UHFFFAOYSA-N 0.000 description 1
- QDSFNOHWQKVVEB-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)morpholine Chemical compound CCOP(=O)(OCC)CN1CCOCC1 QDSFNOHWQKVVEB-UHFFFAOYSA-N 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- STABAPSYCQFWOK-UHFFFAOYSA-N 4-chlorobenzenecarboperoxoic acid Chemical compound OOC(=O)C1=CC=C(Cl)C=C1 STABAPSYCQFWOK-UHFFFAOYSA-N 0.000 description 1
- RJWBTWIBUIGANW-UHFFFAOYSA-N 4-chlorobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=C(Cl)C=C1 RJWBTWIBUIGANW-UHFFFAOYSA-N 0.000 description 1
- AWQSAIIDOMEEOD-UHFFFAOYSA-N 5,5-Dimethyl-4-(3-oxobutyl)dihydro-2(3H)-furanone Chemical compound CC(=O)CCC1CC(=O)OC1(C)C AWQSAIIDOMEEOD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 108090000066 Adenain Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000710189 Aphthovirus Species 0.000 description 1
- 206010053555 Arthritis bacterial Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- WOEFZTDQCQCQID-FIIODCPWSA-N CCOP(=O)(OCC)C\C=C\[C@@H](NC(=O)OC(C)(C)C)CCC1=CC=CC=C1 Chemical compound CCOP(=O)(OCC)C\C=C\[C@@H](NC(=O)OC(C)(C)C)CCC1=CC=CC=C1 WOEFZTDQCQCQID-FIIODCPWSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 241000710190 Cardiovirus Species 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- PCDWYFVSDHAAMR-QKPPBESVSA-N Cl.CCOP(=O)(OCC)C\C=C\[C@@H](N)CCC1=CC=CC=C1 Chemical compound Cl.CCOP(=O)(OCC)C\C=C\[C@@H](N)CCC1=CC=CC=C1 PCDWYFVSDHAAMR-QKPPBESVSA-N 0.000 description 1
- JOLYZWHEYROVJE-UHFFFAOYSA-N ClS(=O)P(Cl)(Cl)=O Chemical compound ClS(=O)P(Cl)(Cl)=O JOLYZWHEYROVJE-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000723607 Comovirus Species 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 241000221756 Cryphonectria parasitica Species 0.000 description 1
- 102000003950 Cysteine Endopeptidases Human genes 0.000 description 1
- 108090000395 Cysteine Endopeptidases Proteins 0.000 description 1
- 101710129179 Cysteine protease inhibitor 10 Proteins 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 238000009007 Diagnostic Kit Methods 0.000 description 1
- 241000224495 Dictyostelium Species 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 241000224431 Entamoeba Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 241000710198 Foot-and-mouth disease virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 241000243976 Haemonchus Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000029523 Interstitial Lung disease Diseases 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- UEQUQVLFIPOEMF-UHFFFAOYSA-N Mianserin Chemical compound C1C2=CC=CC=C2N2CCN(C)CC2C2=CC=CC=C21 UEQUQVLFIPOEMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000907681 Morpho Species 0.000 description 1
- TXXHDPDFNKHHGW-CCAGOZQPSA-N Muconic acid Natural products OC(=O)\C=C/C=C\C(O)=O TXXHDPDFNKHHGW-CCAGOZQPSA-N 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 208000009525 Myocarditis Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- PVUDEYOZNFYDTQ-IZLXSDGUSA-N N1(CCOCC1)C(=O)C1=CC=C(C[C@H](N)C(=O)N[C@H](CCCP(OCC)(=O)OCC)CCC2=CC=CC=C2)C=C1 Chemical compound N1(CCOCC1)C(=O)C1=CC=C(C[C@H](N)C(=O)N[C@H](CCCP(OCC)(=O)OCC)CCC2=CC=CC=C2)C=C1 PVUDEYOZNFYDTQ-IZLXSDGUSA-N 0.000 description 1
- CHFSYDLLXUPPPE-UHFFFAOYSA-N NS(=O)#P=O Chemical compound NS(=O)#P=O CHFSYDLLXUPPPE-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000000474 Poliomyelitis Diseases 0.000 description 1
- 241000710078 Potyvirus Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 241000269435 Rana <genus> Species 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 201000009594 Systemic Scleroderma Diseases 0.000 description 1
- 206010042953 Systemic sclerosis Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000282485 Vulpes vulpes Species 0.000 description 1
- DLELKZFCVLJXKZ-GOTSBHOMSA-N Z-Arg-Arg-NHMec Chemical compound N([C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC1=CC=2OC(=O)C=C(C=2C=C1)C)C(=O)OCC1=CC=CC=C1 DLELKZFCVLJXKZ-GOTSBHOMSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- RTOKKBWQWUKGEF-SFHVURJKSA-N [(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutyl] benzenesulfonate Chemical compound C([C@H](NC(=O)OC(C)(C)C)COS(=O)(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 RTOKKBWQWUKGEF-SFHVURJKSA-N 0.000 description 1
- CMISSMQEZRRSAQ-AWEZNQCLSA-N [(2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-phenylbutyl] methanesulfonate Chemical compound CC(C)(C)OC(=O)N[C@H](COS(C)(=O)=O)CCC1=CC=CC=C1 CMISSMQEZRRSAQ-AWEZNQCLSA-N 0.000 description 1
- RFXLYJKRZZWPLJ-GNLXOOPCSA-N [(e,4s)-4-amino-6-phenylhex-2-enyl]phosphonic acid;hydrochloride Chemical compound Cl.OP(=O)(O)C/C=C/[C@@H](N)CCC1=CC=CC=C1 RFXLYJKRZZWPLJ-GNLXOOPCSA-N 0.000 description 1
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940019748 antifibrinolytic proteinase inhibitors Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 description 1
- 150000001504 aryl thiols Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000000656 azaniumyl group Chemical group [H][N+]([H])([H])[*] 0.000 description 1
- 244000000007 bacterial human pathogen Species 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- VCOVUYXJMHMVNV-FMYROPPKSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-5-(diaminomethylideneamino)-1-[(4-methyl-2-oxochromen-7-yl)amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NC=1C=C2OC(=O)C=C(C)C2=CC=1)C(=O)OCC1=CC=CC=C1 VCOVUYXJMHMVNV-FMYROPPKSA-N 0.000 description 1
- GONOPSZTUGRENK-UHFFFAOYSA-N benzyl(trichloro)silane Chemical compound Cl[Si](Cl)(Cl)CC1=CC=CC=C1 GONOPSZTUGRENK-UHFFFAOYSA-N 0.000 description 1
- 108010085937 benzyloxycarbonyl-phenylalanylarginine-4-methylcoumaryl-7-amide Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 108010037102 carbobenoxy-phenylalanyl-serine(O-benzyl)diazomethane Proteins 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 238000010531 catalytic reduction reaction Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical class OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000009137 competitive binding Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940125758 compound 15 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- FBUXEPJJFVDUFE-UHFFFAOYSA-N diethoxyphosphorylmethylsulfanylbenzene Chemical compound CCOP(=O)(OCC)CSC1=CC=CC=C1 FBUXEPJJFVDUFE-UHFFFAOYSA-N 0.000 description 1
- RCSDMTWWPNXXPP-UHFFFAOYSA-N diethoxyphosphorylmethylsulfonylbenzene Chemical compound CCOP(=O)(OCC)CS(=O)(=O)C1=CC=CC=C1 RCSDMTWWPNXXPP-UHFFFAOYSA-N 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- KZTYYGOKRVBIMI-UHFFFAOYSA-N diphenyl sulfone Chemical compound C=1C=CC=CC=1S(=O)(=O)C1=CC=CC=C1 KZTYYGOKRVBIMI-UHFFFAOYSA-N 0.000 description 1
- AASUFOVSZUIILF-UHFFFAOYSA-N diphenylmethanone;sodium Chemical compound [Na].C=1C=CC=CC=1C(=O)C1=CC=CC=C1 AASUFOVSZUIILF-UHFFFAOYSA-N 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000005095 gastrointestinal system Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002332 glycine derivatives Chemical class 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
- 125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 208000011379 keloid formation Diseases 0.000 description 1
- 238000012933 kinetic analysis Methods 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- MBKDYNNUVRNNRF-UHFFFAOYSA-N medronic acid Chemical compound OP(O)(=O)CP(O)(O)=O MBKDYNNUVRNNRF-UHFFFAOYSA-N 0.000 description 1
- 125000005394 methallyl group Chemical group 0.000 description 1
- LURSUHVHQZXABT-UHFFFAOYSA-N methanesulfinyl chloride Chemical compound CS(Cl)=O LURSUHVHQZXABT-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000006533 methyl amino methyl group Chemical group [H]N(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 229940102859 methylene diphosphonate Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical group O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000001272 nitrous oxide Substances 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 208000008494 pericarditis Diseases 0.000 description 1
- 210000003516 pericardium Anatomy 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- 150000002993 phenylalanine derivatives Chemical class 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-O phosphonium Chemical compound [PH4+] XYFCBTPGUUZFHI-UHFFFAOYSA-O 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 201000001223 septic arthritis Diseases 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- UQDJGEHQDNVPGU-UHFFFAOYSA-N serine phosphoethanolamine Chemical compound [NH3+]CCOP([O-])(=O)OCC([NH3+])C([O-])=O UQDJGEHQDNVPGU-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- NVBFHJWHLNUMCV-UHFFFAOYSA-N sulfamide Chemical class NS(N)(=O)=O NVBFHJWHLNUMCV-UHFFFAOYSA-N 0.000 description 1
- RYTMIGZBRFDNMS-UHFFFAOYSA-N sulfonylmethylphosphonic acid Chemical compound OP(O)(=O)C=S(=O)=O RYTMIGZBRFDNMS-UHFFFAOYSA-N 0.000 description 1
- XTQHKBHJIVJGKJ-UHFFFAOYSA-N sulfur monoxide Chemical class S=O XTQHKBHJIVJGKJ-UHFFFAOYSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 210000001179 synovial fluid Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JGZGULAMZVASKP-SFHVURJKSA-N tert-butyl n-[(2s)-1-(benzenesulfonyl)-4-phenylbutan-2-yl]carbamate Chemical compound C([C@H](NC(=O)OC(C)(C)C)CS(=O)(=O)C=1C=CC=CC=1)CC1=CC=CC=C1 JGZGULAMZVASKP-SFHVURJKSA-N 0.000 description 1
- KCHWFNCWNONEJN-DAFXYXGESA-N tert-butyl n-[(2s)-4-phenyl-1-(1-trimethylsilylethylsulfonyl)butan-2-yl]carbamate Chemical compound C[Si](C)(C)C(C)S(=O)(=O)C[C@@H](NC(=O)OC(C)(C)C)CCC1=CC=CC=C1 KCHWFNCWNONEJN-DAFXYXGESA-N 0.000 description 1
- XBXCNNQPRYLIDE-UHFFFAOYSA-N tert-butylcarbamic acid Chemical compound CC(C)(C)NC(O)=O XBXCNNQPRYLIDE-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 150000003568 thioethers Chemical class 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 230000036964 tight binding Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 1
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 210000002229 urogenital system Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
- C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/6533—Six-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
REVERSIBLE PROTEASE INHIBITORS
FIELD OF THE INVENTION
The invention relates to novel reversible protease inhibitors The inhibitors are selective for cysteine proteases
BACKGROUND OF THE INVENTION
Cysteine or thiol proteases contain a cysteine residue at the active site responsible for proteolysis Since cysteine proteases have been implicated in a number of diseases, including arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephπtis, malaria, and other parasite-borne infections, methods for selectively and irreversibly inactivating them provide opportunities for new drug candidates See, for example, Esser, R E et al , Arthritis & Rheumatism (1994) 37, 236, Meyers, M H M et al , Agents Actions (1993), 39 (Special Conference Issue), C219, Machleidt, W et al, Fibnnolysis (1992), 6 Suppl 4, 125, Sloane, B F et al , Biomed Biochim Acta (1991), 50, 549, Duffy, M J , Clin Exp Metastasis (1992), 10, 145, Rosenthal, P J , Wollish, W S , Palmer, J T , Rasnick, D , J Clin Investigations (1991), 88, 1467, Baricos. W H et al, Arch Biochem Biophys (1991 ), 288, 468, Thornberry, N A et al . Nature (1992), 356, 768
Low molecular weight inhibitors of cysteine proteases have been described by Rich, Proteinase Inhibitors (Chapter 4, "Inhibitors of Cysteine Proteinases"), Elsevier Science Publishers (1986) Such inhibitors include peptide aldehydes, which form hemithioacetals with the cysteine of the protease active site See, for instance, Cheng, H , Keitz, P , and Jones, J B , J Org Chem (1994), 59, 7671 The disadvantage of aldehydes is their in vivo and chemical instabilities
Aldehydes have been transformed into α,β-unsaturated esters and sulfones by means of the Wadsworth-Emmons-Horner modification of the Wittig reaction, shown below (Wadsworth, W S and
Emmons, W D (J Am Chem Soc (1961), 83, 1733)
where R = alkyl, aryl, etc EWG = COOEt, SOjMe. etc
α,β-unsaturated esters (Hanzlik ef al , J Med Chem , 27(6) 711-712 (1984), Thompson ef a/ , J Med Chem 29 104-111 (1986), Liu ef al , J Med Chem , 35(6) 1067 (1992)) and α,β-unsaturated sulfones (Thompson ef al , supra. Liu ef al , supra) were tested as inhibitors of two cysteine proteases, papain and dipeptidyl amino-peptidase I (also called cathepsin C) However, the inhibition of papain by these α,β-unsaturated compounds showed poor inhibition, evidenced by second order rate constants from less than 1 M 'sec ' to less than 70 M 1sec 1 for the σ,β-unsaturated esters, and from less than 20 M 1sec 1 to less than 60 M 'sec 1 for the sulfone
In addition, this chemistry has not been demonstrated with derivatives of σ-amino acids other than those corresponding to glycine, or in the case of the ester, phenylalanine Thus the chirality of these compounds is non-existent for the glycine derivatives and unclear for the phenylalanine derivatives This is significant since inhibition of an enzyme generally requires a chiral compound
Alpha-ammo sulphonic acids were suggested as potential inhibitory compounds, and several were made, although their inhibitory effects were not reported (Mcllwain et al , J Chem Soc 75 (1941 ))
In addition, the Mannich condensation of sulfinic acid, aldehyde, and ethyl carbamate, to form urethanes has been reported (Engberts et al , Recueil 84 942 (1965)
Additional methods for selectively and irreversibly inhibiting cysteine proteases have relied upon alkylation by peptide α-fluoromethyl ketones (Rasnick, D., Anal Biochem (1985), 149, 416), diazomethyl-ketones (Kirschke, H , Shaw, E Biochem Biphys Res. Commun (1981), 101, 454), acyloxymethyl ketones (Krantz, A et al , Biochemistry, (1991), 30, 4678, Krantz, A et al., U S Patent 5,055,451 , issued October 8, 1991), and ketosulfonium salts (Walker, B , Shaw, E , Fed Proc Fed Am Soc Exp Biol , (1985), 44, 1433)
Other families of cysteine protease inhibitors include epoxysuccinyl peptides, including E-64 and its analogs (Hanada, K e a/., Agrιc Biol Chem (1978), 42, 523, Sumiya, S ef a/., Chem Pharm. Bull ((1992), 40, 299 Gour-Salin, B J e a/ , J Med Chem , (1993), 36, 720), α-dicarbonyl compounds,
reviewed by Mehdi, S , Bioorganic Chemistry, (1993), 21, 249, and N-peptidyl-O-acyl hydroxamates (Bromme, D , Neumann, U , Kirschke, H , Demuth, H-U , Biochim Biophys Acta, (1993), 1202, 271 An additional summary of methods for reversibly and irreversibly inhibiting cysteine proteases has recently been compiled see Shaw, E , Advances in Enzymology and Related Areas of Molecular Biology (1990), 63, 271
SUMMARY OF THE INVENTION
An aspect of this invention is a protease inhibitor comprising a targeting group linked through a two carbon atom chain to an electron withdrawing group, wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM
An additional aspect of this invention is a protease inhibitor comprising a targeting group linked either directly or through a linker selected from the group consisting of an intermediate carbon atom or a two carbon atom chain to a sulfone group group, wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM
A further aspect of this invention is a compound, preferably a protease inhibitor, of Formula I
in which n is 0 to 13,
A-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein RJ is hydrogen or as defined below,
X represents a bond, methylene or the linkage -CH2CH(R4)-, wherein R4 is hydrogen, alkyl or arylalkyl
Y is -CH(R5)- or -NR5-, wherein R5 is hydrogen or as defined below,
Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below,
Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below,
R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl,
R7 and Rβ are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylamino, dialkylamino, uπedo, mercapto, alkylthio, carboxy, carbamoyi,
aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3^)methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), and
R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from ammo, guanidino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, preferably wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM
An additional aspect of this invention is a compound, preferably a protease inhibitor, of Formula II
II in which the groups are as defined above and
R9 is cyano, -C(0)OR1°, -P(O)(OR10)2, -S(O)(NR10)R10, C(0)R11, -S(0)R11, -C(0)NR12R13, -S(0)2NR12R13, -C(0)NHR14 or -S(0)2NHR14, wherein each R10 is independently hydrogen, alkyl (optionally substituted with one or more radicals selected from ammo, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R11 is hydrogen, alkyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, perfluoroaryl, perfluoroarylakyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R12 and R13 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyl, and R14 is -C(0)OR1°, in which R10 is as defined above, or a group selected from
Formulae (a) and (b):
(a)
wherein each n, A, B, Y, Z, R1 and R10 are as defined above, and the pharmaceutically acceptable salts; individual isomers and mixtures of isomers thereof, preferably wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM.
A further aspect of this invention is a compound, preferably a protease inhibitor, of Formula III:
in which: the groups are as defined above and
R 5 is hydrogen, methyl, fluoro or a group selected from Formulae (a) and (b) as defined above, and R16 is a group selected from phenyl or (C5^)heteroaryl (which group is optionally substituted with at least one radical selected from aikylcarbamoyl, dialkylcarbamoyi, alkyloxycarbonyl, alkylsulfmamoyl, dialkylsulfinamoyl, alkylsulfonyl, carboxy, nitro, sulfinamoyl, sulfo, carbamoyi, phosphono, alkyloxyphosphinyl, dialkyloxyphosphinyl, alkanoyl, cyano, alkylsulfinyl, sulfamoyl, alkylsulfamoyl, dialkylsulfamoyl, alkyloxysulfonyl, aryl, heteroaryl, hydroxy, alkyloxy, optionally halo-substituted alkyl, arylalkyl, halo, -*N(R17)3, wherein each R17 is independently alkyl, aryl or arylalkyl, or -N(R18)2, wherein each R1B is independently hydrogen, alkyl, aryl or arylalkyl); and the pharmaceutically acceptable salts; individual isomers and mixtures of isomers thereof, preferably wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM.
An additional aspect of this invention is a pharmaceutical composition comprising a therapeutically effective amount of a cysteine protease inhibitor of the invention, or of an individual isomer, a mixture of isomers, or the pharmaceutically acceptable salt or salts thereof, in combination with one or more pharmaceutically acceptable excipients.
A further aspect of this invention is a method for treating a condition capable of amelioration by inhibition of a cysteine protease in an animal in need thereof, which method comprises administering to such animal a therapeutically effective amount of a cysteine protease inhibitor of the invention, or of an individual isomer, mixture of isomer, or the pharmaceutically acceptable salt or salts thereof.
Another aspect of this invention is a method for detecting a cysteine protease in a sample, which method comprises
(a) assaying said sample for protease activity using a protease substrate
(b) assaying for protease activity in the presence of a known concentration of cysteine protease inhibitor on the invention, and
(c) calculating the difference between a) and b) to determine the protease activity due to cysteine protease
An aspect of this invention are the processes for preparing the cysteine protease inhibitors of this invention
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 depicts Scheme I, the synthesis of Formula I compounds when X is a bond The synthetic steps are as follows a) HC02H, H20, b) HBr/acetic acid, c) 4-methylmorpholιne, isobutyl chloroformate, Mu-ROH, and d) chromatographic purification The groups are as defined herein
Figure 2 depicts Scheme 2, the synthesis of Formula I compounds when X is a methylene group The synthetic steps are as follows a) 4-methylmorpholιne, isobutyl chloroformate, followed by NaBH4 reduction in water/THF, b) CH3S02CI, tπethylamine, CH2CI2, c) R,SH, NaH, CH3OH, THF, heat, d) 4-chloroperbenzoιc acid, CH2CI2, e) HCI/dioxane or p-CH3C6H4S03H/ether, and f) Mu-ROH, 4- met ylmorpholine, isobutyl chloroformate
Figure 3 depicts Scheme 3, the synthesis of Formula I compounds when X is a methylene group The synthetic steps are as follows a) (CH3)3CH2CH2SH, NaH, MeOH, THF, heat, b) 4-chloroperbenzoιc acid, c) (n-C4H9)4N , THF, followed by BrCH2CI, heat, d) HCI/dioxane or 4-CH3C6H4S03H/ether, and, e) 4-methylmorpholιne, isobutyl chloroformate, Mu-PheOH
Figure 4 depicts Scheme 4, the synthesis of Formula II compounds The synthetic steps are as follows a) Cl H2N*(CH3)OCH3, dicyclohexylcarboiimide, Et3N/CH2CI2, b) LiAIH ΪΗF, c) NaH/THF, d) Hcl/dιoxane/CH2CI2, e) 4-methylmorpholιne, isobutyl chloroformate/THF, and f) H2, 5% Pd/C
Figure 5 depicts Scheme 5, the synthesis of Formula I compounds when X is an ethylene The synthetic steps are as follows a)(CH20)n, HCI, dioxane, for instance where Ar = 2-naphthyl, b) (EtO)3P, c) CH3CO3H, CH2CI2, d) NaH, THF, e) p-CH3C6H4S03H, Et20, f) 4-methylmorpholιne, isobutyl chloroformate, and g) H2, Pd/C
Figure 6 depicts the synthesis of compounds of Formula II in which R9 is -COOH
Figure 7 depicts the synthesis of compounds of Formula II in which R9 is -P(O)(R10)2. The synthetic scheme is as follows: a) NaH THF; b) anhydrous p-CH3C6H4S03H/ether; c) 4-methylmorpholine, isobutyl chloroformate/THF, and; d) H2, Pd/C.
Figure 8 depicts the synthesis of compounds of Formula II in which R9 is -C(0)NHR14. The synthetic scheme is as follows: a) NaOH/EtOH, followed by Hcl/H20; b) benzylamine, dicyclohexylcarbodiimide, CH2CI2; c) NaH/THF, diethyl benzylamidomethylenephosphonate; d) HCI/dioxane; e) 4-methylmorpholine, isobutyl chloroformate, THF; f) H2, Pd/C, and as an alternative preparation from carboxylates as synthesized via Scheme 6, above; and g) aniline, dicyclohexylcarbodiimide, CH2CI2.
Figure 9 depicts the general synthesis of compounds of Formula II.
Figure 10 depicts the synthesis of compounds of Formula III. The synthetic steps are as follows: a) CH3CN or other suitable solvent, reflux; b) H20, NaOH, followed by extraction into organic medium; c) phosphorane, THF (Wittig reaction); d) p-CH3C6H4S03H, ether; e) Mu-PheOH, 4-methylmorpholine, isobutyl chloroformate, THF; and f) H2, Pd/C.
DEFINITIONS
Unless otherwise stated, the following terms used in the specification and claims are defined for the purposes of this application and have the meanings given below:
"Alkyl", as in alkyl, alkyloxy, alkylthio, alkylsulfonyl, aikylcarbamoyl, dialkylcarbamoyi, heteroarylalkyl, arylalkyl, and the like, means a straight or branched, saturated or unsaturated hydrocarbon radical having from 1 to 10 carbon atoms or the number of carbon atoms indicated (e.g., methyl, ethyl, propyl, isopropyl, butyl, sec-butyl, isobutyl, ferf-butyl, vinyl, allyl, 1-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, 2-methylallyl, ethynyl, 1-propynyl, 2-propynyl, etc.).
"Alkyloxyphosphinyl" and "dialkyloxyphosphinyl" mean the radicals -P(0)(OH)OR and -P(0)(OR)2, respectively, wherein R is alkyl as defined above.
"Alkanoyl", as in alkanoyl, alkanoyloxy, heterocycloalkylalkanoylamino, and the like, means the radical -C(0)R, wherein R is alkyl as defined above, having overall from 1 to 11 carbon atoms or the number of carbon atoms indicated (e.g., (C,^)alkanoyl includes the radicals formyl, acetyl, propionyl, isopropionyl, butyryl, isobutyryl, crotonoyl, isocrotonyl, etc.).
"Aryl" means an aromatic monocyclic or polycyclic hydrocarbon radical containing 6 to 14 carbon
O 96/30353 US96/03844
atoms or the number of carbon atoms indicated and any carbocylic ketone or thioketone derivative thereof, wherein the carbon atom with the free valence is a member of an aromatic ring, (e g , aryl includes phenyl, naphthyl, anthracenyl, phenanthrenyl, 1 ,2,3,4-tetrahydro-5-naphthyl, 1 -oxo-1 , 2-dιhydro-5-naphthyl, 1-thιoxo-1 ,2-dιhydro-5-naphthyl, etc )
"Aroyl" means the radical -C(0)Ar, wherein Ar is aryl as defined above, having overall from 7 to 15 carbon atoms or the number of carbon atoms indicated (e g , (C7 n)aroyl includes benzoyi, naphthoyi, etc )
"Cycloalkyl", as in cycloalkyl and cycloalkylalkyl, means a saturated or unsaturated, monocyclic or polycyclic hydrocarbon radical containing 3 to 20 carbon atoms or the number of carbon atoms indicated, wherein the carbon atom with the free valence is a member of a non-aromatic ring and any carbocyclic ketone and thioketone derivative thereof (e g , the term cycloalkyl is meant to include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, bιcyclo[2 2 2]octyl, 1 ,2,3,4-tetrahydro- 1 -naphthyl, oxocyclohexyl, dioxocyclohexyl, thiocyclohexyl, 9-fluorenyl, etc )
"Halo ' means fluoro, chloro, bromo or lodo
"Heterocycloalkyl", as in heterocycloalkyl, heterocycloalkylalkanoylamino, heterocycloalkylcarbonyl, heterocycloalkylcarbonyl, and the like, means cycloalkyl as defined above wherein 1 to 5 of the indicated carbon atoms is replaced by a heteroatom chosen from N, O, S, P or As, wherein the atom with the free valence is a member of a non-aromatic ring, and any heterocychc ketone, thioketone, sulfone or sulfoxide derivative thereof, (e g , the term heterocycloalkyl is meant to include pipeπdyl, pyrrolidinyl, pyrrolinyl, imidazo dinyl, indolmyl, quinuclidinyl, morpholinyl, piperazinyl, Λ/-methylpιperazιnyl, piperadinyl, 4,4-dιoxo-4-thιapιpeπdιnyl, 1 ,2,3,4-tetrahydro-3-ιsoquιnolyl, 2,4-dιaza-3-oxo-7-thιa-6-bιcyclo[3 3 OJoctyl, etc ) Thus, hetero(C6)cycloalkyl includes the radicals morpholinyl, piperazinyl, pipendinyl and the like
"Heteroaryl" means an aromatic monocyclic or polycyclic hydrocarbon radical containing overall from 5 to 14 atoms or the number of atoms indicated, wherein 1 to 5 of the indicated carbon atoms are replaced by a heteroatom chosen from N, O, S, P or As, wherein the atom with the free valence is a member of an aromatic ring, and any heterocychc ketone and thioketone derivative thereof (e g , the term heteroaryl is meant to include thienyl, furyl, pyrrolyl, pyπmidmyl, isoxazolyl, oxaxolyl, dolyl, benzo[b]thιenyl, isobenzofuranyl, punnyl, isoqumolyl, pterdinyl, pyπmidinyl, imidazolyl, pyπdyl, pyrazolyl, pyrazinyl, 4-oxo-1 ,2-dιhydro-1 -naphthyl, 4-thιoxo-1,2-dιhydro-1 -naphthyl, etc ) Thus, hetero(C6)aryl includes the radicals pyπdyl, pyπmidinyl, and the like
"1,2-Phenylenedimethylene" means a divalent radical of the formula -CH2C6H4CH2-. For example, the group RΥ-Z-A- in which Y is -N(R5), Z is -CH(R7)-, A is carbonyl and R7 together with R5 forms 1 ,2-diphenylenedimethylene" means a group of following formula:
and substituted derivatives and individual stereoisomers and mixture of stereoisomers thereof. Substituted derivatives of the 1 ,2-phenylenedimethylene divalent radical may contain a hydroxy group on any carbon within the ring system or an oxo group on either of the unsaturated ring carbon atoms.
"Phosphono" means the radical -P(0)(OH)2.
"Methylene" as in "(C3J))methylene"and "(C3.7)methylene" mean a straight, saturated divalent radical having the number of carbon atoms indicated; "(C3^)methylene" includes trimethylene (-(CH2)3-) and tetramethylene (-(CH2)4-) For example, a preferred embodiment herein utilizes a proline residue as an A-B-Z group, wherein A-B represents CH2-NR3 and R3 together with either R7 or Rβ form a C3 methylene. Thus, the group R1-Y-Z-A- in which Y is -(NR5)-, Z is -CH(R7)-, A is carbonyl and R7 together with R5 forms trimethylene means a group of following formula:
and the individual stereoisomers and mixtures of stereoisomers thereof. Substituted derivatives of the trimethylene and tetramethylene divalent radicals may contain a hydroxy group, or a protected derivative thereof, or an oxo group on any of the ring carbon atoms. Suitable hydroxy protective groups are defined below.
"Oxa(C3.7)methylene" and "aza(C3.7)methylene" mean methylene as defined above wherein one of the indicated carbon atoms is replaced by an oxygen or nitrogen atom, respectively. For example, "oxa(C5)methylene" includes 3-oxapentamethylene (-CH2CH2OCH2CH2-) and 2-oxapentamethylene (-CH2OCH2CH2CH2-). Thus, -CfOJNR^R22 means the radical 4-morpholinylcarbonyl when R21 and R22 together form 3-oxapentamethylene and the radical 1-piperazinylcarbanoyl when R21 and R22 together form 3-azapentamethylene.
"Adjacent", as use in the phrase "R7 together with an adjacent R3", means that the atoms to which the R7 and R3 groups are respectively attached are in turn attached to one another
"Animal" includes humans, non-human mammals (e g , dogs, cats rabbits, cattle, horses, sheep, goats, swine, deer, etc ) and non-mammals (e g , birds, etc )
"Disease" specifically includes any unhealthy condition of an animal or part thereof and includes an unhealthy condition which may be caused by, or incident to, medical or veterinary therapy applied to that animal, i e , the "side effects" of such therapy
"Electron withdrawing group" (EWG) means a functional group that in its broadest sense is a group able to exert a polarizing force on the bond between itself and the carbon to which it is attached, such that electrons are polarized in favor of the electron withdrawing group While not being limited to any particular theory, it is believed that the polarizing property enables the electron withdrawing group to participate in hydrophobic or hydrogen bonding interactions with an active site of the cysteine protease, resulting in inhibition of the enzyme In general, a moiety is suitable as an electron withdrawing group if when present in the α-position of a phosphonium ylide of the general structure Ph3P=C(R)EWG it exerts sufficient polarization to stablize the ylide against undergoing decomposition reactions with oxygen, water, hydroha c acids, alcohols, and the like Preferred electron withdrawing groups are those which would similarly stabli ze ylides of the general formula (RO)2P(0)C(R)EWG Suitable electron withdrawing groups include cyano, -S(0)2R2, -C(0)OR1°, -P(O)(OR10)2, -S(O)(NR10)R10, C(0)R11, -S(0)R11, -C(0)NR12R13, -S(0)2NR12R13, -C(0)NHR14, -S(0)2NHR14, phenyl and (C5^)heteroaryl, wherein each R2, R10, R11, R12, R13 and R14 are as defined in their broadest definitions set forth in the Summary of the Invention When the electron withdrawing group is phenyl or (C5^)heteroaryl the ring may be substituted with one or more meta directing groups (e g , alkyloxycarbonyl, alkylsulfinamoyl, dialkylsulfinamoyl, alkylsulfonyl, carboxy, nitro, sulfmamoyl, sulfo, phosphono, alkyloxyphosphinyl, dialkyloxyphosphinyl, alkanoyl, cyano, alkylsulfinyl, sulfamoyl, alkyisulfamoyl, dialkylsulfamoyi, alkyloxysulfonyl, disubstituted ammo, tnsubstituted ammonio, and the like), ortho and para directing groups (e g , hydroxy, alkyloxy, optionally halo-substituted alkyl, aryl, arylalkyl, halo, and the like) and electron withdrawing moieties (e g , aikylcarbamoyl, dialkylcarbamoyi, alkyloxycarbonyl, alkylsulfinamoyl, dialkylsulfinamoyl, alkylsulfonyl, carboxy, nitro, sulfmamoyl, sulfo, carbamoyi, phosphono, alkyloxyphosphinyl, dialkyloxyphosphinyl, alkanoyl, cyano, alkylsulfinyl, sulfamoyl, alkyisulfamoyl, dialkylsulfamoyi, alkyloxysulfonyl, aryl, heteroaryl, and the like)
"Leaving group" has the meaning conventionally associated with it in synthetic organic chemistry, i e , an atom or group displaceable under alkylatmg conditions, and includes halo and alkane- or arenesulfonyloxy, sucha mesyloxy, ethanesulfonyloxy, benzenesulfonyloxy and tosyloxy, and
alkaesulfonylamino, alkanecarbonylamino, aminosulfonylamino, aminocarbonylamino and the like.
Isomerism is the phenomenon wherein compounds have identical molecular formulae but differ in the nature or sequence of bonding of their atoms or in the arrangement of theri atoms in space. Isomers that differ in the arrangement of their atoms in space are termed "steroisomers". Stereoisomers that are not mirror images of one another are termed "diastereomers" and stereoisomers that are nonsuperimposable mirror images are termed "enantiomers" or sometimes "optical isomers". A carbon atom bonded to four nonidentical substituents is termed a "chiral center".
A compound with one chiral center has two enantiomeric forms of opposite chirality is termed a "racemic mixture". A compound that has more than one chiral center has 2π 1 enantiomeric pairs, where n is the number of chiral centers. Compounds with more than one chiral center may exist as ether an individual diasteromer or as a mixture of diastereomers, termed a "diastereomeric mixture".
Compounds of Formulae I, II and III can exist as individual steroisomers or mixtures of stereoisomers. For example, compounds of Formulae I, II and III contain a chiral center at the carbon to which the substituent Rβ is attached. Furthermore, compounds of Formulae I, II and III in which Z is -C(R6)(R7) contain a chiral center at the carbon to which the R7 substituent is attached. Thus, for example, compounds of Formulae I, II and III in which n is 0 and Z is -C(R6)(R7) will have two chiral centers and can exist as four individual stereoisomers or any mixture thereof.
Individual stereoisomer may be characterized by the absolute configuration of their chiral centers. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog and then the absolute descriptor R is assigned if the three highest ranked substituents are arranged in space (with the fourth lowest ranked substituent directed away from the observer) from high to low priority in a clockwise sequence and the absolute descriptor S is assigned for a counterclockwise arrangement. When an individual stereoisomer containing one chiral center is described the absolute descriptor R or S is cited in parenthesis followed by a hyphen and the chemical name of the compound. For the purposes of this invention, when an individual stereoisomer or mixture of stereoisomers containing two or more chiral centers is described, the absolute descriptor R or S is cited immediately after the appropriate locant. Acyl radicals derived from naturally occurring amino acids are referred to as their amino acid radicals preceded by the descriptor L (e.g., L-phenylalanine). The nonnatural enantiomers of amino acid acyl radicals are preceded by the descriptor D. Preferably, the amino acid side chains are the (S) or L-form, due to the stereospecificity of enzymes, although the D-forms may be used in some cases. When no absolute descriptor is cited for a chiral center, the description is meant to include both configurations and
mixtures thereof, racemic or otherwise Thus, for example, a compound of the following formula
is named
Λ/2-(4-morpholιnylcarbonyl)-Λ 1-[3-phenyl-1 S-(2-phenylsulfonylethyl)propyl]-L-phenylalanιnamιde, when
R1 is 4-morpholιnylcarbonyl, R8 is 2-phenylethyl and lies on the same side of the reference plane as the R7 substituent, R7 is benzyl and R19 is phenylsulfonyl,
Λ/2-4-morpholιnylcarbonyl-Λ 1-[3-phenyl-1-(2-phenylsulfonylethyl)propyl]-L-phenylalanιnamιde, when R1 is 4-morpholιnylcarbonyl, R8 is 2-phenylethyl and lies on either or both sides of the reference plane, R7 is benzyl and R 9 is phenylsulfonyl,
Λ/2-4-morpholιnylcarbonyl-Λ/-[3-phenyl-1 S-(2-phenylsulfonylethyl)propyl]-β-(2-naphthyl)-L-alanιnamιde, when R1 is 4-morpholιnylcarbonyl, R8 is 2-phenylethyl lies on the same side of the reference plane as the R7 substituent, R7 is 2-naphthylmethyl and R19 is phenylsulfonyl and ethyl 4S-(Λ/-4-morpholιnylcarbonyl-L-phenylalanylamιno)-6-phenylhexanoate, when R1 is
4-morpholιnylcarbonyl, R8 is 2-phenylethyl and lies on the same side of the reference plane as the R7 substituent, R7 is benzyl and R19 is ethoxycarbonyl
In a preferred embodiment, the compositions of the invention are pure diasteromers Alternatively, the compositions contain mixtures of diasteromers Preferred embodiments have greater than about 70% of a single disasteromer, with at least about 90% being particularly preferred
"Protective group" has the meaning conventially associated with it in synthetic organic chemistry, i e , a group which blocks a reactive site in a compound See for example Greene et al , Protective Groups in Organic Synthesis, 2nd Ed , John Wiley & Sons, 1991 , hereby incorporated by reference Examples of hydroxy protective groups include heterocycloalkyl-carbonyl such as 4-morpholιnylcarbonyl and the like, aroyl such as benzoyi and arylalkyl such as benzyl and the like Examples of am o protective groups include aryloxycarbonyl such as benzyloxycarbonyl and the like, aroyl such as benzoyi and the like and oxycarbonyl such as ethoxycarbonyl and 9-fluorenylmethoxycarbonyl and the like Examples of guanidino protective groups include sulfonyl such as 2,3,5-tπmethyl-4-methoxyphenyl-sulfonyl and the like Examples of suitable carboxy protective groups that form ester moieties are alkoxylcarbonyl of overall 4 to 8 carbon atoms, particularly fe t-butoxycarbonyl (BOC) or benzyloxycarbonyl (CBZ, Z), especially cycloalkylammocarbonyl or oxacycloalkylammocarbonyl of overal 4 to 8 atoms in the ring, particularly 4-morpholιnecarbonyl (Mu) and the like.
"Protected" in reference to a compound of a group means a derivative of a compound or group in which a reactive site or sites are blocked with protective groups
"Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances wherein the event or circumstance occurs and instances in which it does not For example, "optionally further substituted with one or more functional groups" means that the substituents may or may not be present in order for the compound described to fall within the invention, and the invention includes those compounds wherein one or more functional groups are present and those compounds in which no functional groups are present
By "cysteine protease-associated disorders" herein is meant pathological conditions associated with cysteine proteases In some disorders, the condition is associated wtih increased levels of cysteine proteases, for example, arthritis, muscular distrophy, inflammation, tumor invasion, and glomerulonephritis are all associated with increased levels of cysteine proteases In other disorders or diseases, the condition is associated with the appearance of an extracellular cysteine protease activity that is not present in normal tissue In other embodiments, a cysteine protease is associated with the ability of a pathogen, such as a virus, to infect or replicate in the host organism
Specific examples of cysteine protease associated disorders include, but are not limited to, arthritis, muscular distrophy, inflammation, tumor invasion, glomerulonephπtits, malaria, Alzheimer's disease, cancer metastasis, trauma, inflammation, gingivitis, leishmaniasis, filaπasis, and other bacterial and parasite-borne infections In particular, disorders associated with interleukin 1β converting enzyme (ICE) are included
"Pharmaceutically acceptable" means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary use as well as human pharmaceutical use
"Pharmaceutically acceptable salts" means salts which are pharmaceutically acceptable, as defined above, and which possess the desired pharmacological activity Such salts include acid addition salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfunc acid, nitric acid, phosphoric acid, and the like, or with organic acids such as acetic acid, propionic acid, hexanoic acid, heptanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succtnic acid, malic acid, maleic acid, fumaric acid, tartatic acid, citric acid, benzoic acid, o-(4-hydroxybenzoyl)benzoιc acid, cmnamic acid, madelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedιsulfonιc acid, 2-hydroxyethanesulfonιc acid, benzenesulfonic acid, p-chlorobenzenesulfonic acid, 2-naphthalenesulfonιc acid, p-toluenesulfonic acid, camphorsulfonic
acid, 4-methylbιcyclo[2 2 2]oct-2-ene-1-carboxylιc acid, glucoheptonic aicd, 4,4'-methylenebιs(3-hydroxy-2-ene-1-carboxylιc acid), 3-phenylpropιonιc acid, tnmethylacetic acid, tertiary butylacetic acid, lauryl sulfunc acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid and the like
Pharmaceutically acceptable salts also include base addition salts which may be formed when acidic protons present are capable of reacting with inorganic or organic bases Acceptabale inorganic bases include sodium hydroxide, sodium carbonate, potassium hydroxide, aluminum hydroxide and calcium hydoxide Acceptable organic bases include ethanolamine, diethanolamine, tπethanolamine, tromethamine, Λ/-methylglucamιne and the like
"Therapeutically effective amount" means that amount which when administered to an animal for treating a disease includes
(1) preventing the disease from occurring in an animal which may be predisposed to the disease but does not yet experience or display symptoms of the disease,
(2) inhibiting the disease, i e , arresting its development, or
(3) ameliorate the disease, i e causing regression of the disease
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to novel cysteine protease inhibitors Without being bound by theory, it is believed that the inhibitors bind to cysteine proteases based on the following scheme
enzyme inhibitor complex
It is believed that the enzyme is thus reversibly inhibited by means of interactions between the R, Y and Z moieties of the inhibitor and the surface of the binding sites of the enzyme, and by means of hydrogen bonding interactions between the sulfone and active site ammo acid side chains
This mechanism of reversible inhibition permits specificity of the enzyme inhibitors for cysteine proteases Generally, the inhibitors of the present invention inhibit cysteine proteases and do not inhibit serine, aspartyl, and zinc proteases However, in some embodiments, the protease inhibitors of the present invention may have activity against other types of proteases, such as serine, aspartyl or
other metalloproteases, but to a lesser extent
In addition, the electron withdrawing properties of the sulfone group of Formula I polarize the electrons between the sulfone group and the carbon to which it is attached, thus permitting hydrogen bonding between itself and active site residues of a cysteine protease, to allow tight binding between the inhibitor and the cysteine protease, as is generally described below It is to be understood that there is presumably additional electron withdrawing or electron polarization occurring between the sulfur atom and the oxygen atoms, which allows the oxygen atoms to participate in hydrogen bonding with active site residues of the protease and thus contributing even further to the inhibition of the enzyme
The present invention generally provides new peptide-based and peptidomimetic cysteine protease inhibitors for use as reversible cysteine protease inhibitors By "cysteine protease inhibitor" herein is meant an inhibitor which inhibits cysteine proteases In a preferred embodiment, the cysteine protease inhibitors are specific to cysteine proteases, that is, they do not inhibit other types of protease such as serine, aspartyl, or other metalloproteases However, in alternative embodiments, the cysteine protease inhibitors of the invention may inhibit other types of proteases as well
By "reversible" herein is meant that the inhibitor binds non-covalently to the enzyme, and is to be distinguished from irreversible inhibition See Walsh, Enzymatic Reaction Mechanisms, Freeman & Co , N Y , 1979 "Reversible" in this context is a term understood by those skilled in the art In addition, the reversible cysteine protease inhibitors are competitive inhibitors, that is, they compete with substrate in binding reversibly to the enzyme, with the binding of inhibitor and substrate being mutually exclusive In addition, the stoichiometry of inhibition is 1 1 , that is, a single inhibitor molecule is sufficient to inhibit a single enzyme molecule
The cysteine protease inhibitors herein are designed to bind reversibly to cysteine proteases This binding is accomplished by using peptide-based or peptidomimetic structures as targeting groups that mimic naturally occurring substrates and/or inhibitors "Peptidomimetic", for the purposes of this invention, means ammo acid or peptide-hke in structure but wherein one or more of the peptide linkages (i e , -C(O)NR-) is substituted by an isosteπc form, i e -CH2NR-, -C(0)CH2- or -NRC(O)- and/or wherein non-naturally occurring ammo acid substituents are present
"Targeting group", for the purposes of this application, means a peptide or peptidomimetic residue of the cysteine protease inhibitor that allows the binding of the inhibitor to a cysteine protease In a preferred embodiment, the targeting group of a cysteine protease inhibitor comprises at least two ammo acid side chains or side chain analogs, linked via a peptide bond or isostere The targeting group may comprise up to about 15 am o acids or analogs, although inhibitors are generally from
about 1 to 7 ammo acids or analogs, since smaller inhibitors are usually desired in therapeutic applications Thus, in Formulae I, II and III, n is preferably from 0 to 13, with from 0 to 5 being preferred and from 0 to 3 being particularly preferred
As depicted in Formulae I, II and III, the targeting group can be represented by a naturally or non-naturally occurring peptide residue of the following formula
wherein the R8 and R7 components represent naturally or non-naturally occurring am o acid analogs or substituents as is more fully described below The targeting group of the inhibitor may also contain additional functional groups, as depicted by R1 and described herein
While not being limited to any particular theory, it is believed that the am o acid substituents of the targeting group interact with the surface binding sites of the protease to promote binding It is also believed that the ammo acid substituent proximal to the electron withdrawing group (e g , R8 of the above formula) will occupy the S, position of the substrate binding site and therefore is designated the P, residue of the inhibitor Similarly, the next adjacent ammo acid substituent (e g , R7 of the above formula) will occupy the S2 position of the substrate binding site and is designated the P2 residue of the inhibitor If present, additional am o acid substituents will occupy the S3, S4, etc positions of the substrate binding site and be designated as the P3, P4, etc residues of the inhibitor An additional targeting group may be attached to the electron withdrawing group and, if present, its ammo acid substituents will occupy the S,', S2', etc positions of the substrate binding sites and are designated the P3', P4', etc residues of the inhibitor, respectively
In general, targeting groups for specific enzymes are determined by rules governing substrate specificity in cysteine proteases (e g , see "Protemase Inhibitors", in Research Monographs in Cell and tissue Physiology (1986), ed Barret ef a/ , Vol 12, Chapter 4 Inhibitors of Cysteine Proteinases, Daniel Rich, Elsevier, New York, and Thornberry ef al , supra , hereby expressly incorporated by reference) For example, ιnterleukιn-1 converting enzyme (ICE) accepts an aspartic acid substituent (i e , 2-carboxyethyl) at the P, position and an alanme (methyl), val e (isopropyl) or histidme (4-ιmιdazolylmethyl) substituent at the P2 position Papain accepts a argmine, lysine, N- benzyloxycarbonyllysine (i e 4-benzyloxycarbonylamιnobutyl), homophenylalanme (i e 2-phenylethyl), Guanidmo-phenylalnine (i e , 4-guanιdιnobenzyl) or norluecme (i e , butyl) substitutents at the P, position and phenylalnme, tyrosme, β-)2-naphthyl)alanιne (i e , 2-naphthyl), leucme, norleucme
isoleucine or alanme substituents at the P2 position Cathepsin B accepts a argmine, lysme, N- benzyloxycarbonyllysme, guanidmo-phenylalanine, homophenylalanine or norleucme substituents at the P, position and phenylalanine, tyrosme, 3,5-dιιodotyrosιne (i e , 3,5-dιιodo-4-hydroxybenzyl), β-(2- naphthyl)alanme, argmine, guanidmo-phenylalanine or citrulline (i e , 3-ureιdopropyl) sybstituents at the P2 position Cathepsin L and cruzam accept argmine, lysme, homophenylalanine, guanmdino- phenylalanme, citrulline or norleucme substituents at the P, position and phenylalanine, tyrosme or β-(2-naphthyl)alanιne substituents at the P2 position Cathepsin S accepts a argmine, lysme, homophenylalanine, guanidmo-phenylalanine, citrulline or norleucme substituents at the P, position and phenylalanine, tyrosme, β-(2-naphthyl)anιne, valme, leucme, norleucme, isoleucine or alanme substituents at the P2 position DPP-1 accepts phenylalanine or tyrosme substituents at the P, position and no subsutituent or alanme at the P2 position Calpain accepts phenylalanine, tyrosme, methionine, β-methylsulfonylmethylalanine (i e , 2-methylsulfonylethyl) or valme substituent at the P, position and valme, leucme, norleucme or isoleucine substituents at the P2 position
Thus, R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylamino, dialkylamino, uπedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, am o, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or Rs forms a divalent radical selected from (C3^)methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo)
Accordingly, preferred R7 and R8 groups are the naturally occunng ammo acid side chains and homologous derivatives These include, but are not limited to, alanme (methyl), argmine (3- guanidmopropyl), asparagme (carbamoylmethyl), citurlline (3-ureιdopropyl), aspartic acid (carboxymethyl), cysteine (mercaptomethyl), glutamic acid (2-carboxyethyl), glutamine (2- carbamoylethyl), glycine (hydrogen), histidme (4-ιmιdazolylmethyl), homophenylalanine (2- phenylethyl), homoseπne (2-hydroxylethyl), isoleucine ((1-methylpropyl), leucme (isobutyl), lysme (4- aminobutyl), methionine (2-methylthιoethyl), β-(1-naphthyl)alanιne (1-napthylmethyl), β-(2- naphthyl)alanιne (2-napthylmethyl), norleucme (butyl), norval e (propyl), ornithine (3-amιnopropyl), phenylalanine (benzyl), proline (as described herein), sarcosme (methylaminomethyl), serine (hydroxymethyl), threonme (1-hydroxyethyl), tryptophan (3-ιndolymethyl), tyrosme (4-hydroxybenzyl), and valme (isopropyl)
While the broadest definition of this invention is set forth in the Summary of the Invention, certain
18 compounds of the invention are preferred For example, generally preferred compounds of Formulae I, II and 111 are those in which n is 0 to 5, A-B represents a linkage selected from -C(0)NR3-, wherein R3 is hydrogen or as defined below, Y is -N(R5)-, wherein R5 is hydrogen or as defined below, Z is -(CH2)2- or -C(R6)(R7)-, Z1 is -CH(R8)-, R is hydrogen, alkyloxycarbonylalkanoyl of overall 3 to 10 carbon atoms, (C, 9)alkoxycarbonyl, (C2 10)alkanoyl (optionally substituted with a radical selected from carboxy, (C, 9)alkyloxycarbonyl and hetero(C4 β)cycloalkyl(C2 10)alkanoylamιno), (C4 9)cycloalkyl- carbonyl, hetero(C4 B)cycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, (C, 5)alkyl, (C, 5)alkanoyl, (C, 5)alkyloxycarbonyl, (C6 10)aryl(C, s)alkyloxycarbonyl and hetero(C4^)cycloalkylcarbonyl), (C6 10)aryl(C, 5)alkyloxycarbonyl, carbamoyi, (C, 5)alkylcarbamoyl, dι(C, 5)alkylcarbamoyl, (C6 10)arylcarbamoyl, (C6 10)aryl(C, 5)alkylcarbamoyl, (Cg ^ary C, 5)alkanoyl, (C7 n)aroyl, (C, 5)alkylsulfonyl, dι(C, 5)alkylammosulfonyl, (C6 ,0)arylsulfonyl or hetero(C5 8)arylsulfonyl, and R7 and R8 are independently (C. 5)alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylam o, dialkylammo, unedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino or a protected derivative thereof) (C3 7)cycloalkyl, (C3 7)cycloalkyl(C1 5)alkyl, pyπdyl. thienyl, furyl, imidazolyl, mdolyl, pyπdyl(C1^)alkyl,
a group selected from or a group selected from phenyl, naphthyl, phenyl(C,^)alkyl, naphthyl(C,^)alkyl, (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, chloro, bromo, lodo, fluoro, methyl, tπfluoromethyl, methoxy and phenyl, or a protected derivative thereof) or together with an adjacent R3 or R4 forms a divalent radical selected from (C3j,)methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo)
More preferred compounds of Formulae I, II and III are those in which n is 0 to 2, A-B represents a linkage selected from -C(0)NR3-, wherein R3 is hydrogen or as defined below, Y is -N(R5)-, wherein R5 is hydrogen or as defined below, Z is -(CH2)2- or -C(R6)(R7)- (with the proviso that when n is 0, Z is not -(CH2)2-), Z1 is -CH(R8)-, R1 is hydrogen, (C4 β)alkoxycarbonyl, (C2^)alkanoyl (optionally substituted with a radical selected from carboxy, (C, 5)alkyloxycarbonyl and hetero(C4^)cycloalkyl(C4^) alkanoylam o), -C(0)NR21R22 wherein R21 and R22 together form aza(C2-6)methylene, oxa(C2^)methylene or (C3.7)methylene, (C4^)cycloalkylcarbonyl, benzyloxycarbonyl, acetyl, benzoyi or dimethylammosulfonyl, and R8 and R7 are independently (C5^)cycloalkyl, (C5-6)cycloalkylmethyl, 3-pyπdyl, 2-thιenyl, 2-furyl, 4-ιmιdazolyl, 3-ιndolyl, 3-pyrιdylmethyl, 2-thιenylmethyl, 2-furylmethyl,4-ιmιdazolylmethyl, 3-ιndolylmethyl, (C*.5)alkyl (optionally substituted with a radical selected from mercapto, carboxy, ammo, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyl, guanidino and hydroxy, or a protected derivative thereof), a group selected from phenyl, 1-naphthyl, 2-naphthyl, benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, ammo, chloro, bromo and fluoro, or a
protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3Jl)methylene and 1,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo)
Particularly preferred compounds of Formulae I, II and III are those in which n is 0 to 1, A-B represents a linkage selected from -C(0)NR3-, Y is -N(R5)-, wherein R5 is hydrogen or as defined below, Z is -C(Rβ)(R7)-, is -CH(R8)-, R1 is hydrogen, fert-butoxycarbonyl, benzyloxycarbonyl, acetyl, 3-carboxypropιonyl, 3-methoxycarbonylpropιonyl, biotinylaminohexanoyl, phenylacetyl, benzoyi, dimethylammosulfonyl, benzylsulfonyl, 1-pιperazιnylcarbonyl, 4-methylpιperazιn- 1-ylcarbonyl or 4-morpholιnylcarbonyl, R7 is 3-pyrιdylmethyl, 2-thιenylmethyl, 2-furylmethyl, 4-ιmιdazolylmethyl, 3-ιndolylmethyl, (C, 5)alkyl (optionally substituted with a radical selected from mercapto, carboxy, ammo, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyl, guanidino and hydroxy, or a protected derivative thereof), a group selected from benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, am o, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3-4)methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), and R8 is butyl, 2-phenylethyl, 2-methylsulfonylethyl, 2-fert-butoxycarbonylethyl, 2-fert-butoxycarbonylmethyl, 4-fert-butoxycarbonylamιnobutyl, 4-benzoylamιnobutyl or benzyloxymethyl
More particularly preferred compounds of Formulae I, II and III are those in which n is 0, A-B represents a linkage selected from -C(0)NH-, Y is -NH-, Z is -CH(R7)-, T is -CH(R8)-, R1 is hydrogen, fer -butxoycarbonyl, benzyloxycarbonyl, biotinylaminohexanoyl, benzoyi, pιperιzιn-1-ylcarbonyl, 4-methylpιperazιn-1-ylcarbonyl or 4-morpholιnylcarbonyl, R7 is (C, 5)alkyl, optionally substituted benzyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-pyrιdιnylmethyl or 2-methylsulfonylethyl, and R8 is butyl, 2-phenylethyl or 2-methylsulfonylethyl
Most preferred compounds of Formula I, II and III are those in which n is 0, A-B represents a linkage selected from -C(0)NH-, Y is -NH-, Z is -CH(R7)-, Z1 is -CH(R8)-, R1 is 1-pιperιzιnylcarbonyl, 4-methyl- 1-pιperazιnylcarbonyl or 4-morpholιnylcarbonyl; R7 is optionally substituted benzyl, 1-naphthylmethyl or 2-naphthylmethyl, and R8 is 2-phenylethyl
Generally preferred compounds of Formula I are those in which R2 is independently (C,.5)alkyl (optionally substituted with one or two radicals selected from ammo, chloro, bromo, fluoro, hydroxy and methoxy, or a protected derivative thereof). perhalo(C,.5)alkyl, (C3.7)cycloalkyl, (C 3-7)cycloalkyl(C,^)alkyl or a group selected from phenyl, pentafluorophenyl, naphthyl and phenyl(C,^)alkyl (which group is optionally substituted at its aryl ring with one to two radicals selected
from ammo, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl, or a protected derivative thereof) and R4 is hydrogen, (C, 5)alkyl or (C6 ,0)aryl(C, 5)alkyl More preferred compounds of Formula I are those in which in which R2 is (C, 5)alkyl (optionally substituted with one or two radicals selected from ammo, chloro, bromo, fluoro and hydroxy, or a protected deπvative thereof), perfluoro(C, 5)alkyl, (C5^)cycloalkyl, (C5^)cycloalkylmethyl or a group selected from phenyl, naphthyl and benzyl (which group is optionally substituted with one radical selected from ammo hydroxy, chloro, bromo or fluoro, or a protected derivative thereof) and R4 is hydrogen or methyl Particularly preferred compounds of Formula I are those in which R2 is methyl, tπfluoromethyl, optionally substituted phenyl, 2-naphthyl or 2-phenylethyl Most preferred compounds of Formula I in which R2 is phenyl, 2-naphthyl or 2-phenylethyl, particularly phenyl or 2-naphthyl, and R4 is hydrogen
Generally preferred compounds of Formula II in which R9 is -C(0)OR10, -P(O)(OR10)2, -S(O)(NR10)R10, -C(0)NHC(0)R10 or -S(0)2NHC(0)R10 are those in which each R10 is independently (C, 5)alkyl (optionally substituted with one or two radicals selected from ammo, chloro, bromo, fluoro, hydroxy and methoxy or a protected derivative thereof), (C37)cycloalkyl, (C3 7)cycloalkyl(C, 5)alkyl, or a group selected from phenyl or phenyl(C1-6)alkyl (which group is optionally substituted at its phenyl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl, or a protected derivative thereof) More preferred compounds of Formula II in which R9 is -C(0)OR10, -P(0)(OR1°)2, -S(O)(NR10)R10, -C(0)NHC(0)R10 or -S(0)2NHC(0)R10 are those in which in which R10 is ethyl, (C5^)cycloalkyl, (C5^)cycloalkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from ammo hydroxy, chloro, bromo or fluoro, or a protected derivative thereof)
Generally preferred compounds of Formula II in which R9 is C(0)R11 or -S(0)R11 are those in which R11 is (C, 5)alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl(C1 5)alkyl or a group selected from phenyl and phenyl(C,^)alkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methyl, tπfluoromethyl and methoxy) More preferred compounds of Formula II in which R" is C(0)R" or -S(0)R11 are those in which in which R11 is ethyl, cyclo(C5^)alkyl, cyclo(C5^)alkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from ammo hydroxy, chloro, bromo or fluoro, or a protected derivative thereof)
Generally preferred compounds of Formula II in which R9 is -C(0)NR12R13 or -S(0)2NR1 R13 are those in which R12 and R13 are independently (Chalky!, (C3.7)cycloalkyl, (C37)cycloalkyl (C, 5)alkyl or a group selected from phenyl and pheny^C^alkyl (which group is optionally substituted at its phenyl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl) More preferred compounds of Formula II in which R9 is -C(0)NR12R13 or
O 96/30353
21
-S(0)2NR12R13 are those in which R12 and R13 are independently ethyl, (C5<)cycloalkyl, (C-^cycloalkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from amino hydroxy, chloro, bromo or fluoro, or a protected derivative thereof).
Preferred compounds of Formula II in which R9 is -C(0)NHR14 or -S(0)2NHR14 wherein R14 is a group selected from Formulae (a) and (b) are those in which each n, A, B, Y, Z, R1 and R10 are as defined above with respect to preferred compounds of Formulae I, II and III.
Generally preferred compounds of Formula III are those in which R15 is a group selected from 2-furyl, 2-thienyl, 2-pyrrolyl, 2-phospholyl, 2-arsoyl, 3-pyridyl or 3-phosphorinyl (which group is optionally substituted with at least one radical selected from (CL^alkylcarbamoyl, di(C1.5)alkylcarbamoyl, (C1.5)alkyloxycarbonyl, (C,.5)alkylsulfinamoyl, di(C,.5)alkylsulfιnamoyl, (C^Jalkylsulfonyl, carboxy, nitro, sulfmamoyl, sulfo, carbamoyi, phosphono, (C,.5)alkyloxyphosphιnyl, d C^alkyloxyphosphinyl, (CLj alkanoyl, cyano, (C1.5)alkylsulfinyl, sulfamoyl, (CLj alkylsulfamoyl, d^CLsJalkylsulfamoyl, (C,.5)alkyloxysulfonyl, (C,.5), phenyl, naphthyl, pyridyl, thienyl, fury!, imidazolyl, indolyl, hydroxy, (C^sJalkyloxy, optionally halo-substituted (C,.5)alkyl, benzyl, halo, -*N(R17)3, wherein each R17 is independently (Chalky!, phenyl or benzyl, or -N(R18)2, wherein each R 8 is independently hydrogen, (C,.5)alkyl, phenyl or benzyl). More preferred compounds of Formula III are those in which R16 is a group selected from 2-furyl, 2-thienyl, 2-pyrrolyl, 2-phosholyl, 2-arsolyl, 3-pyridyl or 3-phosphorinyl (which group is optionally substituted with at least one radical selected from methylcarbamoyl, dimethylcarbamoyl, methyloxycarbonyl, methylsulfinamoyl, dimethylsulfinamoyl, methylsulfonyl, carboxy, nitro, sulfmamoyl, sulfo, carbamoyi, phosphono, methyloxyphosphinyl, dimethyloxyphosphinyl, formyl, cyano, methylsulfinyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl, methoxysulfonyl, methylsulfonimidoyl, phenyl, naphthyl, pyridyl, thienyl, furyl, imidazolyl, indolyl, hydroxy, methoxy, methyl, trifluromethyl, benzyl, halo, -*N(R17)3, wherein each R17 is independently methyl, phenyl or benzyl, or -N(R18)2, wherein each R18 is independently hydrogen, methyl, phenyl or benzyl). Generally preferred compounds of Formula III in which R16 is a group selected from Formulae (a) and (b) are those in which each n, A, B, Y, Z, R1 and R10 are as defined above with respect to preferred compounds of Formulae I, II and III.
In general, preferred cysteine protease inhibitors of the invention are those in which the absolute configuration of each chiral center present is the (S)-confιguration. However, preferred compounds of Formula I in which n is 0 are those in which the absolute configuration of chiral center to which the R7 substituent is attached is in the (/^-configuration. For example, preferred compounds of Formula I include: /V2-(4-moφholinylcarbonyl)-Λ/1-(3-phenyl-1R-phenylsulfonylpropyl)-L-phenylalaninamide (compound 1 ), Λ/2-(4-morpholinylcarbonyl)-Λ/1-(3-phenyl-1 S-phenylsulfonylpropyl)-L-phenyalaninamide
(compound 2), Λ/2-(4-morpholιnylcarbonyl)-Λ/1-(3-phenyl-1-phenylsulfonylpropyl)-L-phenylalanιnamιde (compound 3), Λ/2-(4-morpholιnylcarbonyl)-/V1-(3-phenyl-1-benzylsulfonylpropyl)-L-leucιnamιde (compound 4), Λ^^-morpholinylcarbony -rV S-phenyl-l-tnfluoromethylsulfonylpropyl)- L-phenylalanmamide (compound 5), Λ/2-(4-morpholιnylcarbonyl)-Λ 1-(3-phenyl-1 -benzylsulfonylpropyl)- L-phenylalanmamide (compound 6), Λ/2-(4-morpholιnylcarbonyl)-Λ 1-(3-phenyl-1-phenylsulfonylpropyl)- L-leucmamide (compound 7), Λ/2-(4-morpholιnylcarbonyl)-Λ/1-(3-phenyl-1-fluoromethylsulfonylpropyl)- L-phenylalaninamide (compound 8), Λ/2-(4-morpholιnylcarbonyl)-Λ 1-(3-phenyl- 1 S-phenylsulfonylmethylpropyl)-L-phenylalanιamιde (compound 9), Λr?-(4-morpholιnylcarbonyl)- Λ/1-{3-phenyl-1 S-[2-(2-phenylethylsulfonyl)ethyl] propyl}-L-phenylalanιnamιde (compound 10), Λ/2-(4-morpholιnylcarbonyl)-Λ/1-{3-phenyl-1S-[2-(2-naphthylsulfonyl)ethyl]propyl}-β-(2-naphthyl)- L-alanmamide (compound 11),
L-phenylalaninamide (compound 12), Λ/2-(Λ/-benzyloxycarbonyl-β-alanyl)-Λ/1-[3-phenyl- 1 S-(2-phenylsulfonylethyl)propyl]-L-phenylalanιnamιde (compound 13), 3-{2-phenyl-1 S-[3-phenyl- 1 S-(2-phenylsulfonylethyl)propylcarbamoyl]ethylcarbamoyl}propιonιc acid (compound 14), 3-{2-naphthyl-1 S-[3-phenyl-1 S-(2-phenylsulfonylethyl)propylcarbamoyl] ethylcarbamoyl}propιonιc acid (compound 15), Λ/2-(4-morpholιnylcarbonyl)-/V1-{3-pheny!-1 S-[2-(2-naphthylsulfony l)ethyl]propyl}- L-tyrosinamide (compound 16), methyl 3-{2-phenyl-1 S-[3-phenyl- 1 S-(2-phenylsulfonylethyl)propylcarbamoyl]ethylcarbamoyl}propιonate (compound 17), Λ^-(4-morpholιnylcarbonyl)-Λ 1-[3-phenyl-1 S-(2-phenylsulfonylethyl)propyl]-L-phenylalanιnamιde (compound 18), Λ 2-(β-alanyl)-Λ 1-[3-phenyl-1S-(2-phenylsulfonylethyl) propyl]-L-phenylalanιnamιde (compound 19), and 5-phenylsulfonyl-3S-{Λ/-[Λ/-(Λ/-acetyl-L-tyrosyl)-L-valyl]-L-alanylamιno}valeπc acid (compound 20) Preferred compounds of Formula II include ethyl 4S-(Λ/-benzylsulfonyl- β-(2-naphthyl)-L-alanylamιno)-6-phenylhexanoate (compound 21 ), ethyl 4S-(Λ/-benzylcarbamoyl- β-(2-naphthyl)-L-alanylamιno)-6-phenylhexanoate (compound 22), ethyl
4S-[Λ/-(4-morpholιnylcarbonyl)-β-2-(naphthyl-L-alanylamιno]-6-phenylhexanoate (compound 23), ethyl 4S-(Λ/-benzylcarbamoyl-L-phenylalanylamιno)-6-phenylhexanoate (compound 24), ethyl 4S-[Λ/-(4-morpholιnylcarbonyl)-L-phenylalanylamιno]-6-phenylhexanoate (compound 25), Λ/2-(4-morpholιnylcarbonyl)-Λ/'-[3-phenyl-1 S-(2-phenylcarbamoylethyl)propyl]-L-phenylalanιnamιde (compound 26), and Λ/^-morpholinylcarbonylHV-β-phenyl-l S-(2-benzylcarbamoylethyl)propyl]- L-phenylalanmamide (compound 27) Preferred compounds of Formula III include Λ/2-(4-morpholιnylcarbonyl)-Λ 1'{3-phenyl-1S-[2-(4-methoxyphenyl)ethyl]propyl}-L-phenylalanιnamιde (compound 28), and Λ/2-(4-morpholιnylcarbonyl)-ΛT"{3-phenyl-1S-[2-(4-amιnophenyl)ethyl]propyl}- L-phenylalanmamide (compound 29)
As will be appreciated by those in the art, Formula I includes structures represented by preferred
Species IV as depicted below.
wherein M is zero, one or two carbon atoms, A-B are as defined above, R\ R2, R7 and R8 are as defined above, and Q is NH or CH2. Preferred embodiments utilize A-B linkages which contain nitrogen at the B position. In this embodiment, the number of carbon atoms between the carbon to which the R8 group is attached and the sulfur atom of the sulfone group determines whether the compound is an α-amιnosulfone, a β-aminosulfone, or a γ-aminosulfone. As is discussed below in the Examples, compounds may be named as aminosulfones using the names of the amino acids or using the chemical names.
Thus, for example, Species V is an α-aminosulfone:
Species VI is a β-aminosulfone:
Species VII is a γ-aminosulfon
Formula II includes structures of Species VIII, referred to as γ-amino groups, particularly when R9 is an electron withdrawing group:
VIII
In a preferred embodiment, the dissociation constant for inhibition of a protease with an inhibitor of the invention, generally referred to by those in the art as K,, is at most 100 μM. By the term "binding constant" or "dissociation constant" or grammatical equivalents herein is meant the equilibrium dissociation constant for the reversible association of inhibitor with enzyme. The dissociation constants are defined and determined as below.
The determination of dissociation constants is known in the art. For example, for reversible inhibition reactions such as those of the present invention, the reaction scheme is as follows:
Equation 3
E + I * E k
The enzyme and the inhibitor combine to give an enzyme-inhibitor complex, E-l This step is assumed to be rapid and reversible, with no chemical changes taking place; the enzyme and the inhibitor are held together by non-covalent forces In this reaction, k, is the second order rate constant for the formation of the E-l reversible complex k2 is the first order rate constant for the disassociation of the reversible E-l complex In this reaction, K, = k2/k,
The measurement of the equilibrium constant K* proceeds according to techniques well known in the art, as described in the examples For example, assays generally use synthetic chromogenic or fluorogenic substrates
The respective K, values may be estimated using the Dixon plot as described by Irwin Segel in Enzyme Kinetics1 Behavior and analysis of rapid equilibrium and steady-state enzyme systems, 1975, Wiley-lnterscience Publication, John Wiley & Sons, New York, or for competitive binding inhibitors from the following calculation
Equation 4
1-(v/v0) = [l]/([l] + K,(1+([S]/KM)))
wherein v0 is the rate of substrate hydrolysis in the absence of inhibitor, and v, is the rate in the presence of competitive inhibitor.
It is to be understood that dissociation constants are a particularly useful way of quantifying the
efficiency of an enzyme with a particular substrate or inhibitor, and are frequently used in the art as such If an inhibitor exhibits a very low K*. it is an efficient inhibitor Accordingly, the cysteine protease inhibitors of the present invention have dissociation constants, K,, of at most about 100 μM Preferred embodiments have inhibitors that exhibit dissociation constants of at most about 10 μM, with the most preferred embodiments having dissociation constants of at most about 1 μM
CHEMISTRY
The synthesis of the inhibitors of the invention proceeds as follows Compounds of Formula I in which X represents a bond can be prepared by the process depicted in Scheme 1 of Figure 1
Treatment of fert-butylcarbamate or benzyl carbamate with an appropriate aldehyde, such as isobutyraldehyde or hydrocinnamaldehyde, along with the sodium salt of a suitable sulfinic acid, such as benzenesulfmic acid (Aldrich Chemical Co ), in the presence of aqueous formic acid affords the corresponding N-protected ammomethyl sulfone Benzyloxycarbonyl protected ammomethyl sulfones are deprotected with hydrogen bromide in acetic acid Coupling with a suitable N-protected am o acid or peptide or a peptidomimetic derivative thereof affords a compound of Formula I in which X represents a bond Alternatively, an appropriate N-termmal protected ammo acid or peptide of peptidomimetic derivative thereof, such as N-(4-morpholιnylcarbonyl)phenylalanιnamιde, is reacted with an appropriate aldehyde along with the sodium salt of a suitable sulfinic acid, in the presence of aqueous formic acid to afford a compound of Formula I in which X represents a bond
Compounds of Formula 1 in which X represents a methylene bond can be prepared by the processes depicted in Schemes 2 and 3, Figures 2 and 3, respectively
Treatment of a suitable N-protected am o acid or peptidomimetic derivative thereof with sodium borohydπde affords the corresponding β-ammoethanol Treatment of the alcohol with methanesulfonyl chloride in the presence of tnethylamine affords the corresponding mesylate Nucleophi c displacement with the anion of a thiol, such as thiophenol, according to the method of Spaltenstein, A , Carpion, P , Miyake, F , and Hopkmgs, P B , J Org Chem (1987) 52, 3759, affords the corresponding β-ammosulfide The sulfide is oxidized by means of 4-chloroperbenzoιc acid to give the corresponding N-protected β-ammoethyl sulfone In a special instance, the mesylate is treated with thiolate ion such as that derived from 2-(trιmethylsιlyl)ethanethιol, the synthesis of which is described by Anderson, M B , Ranas ghe, M B , Palmer, J T , Fuchs, P.L , J Org Chem (1988) 53, 3125, to give the corresponding β-ammoethyl 2-trιmethylsιlylethyl sulfide The 2-tnmethylsιlylethyi sulfide is reduced to the corresponding β-ammoethyl 2-tπmethylsιlylethyl sulfone, which is then subjected to fluoride-mediated cleavage, extruding tπmethylsilyl fluoride and ethene as gaseous by-products, and
an intermediate sulfmate, which sulfmate is alkylated in situ with an appropriate halogen-containing species such as bromochloromethane to give the corresponding N-protected β-aminoethyl halomethyl sulfone The N-protected β-aminoethyl sulfones are deprotected and then coupled with a suitable N-protected ammo acid or peptide or a peptidomimetic derivative thereof to afford a compound of Formula I in which X is methylene
Compounds of Formula II and Formula I in which X represents ethylene can be prepared by the processes depicted in Equations 5, 6 and 7
Equation 5
wherein a) is a) CI-H2N+(Me)OMe, dicyclohexylcarbodiimide, tπethylamine, and b) lithium aluminum hydride
Equation 6
Equation 7
An appropriate N-tert-butoxycarbonyl ammo acid or peptidomimetic derivative thereof is converted to the corresponding ammomethyl aldehyde (e g , see method of Fehrentz, J-A and Castro, B (Synthesis, (1983), 676, Equation 5) The aldehyde is converted to the corresponding vmylogous compound via aWittig reaction or a Wadsworth-Emmons-Horner modification of the Wittig reaction (e g , see Wadsworth et al , J Amer Chem Soc 83 1733 (1991), Equation 6) The vmylogous compound is reduced by catalytic hydrogenation (e g , see Equation 7) and then deprotection and coupling with a suitable N-protected ammo acid or peptide or a peptidomimetic derivative thereof gives
the corresponding compound of Formula I or II Alternatively, the vmylogous compound is deprotected and coupled with the N-protected am o acid or peptide or a peptidomimetic derivative thereof to give the corresponding vmyloguous condensation product, which is then reduced to give the corresponding compound of Formula I or II
Compounds of Formula II can be prepared by the processes depicted in Scheme 4, Figure 4
Preferably, the conversion of N-tert-butoxycarbonyl ammo acid or peptidomimetic derivative thereof to the corresponding ammomethyl aldehyde is carried out with N,0-dιmethylhydroxylamιne hydrochloπde in the presence of tπethylamine and dicyclohexylcarbodiimide in dicloromethane Alternatively, the conversion is carried out by treating the ammo acid or peptidomimetic derivative with tπethylamine and the coupling agent benzotπazol-1-yloxytπs(dιmethylamιno)phosphonιum hexafluorophosphate (BOP) and then reducing with lithium aluminum hydride to give the corresponding aldehyde (e g , see methos of Fehrentz, J-A and Castro, B , Synthesis, (1983), 676-678) The conversion of the aldehyde to the corresponding vmylogous ester can be carried out with the sodium anion of tπethyl phosphonoacetate Deprotection of the vmylogous ester can be carried out with hydrogen chloride in dioxane The hydrogenation is typically carried out in the presence of palladium
Compounds of Formula I in which X is ethylene are conveniently prepared by the process depicted in Scheme 5, Figure 5
Treatment of a suitable N-tert-butoxycarbonyl-α-ammoaldehyde, prepared as described in Equation 5, with the sodium anion of an appropriate sulfonylmethanephosphonate (SMP) (e g, diethyl phenylsulfonylmethanephosphonate, diethyl 2-naphthylsulfonylmethane-phosphonate, diethyl methylsulfonylmethanephosphonate, etc ) gives the corresponding vmylogous sulfone The sulfone is deprotected with anhydrous p-toulenesulfonic acid in ether and then coupled with N-protected ammo acid or peptide or a peptidomimetic derivative thereof to give the corresponding vmyloguous condensation product, which is then reduced to give the corresponding compound of Formula I Suitable arylsulfonylmethanephsophonates can be prepared by treating arylthiols with paraformaldehyde in the presence of hydrogen chloride and reacting with tnethyl phosphite to give the corresponding diethyl phsophonomethyl aryl sulfide and then oxidizing the sulfide Alternatively, suitable sulfides can be obtained commercially (e g , diethylphosphonomethyl methyl sufide obtained from Aldrich Chemical Co , diethylphosphonomethyl phenyl sulfide, etc ) and oxidized to their corresponding sulfones
Compounds of Formula II in which R9 is -COOH can be prepared by the process depicted in Scheme 6, Figure 6
28
Generally, saponification of a compound of Formula II in which R9 is -COOR10 results in the cooresponding carboxylate, which upon treatment with acid gives the corresponding carboxylic acid.
Compounds of Formula II in which R9 is -P(O)(R10)2 can be prepared as depicted in Scheme 7 (Figure 7) by proceeding as in Scheme 6, but substituting for the SMP the sodium anion of an appropriate methylenediphosphonate (e.g., tetraethyl methylenediphosphonate, etc.)
Compounds of Formula II in which R9 is -C(0)NHR14 can be prepared as depicted in Scheme 8 (Figure 8) by proceeding as in Scheme 5, but substituting for the SMP an appropriate diethyl amidomethylenephsophonate (e.g , diethyl benzylamidomethylenephosphonate, etc.).
Suitable amidomethylenephosphonates can be prepared by reacting the saponification product of tnethyl phosphonoacetate with an appropriate amme Altenatively, compounds of Formula II in which R9 is -C(0)NHR14 can be prepared by reacting a compound of Formula I in which R9 is -COOH with an appropriate amme For example, the reaction can be carried out in the presence of dicyclohexylcarbodiimide in dichloromethane or by any other peptide coupling reaction sequences known to those of skill in the art.
In general, compounds of Formula II can be prepared by the process depicted in Scheme 9 (Figure 9) and substituting the starting materials represented by Structures l-VII
Structure I
Synthesis of ketones is performed by means of the Wadsworth-Emmons reaction between Boc-α- ammo aldehydes and the appropriate phosphonate, followed by catalytic reduction with hydrogen in the presence of palladium. Generally, the aldehyde portion is synthesized as outlined above. The phosphonate, if not commercially available, is synthesized by treatment of the enolate anion of methyl or substituted methyl ketones, such as acetone or acetophenone, with diethyl chlorophosphonate. The enolate anion is generated, for example, by treatment of a tetrahydrofuran solution of diisopropylamine with butyllithium, followed by addition of the ketone to the lithium diisopropylamide (LDA) solution (H.O. House, Modern Synthetic Reactions, 2nd Ed. (W. Benjamin, Inc., Menlo Park, CA, Chapter 9). Following formation of the enolate, diethyl chlorophosphonate is added. The Wadsworth-Emmons reagent forms as a consequence of coupling of the enolate with diethyl chlorophosphate.
For the synthesis of cysteine protease inhibitors with nitπles as the EWG, structure II is used
Structure II
Synthesis of nitπles is performed by means of the Wadsworth-Emmons reaction between Boc-α- ammo aldehydes and the appropriate phosphonate, followed by hydrogenation in the presence of a suitable catalyst Generally, the aldehyde portion is synthesized as outlined above The phosphonate is commercially available
For the synthesis of cysteine protease inhibitors with sulfoxides as the EWG, structure III is used
Structure III
Synthesis of sulfoxides is performed by means of the Wadsworth-Emmons reaction between Boc-α- ammo aldehydes and the appropriate phosphonate, followed by hydrogenation in the presence of a suitable catalyst Generally, the aldehyde portion is synthesized as outlined above The phosphonate is synthesized by treatment of the anion of methyl sulfoxides with diethyl chlorophosphate The anion is generated by addition of BuLi to diisopropylam e, followed by addition of the methyl sulfoxide
For the synthesis of cysteine protease inhibitors with sulfonamides as the EWG, structure IV is used
Structure IV
Synthesis of sulfonamides is performed by means of the Wadsworth-Emmons reaction between Boc- α-ammo aldehydes and the appropriate phosphonate, followed by hydrogenation in the presence of a suitable catalyst Generally, the aldehyde portion is synthesized as outlined above The phosphonate is synthesized, for instances, by a method such as the following a) diethylphosphoryl methanesulfonates, as prepared by the method of Carretero and Ghosez (Tetrahedron Lett , 28 1104- 1108 (1987)), are converted to sulfonyl chlorides by treatment with phosphorus pentachloπde (M Quaedvlieg, in "Methoden der Organische Chemic (Houben-Weyl)", ed. E. Muller, Thieme Verlag, Stuttgart, 4th Ed., 1955, Vol. IX, Chapter 14), or b) treatment of the sulfonyl chloride with an amme,
such as ammonia, a primary amme (including an am o acid derivative), or a secondary amine, that results in the formation of the sulfonamide (Quaedvlieg, supra, Chapter 19) The sulfonamide- phosphonate is then reacted with Boc-α-amιnoaldehydes to form the target compounds as per the Wadsworth-Emmons reaction
For the synthesis of cysteine protease inhibitors with sulfinamides as the EWG, structure V is used
Structure V
Synthesis of sulfinamides is performed by means of the Wadsworth-Emmons reaction between Boc-α- amino aldehydes and the appropriate phosphonate, followed by hydrogenation in the presence of a suitable catalyst Generally, the aldehyde portion is synthesized as outlined above The phosphonate may be synthesized using one of the following methods Treatment of methyl dialkyl phosphonates such as the commercially available methyl diethyl phosphonate (Aldrich), with thionyl chloride in the presence of aluminum chloride gives the dialkylphosphoryl methanesulfinyl chloride (Vennstra ef al , Synthesis (1975) 519 See also Anderson, "Comprehensive Organic Chemistry (Pergamon Press)", Vol 3, Chapter 11 18, (1979) Alternatively, treatment of the dialkyl phosphoryl sulfinyl chloride with amines (Stirling, Internat J. Sulfur Chem (B) 6.277 (1971)), yields the dialkyl phosphoryl sulfinamide
For the synthesis of cysteine protease inhibitors with sulfoximines as the EWG, structure VI is used
Structure VI
Synthesis of sulfoximines is performed by means of the Wadsworth-Emmons reaction between Boc-α- ammo aldehydes and the appropriate phosphonate, followed by hydrogenation in the presence of a suitable catalyst. Generally, the aldehyde portion is synthesized as outlined above The phosphonate may be synthesized in several ways. For example, N-alkyl or N-aryl phenyl methyl sulfoximines are made by the methods described by Johnson, in "Comprehensive Organic Chemistry (Pergamon Press), supra, Chapter 11.11. Alternatively, the lithium anion of compounds such as N-alkyl phenyl methyl sulfoximine is prepared by the treatment of the neutral compound with buthyl lithium in THF (Cram ef al., J. Amer. Chem. Soc. 92:7369 (1970)). Reaction of this lithium anion with dialkyl chlorophosphates such as the commercially available diethyl chlorophosphate (Aldrich) results in the
Wadsworth-Emmons reagent necessary for synthesis of the sulfoximme compounds
For the synthesis of cysteine protease inhibitors with sulfonates as the EWG, structure VII is used
Structure VII
Synthesis of sulfonates is performed by means of the Wadsworth-Emmons reaction between Boc-α- ammo aldehydes and the appropriate phosphonate, for instance diethylphosphoryl methanesulfonate, followed by hydrogenation in the presence of a suitable catalyst, such as Raney nickel The phosphonate may be synthesized as follows The anion of methyl dialkyl phosphonates such as the commercially available methyl diethyl phosphonate (Aldrich) is generated by treatment of said phosphonate with a strong base such as LDA The resulting anion is sulfonated with sulfur tπoxide/trimethylamine complex (Carreto ef al , Tetrahedron Lett , 28 1104-1108 (1987)) to form diethylphosphoryl methanesulfonate, which is capable of reacting in the Wadsworth-Emmons procedure with aldehydes to form α,β-unsaturated sulfonates
Compounds of Formula II can be prepared by the process depicted in Scheme 10 (Figure 10)
The chloride compounds containing R8 and R9 groups are generally made using commercially available reagents and products using techniques well known in the art The reaction generally produces a mixture of cis and trans configurations, favoring the trans isomer Upon reduction to the cysteine protease inhibitors of this embodiment, the cis-trans isomeπsm disappears by definition as a single compound is formed
In one embodiment, the cysteine protease inhibitors of the invention are further purified if necessary after synthesis, for example to remove unreacted materials For example, the cysteine protease inhibitors of the present invention may be crystallized, or passed through silica chromatography columns using solvent mixtures to elute the pure inhibitors
In summary, the processes for preparing compounds of the invention are as follows (A) for the preparation of Formula IV
IV
in which n is 0 to 12, R20 is cyano, -S(0)2R2, -CH2S(0)2R2, -CH2CH(R4)S(0)2R2, -(CH2)2C(0)OR10, -(CH2)2P(O)(OR10)2, -(CH2)2S(O)(NR10)R10, -CH2)2C(0)R11, -(CH2)2S(0)R11, -(CH2)2C(0)NR12R13, -(CH2)2S(0)2NR12R13, -(CH2)2C(0)NHR14, -(CH2)2S(0)2NHR14 or -CH2CHR15R16 and each A, B, X, Y, Z, R1, R8 R1, R8, R2, R10, R11, R12, R13, R14, R15 and R16 are as defined in the Summary of the Invention with respect to compounds of Formulae I, II and III, and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, reacting an amme of Formula V
with a compound of the Formula VI
VI
in which each n, A, B, X, Y, Z, R1, R8 and R20 are as defined above, (B) for the preparation of a compound of Formula IV in which R20 is -S(0)2R2, and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, reacting a compound of Formula VII
VII
with an aldehyde of the formula R8CHO and a sodium sulfmate of the formula R2S(0)ONa, in which each n, A, B, X, Y, Z, R1 and R8 are as defined above,
(C) for the preparation of a compound of Formula IV in which R20 is -S(0)2R2, and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof,
(1) reacting a compound of the formula NH2P, wherein P is a protective group, with an aldehyde of the formula R8CHO and a sodium sulfinate of the formula R2S(0)ONa and then deprotecting to give a compound of Formula VIII
H2N S(0) 2R
in which each R2 and R8 are as defined in the Summary of the Invention with respect to Formula I; and (2) reacting the compound of Formula VIM with a compound of Formula VI in which each n, A, B, X, Y, Z and R1 are as defined above;
(D) for the preparation of a compound of Formula IV in which R20 is -CH2S(0)2R2 and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, (1) reacting a compound of Formula IX:
with a thiolate anion of the formula R2S", in which L is a leaving group R2 and R8 are as defined above, to give a compound of Formula X:
(2) oxidizing the compound of Formula X to give a compound of Formula XI:
, S(0) 2R- PHN ' ^*-' and
(3) reacting the compound of Formula XI with a compound of Formula VI in which each n, A, B, X, Y, Z and R are as defined above;
(E) for the preparation of a compound of Formula IV in which R20 is cyano, -(CH2)2S(0)2R2, -(CH2)2C(0)OR10, -(CH2)2P(O)(OR10)2, -(CH2)2S(O)(NR10)R10, -(CH2)2C(0)R11, -(CH2)2S(0)R11, -(CH2)2C(0)NR1 R13, -(CH2)2S(0)2NR1 R13, -(CH2)2C(0)NHR14or -(CH2)2S(0)2NHR14, and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof,
(1) reacting an aldehyde of Formula XII:
with a compound selected from Formulae XIII and XIV:
in which each R8 and R20 are as defined above, and then deprotecting to give a
compound of Formula XV
XV
(2) reacting the compound of Formula XV with a compound of Formula VI in which each n, A, B, X, Y, Z and R1 are as defined above, and
(3) reducing,
(F) for the preparation of a compound of Formula IV in which R20 is -CH2CHR15R16 and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, (1 ) reacting an aldehyde of Formula XII with compound of Formula XVI
XVI
in which each R8, R 5 and R16 are as defined above, and then deprotectmg to give a compound of Formula XVII
XVII
(2) reacting the compound of Formula XVII with a compound of Formula VI in which each n, A, B, X, Y, Z and R1 are as defined above, and
(3) reducing,
(G) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt,
(H) optionally further converting a salt form of a compund of Formula IV into non-salt form; and (H) optionally further separating a compound of Formula IV into individual stereoisomers
In one embodiment, the cysteine protease inhibitors of the present invention are labelled. By a "labelled cysteine protease inhibitor" herein is meant a cysteine protease inhibitor that has at least one element, isotope or chemical compound attached to enable the detection of the cysteine protease inhibitor or the cysteine protease inhibitor bound to a cysteine protease. In general, labels fall into three classes: a) isotopic labels, which may be radioactive or heavy isotopes; b) immune labels, which
may be antibodies or antigens, and c) colored or fluorescent dyes The labels may be incorporated into the cysteine protease inhibitor at any position For example, a label may be attached as the "R1" group in Formula 1 , or a radioisotope incorporated into any position Examples of useful labels include 14C, 3H, biotm, and fluorescent labels as are well known in the art
PHARMACOLOGY AND UTILITY
Once produced, the cysteine protease inhibitors of the present invention may be easily screened for their inhibitory effect The inhibitor is first tested against the cysteine protease for which the targeting group of the inhibitor was chosen, as outlined above Alternatively, many cysteine proteases and their corresponding chromogenic substrates are commercially available Thus, a variety of cysteine proteases are routinely assayed with synthetic chromogenic substrates in the presence and absence of the cysteine protease inhibitor, to confirm the inhibitory action of the compound, using techniques well known in the art The effective inhibitors are then subjected to kinetic analysis to calculate the K, values and the dissociation constants determined
If a compound inhibits at least one cysteine protease, it is a cysteine protease inhibitor for the purposes of the invention Preferred embodiments have inhibitors that exhibit the correct kinetic parameters against at least the targeted cysteine protease
In some cases, the cysteine protease is not commercially available in a purified form The cysteine protease inhibitors of the present invention may also be assayed for efficacy using biological assays For example the inhibitors may be added to cells or tissues that contain cysteine proteases, and the biological effects measured
In one embodiment, the cysteine protease inhibitors of the present invention are synthesized or modified such that the in vivo and in vitro proteolytic degradation of the inhibitors is reduced or prevented Generally, this is done through the incorporation of synthetic ammo acids, derivatives, or substituents into the cysteine protease inhibitor Preferably, only one non-naturally occurring am o acid or am o acid side chain is incorporated into the cysteine protease inhibitor, such that the targeting of the inhibitor to the enzyme is not significantly affected However, some embodiments that use longer cysteine protease inhibitors containing a number of targeting residues may tolerate more than one synthetic derivative In addition, non-naturally occurring ammo acid substituents may be designed to mimic the binding of the naturally occurring side chain to the enzyme, such that more than one synthetic substituent is tolerated Alternatively, peptide isosteres are used to reduce or prevent inhibitor degradation
In this embodiment, the resistance of the modified cysteine protease inhibitors may be tested against a variety of known commercially available proteases in vitro to determine their proteolytic stability Promising candidates may then be routinely screened in animal models, for example using labelled inhibitors, to determine the in vivo stability and efficacy
Specific cysteine proteases that may be inhibited by the inhibitors of the present invention are those of the family of cysteine proteases that bear a thiol group at the active site These proteases are found in bacteria, viruses, eukaryotic microorganisms, plants, and animals Cysteine proteases may be generally classified as belonging to one of four or more distinct superfamilies Examples of cysteine proteases that may be inhibited by the novel cysteine protease inhibitors of the present invention include, but are not limited to, the plant cysteine proteases such as papain, ficin, aleuram, oryzam and actmidam, mammalian cysteine proteases such as cathepsms B, H, J, L, N, S, T, O, and C, (cathepsin C is also known as dipeptidyl peptidase I), interleukm converting enzyme (ICE), calcium-activated neutral proteases, calpam I and II, bleomyαn hydrolase, viral cysteine proteases such as picornian 2A and 3C, aphthovirus endopeptidase, cardiovirus endopeptidase, comovirus endopeptidase, potyvirus endopeptidases I and II, adenovirus endopeptidase, the two endopeptidases from chestnut blight virus, togavirus cysteine endopeptidase, as well as cysteine proteases of the polio and rhinoviruses, and cysteine proteases known to be essential for parasite lifecycles, such as the proteases from species of Plasmodia, Entamoeba, Onchocera, Trypansoma, Leishmanta, Haemonchus, Dictyostelium, Thenleπa, and Schtstosoma, such as those associated with malaria (P falcipanum), trypanosomes (T cruzi, the enzyme is also known as cruzain or cruzipam), murine P vinckei, and the C elegans cysteine protease For an extensive listing of cysteine proteases that may be inhibited by the cysteine protease inhibitors of the present invention, see Rawlmgs ef al , Biochem J 290 205-218 (1993), hereby expressly incorporated by reference
Accordingly, inhibitors of cysteine proteases are useful in a wide variety of applications For example, the inhibitors of the present invention are used to quantify the amount of cysteine protease present in a sample, and thus are used in assays and diagnostic kits for the quantification of cysteine proteases in blood, lymph, saliva, or other tissue samples, in addition to bacterial, fungal, plant, yeast, viral or mammalian cell cultures Thus in a preferred embodiment, the sample is assayed using a standard protease substrate A known concentration of cysteine protease inhibitor is added, and allowed to bind to a particular cysteine protease present The protease assay is then rerun, and the loss of activity is correlated to cysteine protease activity using techniques well known to those skilled in the art
The cysteine protease inhibitors are also useful to remove or inhibit contaminating cysteine proteases in a sample For example, the cysteine protease inhibitors of the present invention are added to samples where proteolytic degradation by contaminating cysteine proteases is undesirable
Alternatively, the cysteine protease inhibitors of the present invention may be bound to a chromatographic support, using techniques well known in the art, to form an affinity chromatography column A sample containing an undesirable cysteine protease is run through the column to remove the protease
In a preferred embodiment, the cysteine protease inhibitors are useful for inhibiting cysteine proteases implicated in a number of diseases In particular, cathepsms B, L, and S, cruzain, calpains I and II, and mterleukin 1β converting enzyme are inhibited These enzymes are examples of lysosomal cysteine proteases implicated in a wide spectrum of diseases characterized by tissue degradation Such diseases include, but are not limited to, arthritis, muscular dystrophy, inflammation, tumor invasion, glomerulonephritis, parasite-borne infections, Alzheimer's disease, peπodontal disease, and cancer metastasis For example, mammalian lysosomal thiol proteases play an important role in intracellular degradation of proteins and in the processing of some peptide hormones Enzymes similar to cathepsms B and L are released from tumors and may be involved in tumor metastasis Cathepsin L is present in diseased human synovial fluid and transformed tissues Similarly, the release of cathepsin B and other lysosomal proteases from polymorphonuclear granulocytes and macrophages is observed in trauma and inflammation
The cysteine protease inhibitors also find application in a multitude of other diseases, including, but not limited to, gingivitis, malaria, leishmaniasis, filaπasis, and other bacterial and parasite-borne infections The compounds also offer application in viral diseases, based on the approach of inhibiting proteases necessary for viral replication For example, many picornoviruses including poliovirus, foot and mouth disease virus, and rh ovirus encode for cysteine proteases that are essential for cleavage of viral polyprotems
Additionally, these compounds offer application in disorders involving ιnterleukιn-1β converting enzyme (ICE), a cysteine protease responsible for processing mterleukin 1β, for example, in the treatment of inflammation and immune based disorders of the lung, airways, central nervous system and surrounding membranes, eyes, ears, joints, bones, connective tissues, cardiovascular system including the pericardium, gastrointestinal and urogenital systems, the skin and the mucosal membranes These conditions include infectious diseases where active infection exists at any body site, such as meningitis and salpmgitis, complications of infections including septic shock, disseminated mtravascular coagulation, and/or adult respiratory distress syndrome, acute or chronic inflammation due to antigen, antibody and/or complement deposition, inflammatory conditions including arthritis, chalangitis, colitis, encephalitis, endocarditis, glomerulonephritis, hepatitis, myocarditis, pancreatitis, pericarditis, reperfusion injury and vascuhtis Immune-based diseases include but are not limited to conditions involving T-cells and/or macrophages such as acute and
delayed hypersensitivity, graft rejection, and graft-versus-host disease, auto-immune diseases including Type I diabetes mellitus and multiple sclerosis Bone and cartilage reabsorption as well as diseases resulting in excessive deposition of extracellular matrix such as interstitial pulmonary fibrosis, cirrhosis, systemic sclerosis, and keloid formation may also be treated with the inhibitors of the present invention The inhibitors may also be useful in the treatment of certain tumors that produce IL 1 as an autocπne growth factor and in preventing the cachexia associated with certain tumors Apoptosis and cell death are also associated with ICE and ICE-hke activities and may be treated with the inhibitors of the present invention
Furthermore, the cysteine protease inhibitors of the present invention find use in drug potentiation applications For example, therapeutic agents such as antibiotics or antitumor drugs can be inactivated through proteolysis by endogeneous cysteine proteases thus rendering the administered drug less effective or inactive For example, it has been shown that bleomycm, an antitumor drug, can be hydrolyzed by bleomycm hydrolase, a cysteine protease (see Sebti et al , Cancer Res January 1991 , pages 227-232) Accordingly, the cysteine protease inhibitors of the invention may be administered to a patient in conjunction with a therapeutic agent in order to potentiate or increase the activity of the drug This co-administration may be by simultaneous administration, such as a mixture of the cysteine protease inhibitor and the drug, or by separate simultaneous or sequential administration
In addition, cysteine protease inhibitors have been shown to inhibit the growth of bacteria, particularly human pathogenic bacteria (see Bjorck et al , Nature 337 385 (1989)) Accordingly, the cysteine protease inhibitors of the present invention may be used as antibacterial agents to retard or inhibit the growth of certain bacteria
The cysteine protease inhibitors of the invention also find use as agents to reduce the damage of bacterial cysteine proteases to host organisms For example, staphylococcus produces a very active extracellular cysteine protease which degrades insoluble elastin, possibly contributing to the connective tissue destruction seen in bacterial infections such as septicemia, septic arthritis and otitis See Potempa et al , J Biol Chem 263(6) 2664-2667 (1988) Accordingly, the cysteine protease inhibitors of the invention may be used to treat bacterial infections to prevent tissue damage
ADMINISTRATION AND PHARMACEUTICAL COMPOSITION
In general, cysteine protease inhibitors of this invention will be administered in therapeutically effective amounts via any of the usual and acceptable modes known in the art, either singly or in combination with another cysteine protease inhibitor of the invention or with another therapeutic agent A
therapeutically effective amount may vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used and other factors. Therapeutically effective amounts of the cysteine protease inhibitors of this invention may range from 10 micrograms per kilogram body weight (μg/kg) per day to 10 milligram per kilogram body weight (mg/kg), typically 100 μg/kg/day to 1 mg/kg/day. Thus, a therapeutically effective amount for a 80 kg human may range from 1 mg/day to 1000 mg/day, typically 10 mg/day to 100 mg/day.
One of ordinary skill in the art of treating such diseases will be able, without undue experimentation and in reliance upon personal knowledge and the disclosure of this application, to ascertain a therapeutically effective amount of a cysteine protease inhibitor of this invention for a given disease.
In general, the cysteine protease inhibitors of this invention will be administered as pharmaceutical compositions by one of the following routes: oral, systemic (e.g., transdermal, intranasal, intrapulmonary, or by suppositiory) or parenteral (e.g., intramuscular, intravenous, intrapulmonary or subcutaneous). Compositions can take the form of tablets, pills, capsules, semisolids, powders, sustained release formulations, solutions, suspensions, elixiers, aerosols or any other appropriate composiiton and are comprised of, in general, a cysteine protease inhibitor of the invention in combination with at least one pharmaceutically acceptable excipient. Acceptable excipients are non-toxic, aid administration, and don not adversely affect the therapeutic benefit of the cysteine protease inhibitor of this invention. Such excipient may be any solid, liquid, semisolid or, in the case of an aerosol composition, gaseous excipient that is generally available to one of skill in the art.
Solid pharmaceutical excipients include starch, cellulose, talc, glucolse, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium sterate, glycerol monostearate, sodium chloride, dried skim milk and the like. Liguid and semisolid excipients may be selected from water, ethanol, glycerol, propylene glycol and various oils, includingthose of petroleum, animal, vegetable or synthetic origin (e.g., peanut oil, soybean oil, mineral oil, sesame oil, etc.). Preferred liquid carriers, particularly for injectable solutions, include water, saline, aqueous dextrose and glycols.
Compressed gases may be used to disperse the cysteine protease inhibitor of this invention in aerosol form. Inert gases suitable for this purpose are nitrogen, carbon dioxide, nitrous oxide, etc. Other suitable pharmaceutical carriers and their formulations are described in A.R. Alfonso Reminton's Pharmaceutical Sciences 1985, 17th ed. Easton, Pa.: Mack Publishing Company, hereby expressly incorporated by reference.
The amount of a cysteine protease inhibitor of this invention in the composition may vary widely depending upon the type of formulation, size of a unit dosage, kind of excipients and other factors
known to those of skill in the art of pharmaceutical sciences In general, the final composition will comprise from 0 1%w to 10%w of the cysteine protease inhibitor, preferably 1%w to 10%w, with the remainder being the excipient or excipients
Preferably the pharmaceutical composition is administered in a single unit dosage form for continuous teatment or in a single unit dosage form ad libitum when relief of symptoms is specifically required Representative pharmaceutical formulations containing a cysteine protease inhibitor of the invention are described in Example 20, infra
The following examples serve to more fully describe the manner of using the above-described invention, as well as to set forth the best modes contemplated for carrying out various aspects of the invention It is understood that these examples in no way serve to limit the true scope of this invention but rather are presented for illustrative purposes All references cited herein are expressly incorporated by reference
EXAMPLES
The following abbreviation conventions have been used to simplify the examples
Mu = morpho ne urea
Xaa, = ammo acid at P1 position relative to active site of the enzyme
Xaa2 = ammo acid at P2 position relative to active site of the enzyme γ-C02Et= γ-amιno ethyl ester γ-S02Ph= γ-amιnosulfone with phenyl terminus γ-C02H = γ-amιnocarboxylate γ-PEt = γ-amιnophosphonate γ-AM = γ-amιnoamιde γ-Ar(sub)= γ-amιnoaromatιc compound (substituted as appropriate) β-S02Ph= β-aminosulfone with phenyl substituent α-S02Ph= α-aminosulfone with phenyl substituent
Hph = homophenylalanine
PSMP = diethyl phenylsulfonylmethylenephosphonate
Np2 = 2-naphthylalanιne
S022Np = sulfone with 2-maphthyl terminus
Phac = phenylacetyl β-Aia = β-alanine
MeOSuc = methoxysuccinyl
For instance, Mu-Phe-Hph-β-S02Ph where Xaa2 = Phe (phenylalanine) and Xaa, = Hph (homophenylalanine,), transformed to the β-ammo phenyl sulfone according to the procedure described in the Examples
Example 1 Synthesis of Cysteine Protease Inhibitor Containing a γ-amιnoester as the EWG
Unless otherwise indicated, all reactions were performed under an inert atmosphere of argon or nitrogen at room temperature THF was distilled from sodium benzophenone ketyl All other solvents and commercially available reagents were used without further purification
Synthesis of Ethyl (S)-4-(4-morpholιnecarbonyl-phenylalanyl)-amιno-6-phenylhexanoate, abbreviated Mu-Phe-Hph-γ-C02Et, was as follows Unless otherwise noted, all reagents were obtained from Aldrich, Inc 0 393 g of a 60% mineral oil dispersion (9 82 mmol) of sodium hydride was added to a solution of tnethyl phosphonoacetate (2 20 g, 9 82 mmol) in THF (50 mL) at -10°C The mixture was stirred for 15 minutes, whereupon a solution of Boc-homophenylalanmal (Boc-HphH) (2 35 g, 9 82 mmol, prepared by conversion of Boc-homophenylalanine (Synthetech) to its N,0-dιmethylhydroxamιde, using the Fehrentz method followed by lithium aluminum hydride reduction) in THF (20 mL) was added The mixture was stirred for 45 minutes 1M HCI (30 mL) was added The product was extracted with ethyl acetate (50 mL), washed with saturated aqueous NaHC03 (30 mL) dried over MgS04, filtered, and evaporated to dryness The dried material was dissolved in CH2CI2 (10 mL), and a 4 0 M solution of HCI in dioxane (20 mL) was added The mixture was stirred for 30 minutes The solvents were removed under reduced pressure and the residue, ethyl (S)-4-amιno-6-phenyl-2-hexenoate hydrochloπde, was pumped dry
4-Morpholιnecarbonylphenylalanιne (Mu-PheOH, 2 74 g, 9 82 mmol, prepared according to the method described in Esser, R et al , Arthritis & Rheumatism (1994), 37, 236) was dissolved in THF (50 mL) at -10°C 4-methylmorpholιne (1 08 mL, 9 82 mmol) was added, followed by isobutyl chloroformate (1 27 mL, 9 82 mmol) The mixed anhydride was stirred for 10 minutes, whereupon a solution of ethyl (S)-4-amιno-6-phenyl-2-hexenoate hydrochloπde from the previous step in DMF (10 mL) was added, followed by 4-methylmorpholιne (1.08 mL, 9.82 mmol) The mixture was stirred for 1 hour 1 M HCI (50 mL) was added The product was extracted with ethyl acetate (100 mL), washed with saturated aqueous NaHC03 (50 mL), dπed over MgS04 and decolorizing charcoal (DARCO), filtered, and evaporated to dryness, giving 3 80 g of intermediate (80% yield from Boc-homo- phenylalanmal)
To a solution of this intermediate (1 45 g, 3 09 mmol) in ethanol (25 mL) was added 5% palladium on active carbon (0 5 g) The mixture was reduced on a Parr hydrogenator for 36 hours The solution was filtered and the solvent was removed under reduced pressure, giving 1 19 g (82%) of the product
Thin-layer chromatography (TLC) was performed on each sample Visualization was accomplished by means of UV light at 254 nm, followed by ninhydnn, bromocresol green, or p-anisaldehyde stain The retention factor (RO of the Mu-Phe-Hph-γ-C02Et was 0 35 (5% MeOH/CH2CI2)
NMR spectra were recorded on a Vaπan Gemini 300 MHz instrument All 1H NMR data of this and subsequent examples are reported as delta values in parts per million relative to internal tetramethylsilane, peak assignments in boldface The following abbreviations are used s, singlet, d, doublet, t triplet, q, quartet, br, broad An asterisk (*) implies that a signal is obscured or buried under another resonance
Example 2
Synthesis of a Cysteine Protease Inhibitor containing a γ-amιnosulfone as the EWG
Synthesis of (S)-3-tert-butoxycarbonylamιno-5-phenyl-1-pnenylsulfonylpentane (Boc-Hph-γ-S02Ph) To a solution of PSMP (8 87 g, 30 34 mmol) in THF (150 mL) at 0°C was added sodium hydride (1 21 g of a 60% mineral oil dispersion) The mixture was stirred for 20 minutes, whereupon a solution of Boc-homophenylalaninal, synthesized by the method of Fehrentz and Castro, above, (7 99 g, 30 34 mmol) in THF (20 mL) was added The solution was stirred for 30 minutes at 0°C 1M HCI (100 mL) was added The product was extracted into ethyl acetate (100 mL), washed with saturated aqueous sodium bicarbonate (100 mL), brine (50 mL), dried over MgS04 filtered, and the solvent was removed under reduced pressure The residue was dissolved in ethanol (100 mL) and transferred to a Parr bottle charged with 5% palladium on active charcoal (0 92 g) The mixture was reduced on a Parr apparatus for 24 hours The solution was filtered through Celite and the solvent was removed under reduced pressure TLC of the product indicated a single product in quantitative yield, R, = 0 29 (30% ethyl acetate/hexane) that stained white with paraanisaldehyde spray
Example 3
Synthesis of a Cysteine Protease Inhibitor containing a γ-amιnosulfone as the EWG
Synthesis of (S)-3-amιno-5-phenyl-1-phenylsulfonyl-pentane hydrochloπde (HCI Hph-γ-S02Ph) To a solution of Boc-Hph-γ-S02Ph (12 24 g, 30 34 mmol) in dichloromethane (20 mL) was added hydrogen chloride in dioxane (50 mL of a 4 0M solution) The mixture was stirred for 90 minutes The solvent was removed under reduced pressure, and the residue was dissolved in CH2CI2 (50 mL) The solution
was carefully added to ether (500 mL) with stirring The solid was filtered, washed with ether (50 mL) and dried in vacuo
Example 4
Synthesis of a Cysteine Protease Inhibitor containing a γ-amιnosulfone as the EWG
Synthesis of (S)-3-(4-morpholιnecarbonylphenylalanyl)-amιno-5-phenyl-1 -phenylsulfonylpentane (Mu- Phe-Hph-γ-S02Ph) To a solution of Mu-PheOH (2 94 g, 10 56 mmol) in THF (75 mL) at -10°C were added 4-methylmorpholιne (1 16 mL, 10 56 mmol) and isobutyl chloroformate (1 37 mL, 10 56 mmol) The mixture was stirred for 5 minutes (S)-(E)-3-amιno-5-phenyl-1-phenylsulfonyl-1-pentene p- toluenesulfonate, synthesized by Wadsworth-Emmons condensation between Boc- homophenylalaninal and p-toluenesulfonic acid deprotection (5 00 g, 10 56 mmol) was added, followed by 4-methylmorpholιne (1 16 mL, 10 56 mmol) The mixture was stirred for 45 minutes The solution was diluted with ethyl acetate (100 mL), washed with 1 M HCI (2x50 mL), saturated aqueous sodium bicarbonate (50 mL), brine (50 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure The residue was crystallized from CH2CI2/ether to give 4 27 g (72%) of intermediate 1 17 g of this material (2 08 mmol) was dissolved in ethanol (25 mL) The solution was transferred to a Parr bottle charged with 5% palladium on active charcoal (0 30 g) The mixture was hydrogenated at room temperature overnight on a Parr shaker Ethyl acetate was added to the suspension of product, which had crystallized from the reaction mixture 1 he solution was filtered and concentrated in vacuo, and then was recrystallized from CH2CI2/hexane M p = 176-178°C TLC (50% ethyl acetate/CH2CI2) R, = 0 24
Example 5
Synthesis of a Cysteine Protease Inhibitor containing a γ-amιnosulfone as the EWG
Synthesis of (S)-3-(4-morpholιnecarbony Ity rosyl)-amιno-5-phenyl-1 -phenylsulfonylpentane (Mu-Tyr- Hph-γ-S02Ph) To a solution of 4-morpholιnecarbonyltyrosιne (Mu-TyrOH, synthesized according to the method described in Esser, R et al , Arthritis & Rheumatism (1994), 37, 236, 0 50 g, 1 70 mmol) in THF (10 mL) at -10°C were added 4-methylmorpholιne (0 187 mL, 1 70 mmol) and isobutyl chloroformate (0.220 mL, 1 70 mmol) After 5 minutes, HCI Hph-γ-S02Ph (0 577 g, 1 70 mmol, descπbed in Example 3) was added, followed by 4-methylmorpholιne (0 187 mL, 1 70 mmol) The mixture was stirred for 45 minutes Ethyl acetate (50 mL) was added The solution was washed with 1M HCI, saturated aqueous sodium bicarbonate, and brine (30 mL each), dried over MgS04, filtered, and the solvent was removed under reduced pressure The residue was precipitated from C^CIj ether to give 0.58 g (59%) of Mu-Tyr-Hph-γ-S02Ph M p 104-107°C TLC (10% Me0H/CH2CI2) R, = 0 59
Example 6
Synthesis of a Cysteine Protease Inhibitor containing a γ-amιnosulfone as the EWG
Synthesis of (S)-3-(4-morphlιnecarbonyl-2-naphthyl-alanyl)amιno-5-pheny 1-1 -(2- naphthylsulfonyl)pentane (Mu-Np2-Hph-γ-S022Np) 2-naphthalenethιol (9 64 g, 60 16 mmol) was dissolved in toluene (75 mL) Paraformaldehyde (3 97 g, 132 mmol) and HCI/dioxane (33 mL of a 4 0M solution) were added The mixture was stirred for several days at room temperature The solvent was removed under reduced pressure, and the residue was suspended in hexane (200 mL), dried over MgS04, filtered, and evaporated to dryness This material, crude chloromethyl 2-naphthyl sulfide, was combined with tnethyl phosphite (10 93 g, 65 mmol) and was heated at reflux for 4 hours The mixture was cooled to room temperature, diluted with ether (200 mL), washed with 1M HCI, saturated aqueous sodium bicarbonate, and brine (150 mL each), dried over MgS04, filtered, and concentrated in vacuo to give 17 35 g (93% crude yield) of diethyl 2-naphthylthιomethylene phosphonate This material was dissolved in CH2CI2 (300 mL) and cooled to 0°C Peracetic acid (23 5 mL of a 32% dilute acetic acid solution (Aldrich Chemical Co ) was carefully added The mixture was stirred overnight while warming to room temperature The solution was washed with freshly prepared, saturated aqueous sodium bisulfite solution (100 mL), then with several portions of saturated aqueous sodium bicarbonate, until the aqueous phase became basic The organic phase was dried over MgS04, filtered, and the solvent was removed under reduced pressure Chromatography on 60-200 mesh silica gel (0-10% ethyl acetate'CH2CI2) afforded 6 5 g (34%) of the pure Wadsworth-Emmons reagent, diethyl 2-naphthylsulfonyl-methylene phosphonate along with an approximately equal mass of impure material TLC (20% ethyl acetate/CH2CI2) R, = 0 37
To a solution of diethyl 2-naphthylsulfonylmethylene phosphonate (3 91 g, 11 42 mmol) in THF (60 mL) at 0°C was added sodium hydride (0 457 g of a 60% mineral oil dispersion The mixture was stirred for 15 minutes, whereupon a solution of Boc-homophenylalanmal (3 00 g, 11 42 mmol) in THF (5 mL) was added The mixture was stirred for 30 minutes 1 M HCI (100 mL) was added The product was extracted with ethyl acetate (100 mL), washed with saturated aqueous sodium bicarbonate (75 mL), brine (50 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure The residue was dissolved in dichloromethane (10 mL), to which was added HCI/dioxane (25 mL of a 4 0M solution) The mixture was stirred at room temperature for 1 hour, poured into ether (300 mL), and filtered The solids were washed with ether (2x50 mL) and dried in vacuo to give 3 30 g (74% from Boc-homophenylalanmal) of (S)-(E)-3-amιno-5-phenyl-1-(2- naphthylsulfonyl)-1-pentene
To a solution of Boc-2-naphthylalanιne (2 68 g, 8 51 mmol, (Synthetech, Oregon) in THF (50 mL) at - 10°C were added 4-methylmorpholιne (0.936 mL, 8 51 mmol) and isobutyl chloroformate (1 103 mL,
8 51 mmol) The mixture was stirred for 5 minutes, whereupon (S)-(E)-3-amιno-5-phenyl-1-(2- naphthylsulfonyl)-1-pentene (3 30 g, 8 51 mmol) was added, followed by 4-methylmorpholιne (0 936 mL, 8 51 mmol) The mixture was stirred for 45 minutes, diluted with ethyl acetate (100 mL), washed with 1M HCI (50 mL), saturated aqueous sodium bicarbonate (50 mL), and brine (50 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure The intermediate, (S)-(E)-3- (tert-butoxycarbonyl-2-naphthylalanyl)amιno-5-phenyl-1-(2-naphthylsulfonyl)-1-pentene, was crystallized from a suitable mixture CH2CI2/ether/hexane in 69% yield The resulting material (3 83 g, 5 90 mmol) was dissolved in CH2CI2 (5 mL) and was treated with HCI/dioxane (15 mL of a 4 0M solution The mixture was stirred at room temperature for 1 hour The solution was poured, with stirring, into ether (500 mL) and filtered The solids were washed with ether (2x50 mL) and dried in vacuo to give the intermediate, (S)-(E)-3-(2-naphthylalanyl)-amιno-5-phenyl-1-(2-naphthylsulfonyl)-1- pentene 3 41 g, 99% yield
2 00 g of this material (3 42 mmol) was dissolved in THF (15 mL), and cooled to 0°C 4- methylmorpholine-carbonyl chloride (0 400 mL, 342 mmol) and tπethylamine (0 953 mmol) were added The mixture was stirred for 1 hour at 0°C, and then at room temperature for 2 hours Ethyl acetate (50 mL) was added The solution was washed with 1 HCI (30 mL), saturated aqueous sodium bicarbonate (30 mL), brine (30 mL), dried over MgS04, filtered, and evaporated to dryness, giving 1 58 g (69%) of intermediate, (S)-(E)-3-(4-morpholιnecarbonyl-2-naphthylalanyl)amιno-5- phenyl-1-(2-naphthylsulfonyl)-1-pentene TLC (50% ethyl acetate/hexane) R, = 0 37
0 73 g (1 10 mmol) of this material was dissolved in ethanol (20 mL) and transferred to a Parr bottle charged with 5% palladium on carbon (0 30 g) The mixture was reduced on a Parr hydrogenator for 36 hours The solution was filtered and the solvent was removed under reduced pressure The product was purified by column chromatography on 60-200 mesh silica gel (50% ethyl acetate/CH2CI2 as eluent) to give 0 14 g (19%) of pure product, Mu-Np2-Hph-γ-S022Np, along with impure material TLC (50% ethyl acetate/CH2CI2) R, = 0 34
Example 7
Synthesis of a Cysteine Protease Inhibitor containing a γ-amιnosulfone as the EWG
Synthesis of 3-acetyltyrosylvalylalany lamιno-4-hydroxy-carbony 1-1 -phenylsulfonylbutane (Ac-Tyr-Val- Ala-Asp-γ-S02Ph) Sodium hydride (0 489 g of a 60% mineral oil dispersion, 12 23 mmol) was added to a solution of diethyl phenylsulfonylmethylene phosphonate (3 58 g, 12 23 mmol) in 50 mL of THF at 0°C The mixture was stirred for 15 minutes A solution of Boc-AspH(β-Ot-Bu), (3 04 gm, 11 12 mmol, prepared by converting Boc-Asp(β-O-t-Bu) to its N,0-dιmethyldroxamιde and reducing with lithium aluminum hydπde), in THF (10 mL) was added The mixture was stirred for 1 hour, whereupon
1 M HCI (30 mL) was added The product was extracted with ethyl acetate (100 mL), washed with saturated aqueous NaHC03 (30 mL), bπne (30 mL), dried over MgS04 filtered, and evaporated to dryness, giving the intermediate, Chromatography on silica gel (20-30% ethyl acetate/hexane, gradient elution) afforded 2 07 g 45%) of the intermediate, (S)-(E)-3-tert-butoxycarbonylamιno-4-tert- butoxycarbonyl-1-phenylsulfonyl-1-butene This material was dissolved in ether (2 mL) and was treated with a solution of anhydrous p-toluenesulfonic acid (1 0 g, 5 87 mmol) in ether (2 mL) The mixture was stirred at room temperature overnight, then diluted with ether (25 ml) The white precipitate, was filtered, washed with ether, and dried in vacuo to give 0 80 g (95%) of the next intermediate, (S)-(E)-3-amιno-4-tert-butoxycarbonyl-1-phenylsulfonyl-1-butene-p-toluenesulfonate
This material was coupled, using mixed anhydride chemistry, to Ac-Tyr-Val-AlaOH, itself prepared by standard peptide chemistry, giving the next intermediate (S)-(E)-3-acetyltyrosylvalylalanylamιno-4- tert-butoxycarbonyl-1-phenylsulfonyl-1-butene
This mateπal was treated with tπfluoroacetic acid to remove the t-butyl ester of the aspartic acid side chain, giving (E)-3-acetyltyrosylvalylalanylamιno-4-hydroxycarbonyl-1-phenylsulfonyl-1-butene 0 28 g (0 444 mmol) of this material was dissolved in ethanol (10 mL) The solution was transferred to a Parr bottle, charged with 5% palladium on carbon (0 1 g) The solution was reduced on a Parr hydrogenator overnight The solution was filtered and the solvent was removed under reduced pressure The residue, when dissolved in methanol (5 mL) and diluted with 40x 1 1 CH2CI2/ether, formed a gelatinous precipitate, which was collected on a Buchner funnel to give 0 18 g (64%) yield The isomer ratio of S to R with respect to the Asp residue was estimated as approximately 3 1 based on the integration of the doublets associated with the aromatic region of the NMR as pertains to the Tyr residue
Example 8
Synthesis of a Cysteine Protease Inhibitor with a γ-amιnocarboxylate as the EWG
Synthesis of (S)-4-(4-morpholιnecarbonylphenylalanyl)amιno-6-phenylhexanoιc acid, Mu-Phe-Hph-γ- C02H To a solution of Mu-Phe-Hph-γ-C02Et. prepared according to the procedure described in Example 1 (0 5g, 1 06 mmole) was added aqueous NaOH (1 mL of a 2M solution) After 4 hr the reaction was complete 1 M HCI (4mL) was added along with water (10 mL) The product was extracted with CH2CI2 (2 x 10 mL), THF (15dπed over MgS04 the solvent was removed under reduced pressure, and the residue, Mu-Phe-Hph-γ-C02H, was pumped to a solid Yield = 0 30g (60%)
Example 9
Synthesis of a Cysteine Protease Inhibitor with a γ-amιnophosphonate as the EWG
Synthesis of diethyl (S)-4-(4-morpholinecarbonyl-phenylalanyl)amino-6-phenylhexanephosphonate (Mu-Phe-Hph-γ-S02Ph) was as follows. To a solution of tetraethyl methylenediphosphonate (2.00 g, 6.94 mmol) in THF (30 mL) was added sodium hydride (0.278 g of a 60% mineral oil dispersion, 6.94 mmol). The mixture effervesced rapidly and then clarified. After 5 minutes, a solution of Boc-HphH (1.83 g, 6.94 mmol) in THF (5 mL) was added. The mixture was stirred for 1 hour. 1M HCI (20 mL) was added. The product was extracted into ethyl acetate (50 mL), washed with saturated aqueous NaHC03 (20 mL), brine (10 mL), dried over MgS04, filtered, and evaporated to dryness, giving 2.46 g (89%) of intermediate, diethyl (S)-(E)-4-tert- butoxycarbonylamino-6-phenyl-2-hexenephosphonate. To a solution of this material in CH2CI2 (3 mL) was added 10 mL of a 4.0 M solution of HCI in dioxane. The mixture was stirred at room temperature for 1.5 hours. The solvents were removed under reduced pressure and the residue was dissolved in methanol (10 mL). The solution was poured into ether (400 mL). The precipitate was collected on a Buchner funnel, washed with ether (2x20 mL), and was pumped dry to give 1.25 g (60%) of intermediate, diethyl (S)-(E)-4-amino-6- phenyl-2-hexenephosphonate hydrochloride. To a solution of Mu-PheOH (1.04 g, 3.74 mmol) in THF (15 mL) at -10°C was added 4-methylmorphoiine (0.412 mL, 3.74 mmol), followed by isobutyl chloroformate (0.486 mL, 3.74 mmol). The mixed anhydride was stirred for 5 minutes, whereupon a solution of (S)-(E)-4-amino-6-phenyl-2-hexene-phosphonate hydrochloride (1.25 g, 3.74 mmol) in DMF (5 mL) was added, followed by 4-methylmorpholine (0.412 mL, 3.74 mmol). The mixture was stirred for 1 hour. Ethyl acetate (50 mL) was added. The solution was washed with 1M HCI (25 mL), saturated aqueous NaHC03 (25 mL), and brine (10 mL), dried over MgS04, filtered, and evaporated to dryness. The product, upon treatment with CH2CI2/ether/hexane (315 mL in a 15:200:100 ratio) formed an oil that solidified on drying in vacuo to give 1.44 g (69%) of diethyl (S)- (E)-4-(4-morpholinecarbonyl-phenylalanyl)-amino-6-phenyl-2-hexenephosphonate. 0.85 g of this material was dissolved in ethanol (10 mL) and was transferred to a Parr bottle charged with 5% palladium on active charcoal. The solution was reduced on a Parr hydrogenator for 36 hours. The solution was then filtered through Celite, and the solvent was removed under reduced pressure to give 0.66 g (76%) of the final product as an oil. TLC: (5% MeOH/CH2CI2) R, = 0.27.
Example 10
Synthesis of a Cysteine Protease Inhibitor with a γ-aminoamide as the EWG.
Synthesis of benzyl (S)-3-(4-mo holinecarbonylphenyl-alanyl)-amino-6-phenylhexanamide (Mu-Phe- Hph-γ-AMBzl). The Wadsworth-Emmons reagent diethyl benzylamido-carbonylmethylenephosphonate was synthesized in two steps, first by saponification of triethyl phosphonoacetate to diethyl phosphonoacetic acid, which then was dissolved in ethyl acetate to a 0.2 M concentration, treated with an equivalent of benzylamine, 0.1 equivalents of 4-dimethylamino-pyridine, and one equivalent of dicyclohexyl-carbodiimide. To a solution of this Wadsworth-Emmons reagent (2.59 g, 9.08 mmol) in
THF (40 mL) at 0°C was added sodium hydride (0.363 g of a 60% mineral oil dispersion, 9.08 mmol) The mixture was stirred at room temperature for 15 minutes, whereupon a solution of Boc- homophenylalanmal (2 39 g, 9.08 mmol) in THF (10 mL) was added The mixture was stirred for 1 hour 1 M HCI (30 mL) was added The product was extracted into ethyl acetate (100 mL), washed with saturated aqueous sodium bicarbonate (50 mL), bπne (30 mL), dried over MgS04, filtered, concentrated, and crystallized from ether/hexane to give 1.81 g (51%) of benzyl (S)-(E)-3- tertbutoxycarbonylamιno-6-phenyl-2-hexenamide This material was dissolved in CH2CI2 (5 mL) To the solution was added HCI/dioxane (10 mL of a 4.0M solution). The mixture was stirred for 3 hours at room temperature The solvents were removed under reduced pressure The residue was dissolved in methanol (5 mL) and poured into ether (300 mL), whereupon the intermediate, benzyl (S)-(E)-3- amιno-6-phenyl-2-hexenamιde hydrochloride, separated out as an oil, in 82% yield (1.25 g) To a solution of Mu-PheOH (1 05 g, 3 78 mmol) in THF (15 mL) at -10°C were added 4-methylmorpholιne (0 416 mL, 3 78 mmol) and isobutyl chloroformate (0.490 mL, 3 78 mmol) The mixture was stirred for 10 minutes, whereupon a solution of benzyl (S)-(E)-3-amιno-6-phenyl-2-hexenamιde hydrochloride (1 25 g, 3 78 mmol) in THF (3 mL) was added, followed by 4-methylmorpholιne (0 416 mL, 3 78 mmol) The mixture was stirred for 45 minutes Ethyl acetate (40 mL) was added The solution was washed with 1M HCI (10 mL), saturated aqueous sodium bicarbonate (10 mL), brine (5 mL), dried over MgS04, filtered, and evaporated to dryness. The intermediate, benzyl (S)-(E)-3-(4- morpholιnecarbonyl-phenylalanyl)amιno-6-phenyl-2-hexenamιde, was precipitated from CH2CI2/ether in 56% yield 0 48 g (0 865 mmol) of this material was dissolved in ethanol (10 mL) and transferred to a Parr bottle charged with 5% palladium on active carbon The mixture was reduced on a Parr hydrogenator for 4 hours The solution was filtered through Celite, and the solvent was removed under reduced pressure The final product (Mu-Phe-Hph-γ-AMBzl) was crystallized from ethanol/hexane, giving 0 25 g (52%) TLC- (50% ethyl acetate/hexane) Rf = 0.45
Example 11
Synthesis of a Cysteine Protease Inhibitor with a γ-amιnoamιde as the EWG
Synthesis of phenyl (S)-3-(4-morpholιnecarbonylphenyl-alanyl)-amιno-6-phenylhexanamιde (Mu-Phe- Hph-γ-AMPh) To a solution of Mu-Phe-Hph-γ-C02H, (0.30g, as prepared according to Example 8), in THF (5 mL) at -10°C was added tπethylamine (90 μL, 1 eq ) followed by addition of isobutyl chloroformate (0.083 mL, 1 eq.) After 5 min, aniline (0.058 mL) was added. The cooling bath was removed and the reaction stirred at room temp for 2 hr. CH2CI2(30 mL) was added. The solution was washed with 1M HCI and saturated aqueous sodium bicarbonate (10 mL each), dried over MgS04, filtered, and the solvent was removed under reduced pressure. The residue was triturated with Et20, filtered, and dried in vacuo to give 0.29 g (85%) of the product, Mu-Phe-Hph-γ-AMPh. TLC (10% MeOH/CH2CI2) Rf = 0.70, strongly absorbs UV (254 nm), l2.
Example 12
Synthesis of a Cysteine Protease Inhibitor with a γ-aromatιc as the EWG
Synthesis of (S)-4-amιnophenyl-3-(4-morpholιne-carbonylphenylalanyl)amιno-5-phenylpentane hydrochloride, (Mu-Phe-hPhe-γ-C6H4NH2 HCI)
Tπphenylphosphine (38 17 g, 0 146 mole) and 4-nιtrobenzyl chloride (25g, 0 146 mole) were dissolved in CH3CN (100 mL) and heated at reflux for 2 hours, and then allowed to cool to room temperature The reaction mixture was diluted with Et20 (300 mL), the white solid was filtered, washed with Et20 (200 mL), and dried in vacuo, giving 53 3 g (84%) of 4- nitrobenzyltπphenylphosphonium chloride as a single spot on TLC (Rf=0 71 , 4 1 1 butanol acetic acid water) 1H-NMR (d6-DMSO) 5 40-5 50 (2H, d, CH2P, J=20Hz), 7 20-7 40 (2H, dd, aromatic), 7 40-7 80 (12H, m, aromatic), 7 90-8 00 (3H, m, aromatic), 8 10-8 20 (2H, d, aromatic)
To a stirred suspension of 4-nιtrobenzyltπphenylphosphonιum chloride (10 02 g, 23 1 mmol) in CH2CI2 (100 mL) was added 4-methylmorpholιne (2 54 mL, 23 1 mmol) was added When all the solid had dissolved, Boc-HphH (4 04 g, 15 4 mmol) was added After 24 hrs , the reaction mixture was diluted with CH2CI2 (200 mL), and filtered The filtrate was washed with 1M HCI (200 mL) saturated aqueous sodium bicarbonate (200 mL), dried over MgS04 , filtered and concentrated under reduced pressure, giving 4 00 g of crude intermediate, a portion of which was purified by chromatography (gradient elution 10-30% ethyl acetate/hexane) to permit NMR analysis of the intermediate, (S)-t-butoxycarbonyl-3-amιno-1-(4-nιtrophenyl)-5-phenyl-1-pentene TLC (30% EtOAc /hexane) Rf=0 49 To a solution of this material (2 76 g, 7 2 mmol) in Et20 (25 mL), was added a solution of anhydrous β-toluenesulfonic acid (2 76 g, 16 0 mmol) in Et20 (10 mL) The reaction was left to stir 16 hrs, filtered, washed solid with Et20 (25 mL), and dried in vacuo, giving 2 g (61%) of (S)-3-amιno-1-(4-nιtrophenyl)-5-phenyl-1-pentene as a single spot on TLC (Rf=049, 10% MeOH/CH2CI2)
To a solution of Mu-PheOH (1 29 g, 4 63 mmol) in THF (20 mL) were added 4-methylmorpholιne (0 51 mL, 4 63 mmol) and isobutyl chloroformate (0 61 mL, 4 63 mmol) After 3 minutes, a solution of (S) 3-amιno-1-(4-nιtrophenyl)-5-phenyl-1-pentene hydrochloride, prepared by HCI/dioxane-mediated deprotection of (S) 3-tert-butoxycarbonylamιno-1-(4-nιtrophenyl)-5- phenyl-1-pentene precursor, 1 34 g, 4 20 mmol) in CH2CI2 (20 mL), followed by 4- methylmorpholine (0 51 mL, 4 63 mmol) The mixture was stirred overnight while warming to room temperature The solution mixture was diluted with CH2CI2 (100 mL), washed with 1M HCI (200 mL), saturated aqueous sodium bicarbonate (200 mL), dried over MgS04, filtered, and
concentrated under reduced pressure to give a yellow oil This material was crystallized from CH2CI2/ether (2 100, 20 mL) to give 1 00 g (40%) of (S)-3-(4- morpholιnecarbonylphenylalanyl)amιno-1 -(4-nιtrophenyl)-5-phenyl-1 -pentene as an approximately 4 1 E/Z mixture 0 27 g (0 49 mmol) of this material was dissolved in ethanol (50 mL), transferred to a Parr bottle charged with 5% palladium on carbon (0 10 g) and reduced on a Parr hydrogenator for 8 hours/ The mixture was filtered and the solvent was removed under reduced pressure The residue was dissolved in in 4 1 ether/CH2CI2 (100 mL), to which HCI/dioxane (0 136 mL of a 4 0 M solution) was added The product, Mu-Phe-Hph-γ- C6H4NH2 HCI, was filtered and dried in vacuo Yield = 0 15 g (54%) TLC (10% methanol/CH2CI2) R, = 0 31
Example 13
Synthesis of a Cysteine Protease Inhibitor with a β-ammosulfone as the EWG
Synthesis of (S)-2-(4-morpholmecarbonyIphenyl-alanyl)amιno-4-phenyl-1-phenylsulfonylbutane (Mu-Phe-Hph-β-S02Ph) Preparation of Boc-homophenylalanmol (Boc-Hph-β-OH) and (S)-2- tert-butoxycarbonylamιno-1-methanesulfonyloxy-1-phenylbutane (Boc-Hph-β-OMs or Boc- homophenylalanmol mesylate) followed a similar scheme to that reported by Spaltenstem, Carpmo, Miyake, and Hopkins, above To a solution of Boc-homophenylalanine (10 29 g, 36 84 mmol) in THF (100 mL) at -10°C were added 4-methylmorpholιne (4 05 mL, 36 84 mmol) and isobutyl chloroformate (4 78 mL, 36 84 mmol) The solution was stirred for 10 minutes, and then was filtered The filtrate was carefully added to a stirred solution of sodium borohydπde (2 77 g, 73 67 mmol) in water (100 mL) at 0°C The mixture was stirred for 30 minutes Saturated aqueous sodium bicarbonate (200 mL) was added The product was extracted with CH2CI2 (2x100 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure to give 9 78 g (100%) Boc-homophenyl-alaninol TLC (30% ethyl acetate/hexane) Rt = 0 15 5 83 g (21 97 mmol) of this material was dissolved in CH2CI2 (150 mL), cooled to 0°C, and treated with methanesulfonyl chloride (4 15 mL, 53 71 mmol), and tπethylamine (9 24 mL, 66 3 mmol) The mixture was stirred for 30 minutes Water (100 mL) was added, the mixture was stirred vigorously The organic phase was separated, dried over MgSO, filtered, and the solvent was removed under reduced pressure, giving 7 31 g (97%) yield TLC (30% ethyl acetate/hexane) R, = 0 21 A similar procedure was employed to prepare the corresponding benzenesulfonate ester of Boc-Hph-β-OH
To a solution of thiophenol (0 653 mL, 6 36 mmol) in THF (5 mL) was added sodium hydπde (0 254 g, 6 36 mmol as a 60% mineral oil dispersion The mixture was stirred for 10 minutes A solution of Boc-homophenylalanmol benzenesulfonate (2 58 g, 6 36 mmol) in THF (5 mL) was
added. The solution was stirred at room temperature for 10 minutes. Methanol (2 mL) was then added, and the mixture was heated at reflux for 1 hour. The solution was cooled, diluted with 1M NaOH (25 mL), extracted with CH2CI2 (100 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure. The residue was dissolved in CH2CI2 (35 mL) and cooled to 0°C. To the solution was added 4-chloroperbenzoic acid (3.71 g, 13.99 mmol, estimated peracid content 65% by weight). The mixture was stirred for 1 hour, whereupon 10% NaOH (35 mL) and saturated aqueous NaHS03 (35 mL) were added. The mixture was extracted with CH2CI2 (3x50 mL portions), dried over MgS04, filtered, and the solvent was removed under reduced pressure to give a waxy solid. (S)-2-tert-butoxycarbonylamino-4-phenyl-1-phenylsulfonylbutane. TLC: (30% ethyl acetate/hexane) R, = 0.32. 1.25 g of this material was dissolved in CH2CI2 (5 mL) and treated with HCI/dioxane (5 mL of a 4.0M solution). The mixture was stirred for 2 hours at room temperature. The solution was poured into ether (200 mL), forming an oily residue. The supernatant was discarded. The residue was again dissolved in CH2CI2 (10 mL), and poured into ether (200 mL). The intermediate, (S)-2-amino-4-phenyl-1-phenylsulfonylbutane hydrochloride precipitated out. The solid was filtered and dried in vacuo to give 0.40 g of material (38% yield from Boc-homophenylalaninol benzenesulfonate.
To a solution of Mu-PheOH (0.342 g, 1.23 mmol) in THF (10 mL) at -10°C were added 4- methylmorpholine (0.135 mL, 1.23 mmol) and isobutyl chloroformate (0.159 mL, 1.23 mmol). The mixture was stirred for 10 minutes, whereupon (S)-2-amino-4-phenyl-1-phenylsulfonylbutane hydrochloride (0.40 g, 1.23 mmol) was added, followed by 4-methylmorpholine (0.135 mL, 1.23 mmol). The mixture was stirred for 45 minutes. 1M HCI (15 mL) was added. The product was extracted with ethyl acetate (30 mL), washed with saturated aqueous sodium bicarbonate (15 mL), brine (15 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure. The final product, Mu-Phe-Hph-β-S02Ph, weighed 0.68 g (100% yield).
Example 14
Synthesis of a Cysteine Protease Inhibitor with a β-aminosulfone as the EWG.
Synthesis of (S)-2-tert-butoxycarbonylamino-4-phenyl-1-(1 '-trimethylsilylethyl)-sulfonylbutane (Boc-Hph-β-S02CH2CH2TMS). To a solution of 2-trimethylsilylethanethiol (0.86 g, 6.41 mmol), synthesis described by Anderson, Ranasinghe, Palmer, and Fuchs, above) in THF (10 mL) was added sodium hydride (0.256 g, 6.41 mmol as a 60% mineral oil dispersion). The mixture was stirred for 10 minutes. Boc-homophenylalaninol mesylate (2.00 g, 5.82 mmol, synthesis described in Example 13, above) was added. The solution was stirred for 2 hours. Ethyl acetate (50 mL) was added. The solution was washed with 30 mL each of 1M HCI, saturated aqueous sodium bicarbonate, and brine, dried over MgS04, filtered, and the solvent was removed under
reduced pressure, giving the intermediate (S)-2-tert-butoxycarbonylamιno-4-phenylbutyl tnmethylsilylethyl sulfide TLC (5% ethyl acetate/hexane) Rf = 0 22 This material was dissolved in CH2CI2 (50 mL), cooled to -10°C, and treated with 4-chloroperbenzoιc acid (3 24 g, 12 22 mmol, estimated 65% peracid content) The mixture was stirred overnight The suspension was filtered, and saturated aqueous NaHS03 (40 mL) and saturated aqueous sodium bicarbonate (50 mL) were carefully added to the filtrate The organic phase was separated, dried over MgS04, filtered, and the solvent was removed under reduced pressure to give the product, Boc-Hph-β-S02CH2CH2TMS in quantitative mass recovery from the mesylate TLC (30% ethyl acetate/hexane) Rf = 049
Example 15
Synthesis of a Cysteine Protease Inhibitor with a β-ammosulfone as the EWG
Synthesis of (S)-2-(4-morpholιnecarbony lphenylalanyl)-amιno-1 -chloromethy Isulfony I-4- phenylbutane (Mu-Phe-Hph-β-S02CH2CI To a solution of Boc-Hph-β-S02CH2CH2TMS (0 90 g, 2 18 mmol as described in Example 14) in THF (2 mL) were added tetrabutylammonium fluoride (8 7 mL of a 1 0M THF solution) and several molecular sieves The mixture was stirred overnight at room temperature Bromochloromethane (5 mL) was added The mixture was heated at reflux for 1 hour, cooled, and the volatile components were removed under reduced pressure The residue was dissolved in ethyl acetate (75 mL), washed with 1M HCI (50 mL), dried over MgS04 filtered, and the solvent was removed under reduced pressure The residue, crude (S)- 2-tert-butoxycarbonylamιno-1-chloromethylsulfonyl-4-phenylbutane, was dissolved in ether (3 mL) A solution of anhydrous 4-toluenesulfonιc acid (0 80 g, 4 70 mmol) in ether (3 mL) was added The mixture was stirred at room temperature overnight Ether (100 mL) was added The solid intermediate, (S)-2-amιno-1-chloromethyl-sulfonyl-4-phenylbutane 4-toluenesulfonate (TsOH Hph-β-S02CH2CI), was filtered, the solids were washed with ether (2x20 mL), and dried in vacuo to give 0 193 g of material (24% from Boc-Hph-β-S02CH2CH2TMS)
To a solution of Mu-PheOH (0 109 g, 0 392 mmol) in THF (3 mL) at -10°C were added 4- methylmorpholine (43 μl, 0 392 mmol) and isobutyl chloroformate (51 μl, 0 392 mmol) The mixture was stirred for 10 minutes, whereupon TsOH Hph-β-S02CH2CI (0 17 g, 0 392 mmol) was added, followed by 4-methylmorpholιne (43 μL, 0 392 mmol) The mixture was stirred for 45 minutes Ethyl acetate (20 mL) was added The solution was washed with 1 M HCI, saturated aqueous sodium bicarbonate, and brine (2 mL each) dried over MgS04, filtered, and the solvent was removed under reduced pressure, to give the final product, Mu-Phe-Hph-β-S02CH2CI (90 mg, 48% yield
Example 16
Synthesis of a Cysteine Protease Inhibitor with an α-aminosulfone as the EWG
Synthesis of 1-(tert-butoxycarbonyl)amιno-2-methyl-1-phenylsulfonylpropane (Boc-Val-α- S02Ph) To a stirred suspensionof t-butylcarbamate (2 34 g, 20 mmol) and sodium benzenesulfinate (3 28 g, 20 mmol) in water (20 mL) was added a solution of isobutyraldehyde (2 00 mL, 22 mmol) in formic acid (5 mL) The mixture was stirred at room temperature overnight The precipitate was filtered, washed with water (2x50 mL) and crystallized from isopropanol/water to give 4 72 g (75%) of the product
Example 17
Synthesis of a Cysteine Protease Inhibitor with an α-aminosulfone as the EWG
Synthesis of 1-benzyloxycarbonylamιno-3-phenyl-1-phenylsulfonylpropane (Z-Hph-α-S02Ph) To a suspension of sodium benzenesulfinate (10 g, 60 9 mmol) and benzyl carbamate (9 21 g, 60 9 mmol) in water (40 mL) was added hydrocmnamaldehyde (8 8 mL, 67 mmol) in formic acid (10 mL) The mixture was heated at 70°C for 1 hour, then permitted to cool to room temperature overnight The product crystallized out, it was filtered and recrystallized from hot isopropanol, giving 23 g (100%) yield TLC (30% ethyl acetate/hexane) R, = 0 37
Example 18
Synthesis of a Cysteine Protease Inhibitor with an α-aminosulfone as the EWG
Synthesis of (R)-1 -(4-morpholιnecarbonylphenylalanyl)amιno-3-phenyl-1 -phenylsulfonylpropane and (S)-1-(4-morpholιnecarbonylphenylalanyl)amιno-3-pheny 1-1 -phenylsulfonylpropane (Mu- Phe-Hph-α-S02Ph, epimers separated) Method A Z-Hph-α-S02Ph (1 0 g, 2 44 mmol) was treated with 30% hydrogen bromide in acetic acid (5 mL) After 30 minutes, the mixture was diluted with ether (300 mL), filtered, washed with ether (2x30 mL), and dπed in vacuo to give 0 74 g (86%) 1-amιno-3-phenyM -phenylsulfonylpropane hydrobromide (HBr Hph-α-S02Ph) To a solution of Mu-PheOH (0 64 g, 2 3 mmol) in THF (15 mL) were added 4-methylmorpholιne (0 302 mL, 2 3 mmol) and isobutyl chloroformate (0 312 mL, 2 3 mmol) The mixture was stirred for 10 minutes HBr Hph-α-S02Ph (074 g, 2 1 mmol) was added, followed by 4- methylmorpholine (0 302 mL, 2 3 mmol) After 45 minutes, the mixture was diluted with ethyl acetate (30 mL), washed with 15 L each of 1M HCI, saturated aqueous sodium bicarbonate, and brine, dried over MgS04, filtered, and the solvent was removed under reduced pressure to give 0 75 g (65%) of the product, Mu-Phe-Hph-α-S02Ph
Method B: To a solution of phenylalanine amide hydrochloride (10 g, 50 mmol) in DMF (50 mL) and CH2CI2 (50 mL) were added tπethylamine (13 9 mL, 100 mmol) and 4-morpholιnecarbonyl chloride (5 9 mL, 50 mmol) The mixture was stirred overnight The solvents were removed under reduced pressure The residue was dissolved in ethyl acetate (50 mL), and filtered Ether was added to the filtrate until the solution became turbid 7 2 g (80% yield) of the intermediate, 4-morpholιnecarbonylphenylalanιne amide (Mu-Phe-NH2) crystallized from the solution after 3 days To a solution of Mu-PheNH2 (2 24 g, 8 1 mmol) in formic acid (5 mL) was added, with stirring, hydrocinnamaldehyde (1 17 mL, 8 9 mmol) The mixture was stirred for 5 hours, whereupon sodium benzenesulfinate (1 33 g, 8 1 mmol) was added The mixture was quickly heated to reflux over a five minute period, and was allowed to cool to room temperature The solution was then permitted to stir for three days An equal volume of water was added The product was extracted with CH2CI2 (3x100 mL), dried over MgS04, filtered, and the solvent was removed under reduced pressure The yield of product, diastereomeric (R)- and (S)-1-(4- morpholιne-carbonylphenylalanyl)amιno-3-phenylsulfonyl-1-phenyl-propane, was 3 9 g (90%) TLC (50% ethyl acetate/CH2CI2) Rf = 0.27,0 34
The diastereomers were separated by flash chromatography on 230-400 mesh silica gel (20- 50% ethyl acetate/CH2CI2, gradient elution)
Example 19
Inhibition of Cysteine Proteases with the
Inhibitors of the Invention
Conditions for cathepsin B 50 mM phosphate, pH 6 0, 2 5 mM EDTA, 2 5 mM DTT substrate [Z-Arg-Arg-AMC] = 50 mM (Km = 190 mM) The assay at 25° was started by the addition of cat B (final concentration approx 10 nM) and the increase in fluorescence at 450 nm with excitation at 380 nm was followed over 2 mm The depression in the rate of substrate hydrolysis following addition of varying concentrations of inhibitors was noted The assay was linear throughout the range observed Duplicate runs were measured
Conditions for cathepsin L 50 mM acetate, pH 5 5, 2 5 mM EDTA, 2 5 mM DTT substrate [Z-Phe-Arg-AMC] = 5 mM (Km = 2 mM) The assay at 25°was started by the addition of cat L (final concentration approx 1 nM) and the increase in fluorescence at 450 nm with excitation at 380 nm was followed over 2 mm The depression in the rate of substrate hydrolysis following addition of varying concentrations of inhibitors was noted The assay was linear throughout the range observed Duplicate runs were measured
Conditions for cathepsin S: 50 mM phosphate, pH 6.5, 2.5 mM EDTA, 2.5 mM DTT. substrate : [Z-Val-Val-Arg-AMC] = 10 mM (Km = 18 mM). The assay at 25° was started by the addition of cat S (final concentration approx 30 pM) and the increase in fluorescence at 450 nm with excitation at 380 nm was followed over 2 min. The depression in the rate of substrate hydrolysis following addition of varying concentrations of inhibitors was noted. The assay was linear throughout the range observed. Duplicate runs were measured.
Conditions for cruzain were the same as for cathepsin L with the exception that the Km for the substrate was 1 mM.
The respective K, values were estimated by using the Dixon plot as described by Irwin Segel in Enzyme Kinetics: Behavior and analysis of rapid equilibrium and steady-state enzyme systems, 1975, Wiley-lnterscience Publication, John Wiley & Sons, New York.
The results are shown in Table 2.
Table 2
Z-β-Ala-Phe-HphγS02Ph 52 0 79 3 0 0 54 β-Ala-Phe-HphγS02Ph »50 14 11 14
Mu-Tyr-HphγS02Ph - 2 3 9 5 20
Mu-Phe-HphγC02Et 1 6 0 48 0 19 0 91
Mu-Phe-HphγCONHPh 2 6 2 0 1 3 0 13
Mu-Phe-HphγCONHBzl »50 19 30 7 7
Mu-Phe-HphγPO(02Et)2 17 3 0 1 4 15
Mu-Phe-Hph-γPh-OMe 4 8 0 94 0 37 0 89
Mu-Phe-Hph-γPh-NH2 »50 2 9 9 1 3 0
EXAMPLE 20
The following are representative phamaceutical formulation containing a cysteine protease inhibitor of this invention
ORAL FORMULATION
A representative solution for oral administration contains
Cysteine protease inhibitor 100 to 1000 mg Citric Acid Monohydrate 105 mg Sodium Hydroxide 18 mg Flavoring Water q s to 100 mL
INTRAVENOUS FORMULATION
A representative solution for intravenous admmstration contains
Cysteine protease inhibitor 10 to 100 mg Dextrose Monohydrate q s to make isotonic Citric Acid Monohydrate 1 05 mg Sodium Hydroxide 0 18 mg Saline for Injection q s to 1 0 mL
TABLET FORMULATION
A representative tablet form may contain:
Cysteine protease inhibitor 1 %
Microcrystalline Cellulose 73%
Stearic Acid 25%
Colloidal Silica 1%
Claims (1)
- CLAIMS We Claim1 A protease protease inhibitor comprising a targeting group linked through a two carbon atom chain to an electron withdrawing group, wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM2 A protease inhibitor comprising a targeting group linked either directly or through a linker selected from the group consisting of an intermediate carbon atom or a two carbon atom chain to a sulfonyl group, wherein the dissociation constant for inhibition of the protease with said inhibitor (K,) is no greater than about 100 μM3 A compound of Formula II in whichA-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below,X represents a bond, methylene or the linkage -CH2CH(R4)-, wherein R4 is hydrogen, alkyl or arylalkyl,Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below,Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below,Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below, R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylammosulfonyl, arylsulfonyl or heteroarylsulfonyl,R7 and Rβ are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylammo, dialkylamino, uπedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C-jJmethyiene and 1 ,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); and R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, guanidino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof); and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof.4. A compound according to claim 3 wherein the dissociation constant for inhibition of a protease with said inhibitor (K,) is no greater than about 100 μM.5. The compound of Claim 3 in which n is 0 to 5; A-B represents a linkage selected from -C(0)NR3-; Y is -N(R5)-; Z is -(CH2)2- or -C(R6)(R7)-; is -CH(R8)-; R1 is hydrogen, alkyloxycarbonylalkanoyl of overall 3 to 10 carbon atoms, (C,.9)alkoxycarbonyl, (C2.10)alkanoyl (optionally substituted with a radical selected from carboxy, (C,.9)alkyloxycarbonyl and hetero(C4.β)cycloalkyl(C2.10)alkanoylamin), (C4.9)cycloalkylcarbonyl, hetero(C4.8)cycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, (C,.5)alkyl, (C^alkanoyl, (C1.5)alkyloxycarbonyl, (C^oJarylfCLsJalkyloxycarbonyl and hetero(C4.B)cycloalkylcarbonyl), (C6.l0)aryl(C1.5)alkyloxycarbonyl, carbamoyi, (C1.5)alkylcarbamoyl, di(C1.5)alkylcarbamoyl, (Cβ.10)arylcarbamoyl, (C6.l0)aryl(C1.5)alkylcarbamoyl, (C6.10)aryl(C1.5)alkanoyl, (C7.1,)aroyl, (C,.s)alkylsulfonyl, di(C,.5)alkylaminosulfonyl, (C6.,0)arylsulfonyl or heterofC-^arylsulfonyl; R8 and R7 are independently (C3.7)cycloalkyl, pyridyl, thienyl, furyl, imidazolyl, indolyl, pyridyl(C1-6)alkyl, thienyl(C,^)alkyl, furyl(C1.6)alkyl, imidazoly C^Jalkyl, indolyl(C,^)alkyl, (C1.5)alkyl, (optionally substituted with a radical selected from mercapto, carboxy, amino, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyl, guanidino and hydroxy, or a protected derivative thereof), a group selected from phenyl, naphthyl, pheny C^alkyl, naphthyl(C,^)alkyl, (which group is optionally substituted at its aryl ring with one to three radicals selected from amino, hydroxy, chloro, bromo, fluoro, methyl, trifluoromethyl, methoxy and phenyl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C-j methylene and 1 ,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), R2 is (C^alkyl (optionally substituted with one or two radicals selected from ammo, chloro, bromo, fluoro, lodo, hydroxy and methoxy, or a protected derivative thereof), perhalo(C, 5)alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl(C* 5)alkyl or a group selected from phenyl, pentafluorophenyl, naphthyl and phenyl(C,^)alkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl, or a protected derivative thereof) and R4 is hydrogen, (C, 5)alkyl or (C6 10)aryl(C, 5)alkyl6 The compound of Claim 5 in which n is 0 to 2, Z is -(CH2)2- or -C(R6)(R7)- (with the proviso that when n is 0, Z is not -(CH2)2-), R1 is hydrogen, (C4 8)alkoxycarbonyl, (C2^)alkanoyl (optionally substituted with a radical selected from carboxy, (C, 5)alkyloxycarbonyl and hetero(C4^)cycloalkyl(C4^)alkanoylamιno), -C(0)NR 1R22 wherein R21 and R22 together form aza(C2-6)methylene, oxa(C2^)methylene or (C3 7)methylene, (C4 β)cycloalkylcarbonyl, benzyloxycarbonyl, acetyl, benzoyi or dimethylaminosulfonyl, R8 and R7 are independently (C5^)cycloalkyl, (C5^)cycloalkylmethyl, 3-pyπdyl, 2-thιenyl, 2-furyl, 4-ιmιdazolyl, 3-ιndolyl, 3-pyrιdylmethyl, 2-thιenylmethyl, 2-furylmethyl, 4-ιmιdazolylmethyl, 3-ιndolylmethyl, methoxy, acetoxy, (C, s)alkyl (optionally substituted with a radical selected from mercapto, carboxy, ammo, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyl, guanidino and hydroxy, or a protected derivative thereof), a group selected from phenyl, 1 -naphthyl, 2-naphthyl, benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, ammo, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3j4)methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), R2 is (C, 5)alkyl (optionally substituted with one or two radicals selected from ammo, chloro, bromo, fluoro and hydroxy, or a protected derivative thereof), perfluorc C, 5)alkyl, (C5^)cycloalkyl, (C5^)cycloalkylmethyl or a group selected from phenyl, naphthyl and benzyl (which group is optionally substituted with one radical selected from ammo hydroxy, chloro, bromo or fluoro, or a protected derivative thereof) and R4 is hydrogen or methyl7 The compound of Claim 4 in which n is 0 to 1, Z is -C(R6)(R7)-, R1 is hydrogen, fert-butoxycarbonyl, benzyloxycarbonyl, acetyl, 3-carboxypropιonyl, 3-methoxycarbonylpropιonyl, biotinylaminohexanoyl, phenylacetyl, benzoyi, dimethylaminosulfonyl, benzylsulfonyl, 1-pιperizιnylcarbonyl, 4-methyl-1-pιperazιnylcarbonyl or 4-morpholιnylcarbonyl, Rβ is butyl, 2-phenylethyl, 2-methylsulfonylethyl, 2-ferf-butoxycarbonylethyl, 2-fert-butoxycarbonylmethyl, 4-fert-butoxycarbonylamιnobutyl, 4-benzoylamιnobutyl or benzyloxymethyl, R2 is methyl, tπfluoromethyl, optionally substituted phenyl, 2-naphthyl or 2-phenylethyl; R4 is hydrogen; and R7 is 3-pyridylmethyl, 2-thienylmethyl, 2-furylmethyl, 4-imidazolylmethyl, 3-indolylmethyl, (C,.s)alkyl (optionally substituted with a radical selected from mercapto, carboxy, amino, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof), a group selected from benzyl, 1-naphthylmethyl, 2-πaphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, amino, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (Cj methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo).8. The compound of Claim 7 in which n is 0; R3, R5 and R6 are each hydrogen; R1 is hydrogen, fert-butxoycarbonyl, benzyloxycarbonyl, biotinylaminohexanoyl, benzoyi, 1-piperiziny-carbonyl, 4-methyl-1-piperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is butyl, 2-phenylethyl or 2-methylsulfonylethyl; R2 is phenyl, 1 -naphthyl or 2-phenylethyl; and R7 is (C,.5)alkyl, 2-methylsulfonylethyl, optionally substituted benzyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-pyridinylmethyl or 2-methylsulfonylethyl.9. The compound of Claim 8 in which R1 is 1-piperizinylcarbonyl, 4-methyl- 1-piperazincarbonyl or 4-morpholinylcarbonyl; R8 is 2-phenylethyl; R2 is phenyl or naphth-2-yl; and R7 is optionally substituted benzyl, 1-naphthylmethyl or 2-naphthylmethyl.10. The compound of Claim 9 in which X represents a bond, R is 4-morpholinylcarbonyl, R8 is 2-phenylethyl, R2 is phenyl and R7 is benzyl, namely Λ/2-(4-morpholinylcarbonyl)-rV-(3-phenyl-1-phenylsulfonylpropyl)-L-phenylalaninamide.11. The compound of Claim 9 in which X represents methylene, R1 is 4-morpholinylcarbonyl, Rβ is 2-phenylethyl, R2 is phenyl and R7 is benzyl, namely /V2-(4-morpholinylcarbonyl)-Λ 1-(3-phenyl-1 S-phenylsulfonylmethylpropyl)-L-phenylalaniamide.12. The compound of Claim 9 in which X represents -CH2CH(R4) wherein R4 is hydrogen, R is 4-morpholinylcarbonyl, R8 is 2-phenylethyl, R2 is 2-naphthyl and R7 is 2-naphthylmethyl, namely /v^-morpholinylcarbony -ΛT- -phenyl- 1S-[2-(2-naphthylsulfonyl)ethyl]propyl}-β-(2-naphthyl)-L-alaninamide. 13 The compound of Claim 9 in which X represents -CH2CH(R4) wherein R4 is hydrogen, R1 is 4-morpholιnylcarbonyl, Rβ is 2-phenylethyl, R2 is phenyl and R7 is 4-hydroxybenzyl, namely Λ/2-(4-morpholιnylcarbonyl)-Λ '-{3*-phenyl- 1 S-[2-(2-naphthylsulfonyl)ethyl]propyl}-L-tyrosιnamιde14 The compound of Claim 9 in which X represents -CH2CH(R4) wherein R4 is hydrogen, R1 is 4-morpholιnylcarbonyl, R8 is 2-phenylethyl, R2 is phenyl and R7 is benzyl, namely Λ/2-(4-morpholιnylcarbonyl)-Λ/1-[3-phenyl-1 S-(2-phenylsulfonylethyl)propyl]-L-phenylalanιnamιde15 A compound of Formula IIin whichIIA-B represents a linkage selected from -C(0)NR3- -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below,Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below,Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below, is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below,R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylammo), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl,R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, am o, alkylamino, dialkylammo, uπedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl(which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C3^)methylene and 1 ,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); andR9 is cyano, -C(0)OR1°, -P(O)(OR10)2, -S(O)(NR10)R10, C(0)R11, -S(0)R11, -C(0)NR12R13, -S(0)2NR12R13, -C(0)NHR14 or -S(0)2NHR14, wherein each R10 is independently hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R11 is hydrogen, alkyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, perfluoroaryl, perfluoroarylakyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R12 and R13 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyi and R14 is -C(0)OR1°, in which R10 is as defined above, or a group selected from Formula (a) and (b):wherein each n, A, B, Y, Z, R1 and R10 are as defined above; and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof.16. The compound of Claim 15 in which each n is 0 to 5; each A-B represents a linkage selected from -C(0)NR3-; each Y is -N(R5)-; each Z is -(CH2)2- or -C(R6)(R7)-; Z1 is -CH(R8)-; each R1 is independently hydrogen, alkyloxycarbonylalkanoyl of overall 3 to 10 carbon atoms, (C1.9)alkoxycarbonyl, (C2.10)alkanoyl (optionally substituted with a radical selected from carboxy, (C**.9)alkyloxycarbonyl and hetero(C4^)cycloalkyl(C2.10)alkanoylamino), (C4.9)cycloalkylcarbonyl, hetero(C44)cycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, (Chalky!, (C^alkanoyl, (CLsJalkyloxycarbonyl, (C6.10)aryl(C,.5)alkyloxycarbonyl and hetero(C4^)cycloalkylcarbonyl), (C6-ιo)aryl(C1.5)alkyloxycarbonyl, carbamoyi, (CLsJalkylcarbamoyl, di(C,.5)alkylcarbamoyl, (Cf- oJarylcarbamoyl, (C6.10)aryl(C,.5)alkylcarbamoyl, (C6-1o)aryl(C1.5)alkanoyl, (C^Oaroyl, (C^alkylsulfonyl, d CLsJalkylaminosulfonyl, (C^oJarylsulfonyl or hetero(C5^)arylsulfonyl; Rβ and R7 are independently (C3.7)cycloalkyl, (C3.7)cycloalkyl(C**.5)alkyl, pyridyl, thienyl, furyl, imidazolyl, indolyl, pyridyl(C1-6)alkyl, thienyl(C1-6)alkyl, furyKC-^alkyl, imidazolyl(C^)alkyl, indolyl(C,^)alkyl, a group selected from (C1.5)alkyl, (C2^)alkyloxy and (C,.5)alkanoyloxy (which group is optionally substituted with a radical selected from mercapto, carboxy, ammo, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof), a group selected from phenyl, naphthyl, phenyl(C,^)alkyl, naphthyl(C,^)alkyl, (which group is optionally substituted at its aryl ring with one to three radicals selected from ammo, hydroxy, chloro, bromo, fluoro, methyl, tπfluoromethyl, methoxy and phenyl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3.,) methylene and 1,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), each R10 is independently (C, 5)alkyl (optionally substituted with one or two radicals selected from ammo, chloro, bromo, fluoro, hydroxy and methoxy or a protected derivative thereof), (C3 7)cycloalkyl, (C3 7)cycloalkyl(C, 5)alkyl, or a group selected from phenyl or phenyl(C,^)alkyl (which group is optionally substituted at its phenyl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl, or a protected derivative thereof), R11 is independently (C, 5)alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl(C1 5)alkyl or a group selected from phenyl, and phenyl(C,^)alkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methyl, tπfluoromethyl and methoxy), and R12 and R13 are independently (C, 5)alkyl, (C3 7)cycloalkyl, (C3 7)cycloalkyl (C, 5)alkyl or a group selected from phenyl and phenyl(C,^)alkyl (which group is optionally substituted at its phenyl ring with one to two radicals selected from ammo, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl)17 The compound of Claim 16 in which each n is 0 to 2, Z is -(CH2)2- or -C(R6)(R7)- (with the proviso that when n is 0, Z is not -(CH2)2-), each R1 is hydrogen, (C4 8)alkoxycarbonyl, (C2^)alkanoyl (optionally substituted with a radical selected from carboxy, (C, 5)alkyloxycarbonyl and hetero(C4^)cycloalkyl(C4^)alkanoylamιno), -C(0)NR21R22 wherein R2 and R22 together form aza(C2-6)methylene, oxa(C2^)methylene or (C3.7)methylene, (C4^)cycloalkylcarbonyl, benzyloxycarbonyl, acetyl, benzoyi or dimethylaminosulfonyl, R8 and R7 are independently (C-wsJcycloalkyl, (CM)cycloalkylmethyl, 3-pyπdyl, 2-thιenyl, 2-furyl, 4-ιmιdazolyl, 3-ιndolyl, 3-pyrιdylmethyl, 2-thιenylmethyl, 2-furylmethyl, 4-ιmιdazolylmethyl, 3-ιndolylmethyl, methoxy, acetoxy, a group selected from (C1-S)alkyl (which group is optionally substituted with a radical selected from mercapto, carboxy, ammo, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof), a group selected from phenyl, 1 -naphthyl, 2-naphthyl, benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, am o, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C-j methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); each R10 is ethyl, (C^cycloalkyl, (C^Jcycloalkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from amino hydroxy, chloro, bromo or fluoro, or a protected derivative thereof); R11 is ethyl, cyclo(CM)alkyl, cyclo(CM)alkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from amino hydroxy, chloro, bromo or fluoro, or a protected derivative thereof); and R12 and R13 are independently ethyl, (C5^)cycloalkyl, (C5^)cycloalkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from amino hydroxy, chloro, bromo or fluoro, or a protected derivative thereof)*18. The compound of Claim 17 in which each n is 0 to 1; Z is -C(R6)(R7)-; each R1 is hydrogen, fer -butoxycarbonyl, benzyloxycarbonyl, acetyl, 3-carboxypropionyl, 3-methoxycarbonylpropionyl, biotinylaminohexanoyl, phenylacetyl, benzoyi, dimethylaminosulfonyl, benzylsulfonyl, 1-piperizinylcarbonyl, 4-methy-1-lpiperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is butyl, 2-phenylethyl, 2-methylsulfonylethyl, 2-fert-butoxycarbonylethyl, 2-fert-butoxycarbonylmethyl, 4-fert-butoxycarbonylaminobutyl, 4-benzoylaminobutyl or benzyloxymethyl; and R7 is 3-pyridylmethyl, 2-thienylmethyl, 2-furylmethyl, 4-imidazolylmethyl, 3-indolylmethyl, a group selected from (C,.5)alkyl (which group is optionally substituted with a radical selected from mercapto, carboxy, amino, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof), a group selected from benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, amino, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3-4)methylene and 1 ,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo).19. The compound of Claim 18 in which each n is 0; each R3, R5 and R6 are hydrogen; each R is hydrogen, fert-butxoycarbonyl, benzyloxycarbonyl, biotinylaminohexanoyl, benzoyi, 1-piperizinylcarbonyl, 4-methyl-1-piperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is butyl, 2-phenylethyl or 2-methylsulfonylethyl; and R7 is (Chalky!, 2-methylsulfonylethyl, optionally substituted benzyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-pyridinylmethyl or 2-methylsulfonylethyl.20. The compound of Claim 19 in which each R1 is 1-piperizinylcarbonyl, 4-methyl- 1-piperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is 2-phenylethyl; and R7 is optionally substituted benzyl, 1-naphthylmethyl or 2-naphthylmethyl. 21. The compound of Claim 20 in which R1 is 4-morpholinylcarbonyl, Rβ is 2-phenylethyl, R7 is 2-naphthylmethyl and R9 is ethoxycarbonyl namely ethyl 4S-[Λ/-(4-morpholinylcarbonyl)-β-(2-naphthyl)-L-alanylamino]-6-phenylhexanoate.22. The compound of Claim 20 in which R1 is 4-morpholinylcarbonyl, R8 is 2-phenylethyl, R7 is benzyl and R9 is ethoxycarbonyl namely ethyl 4S-[Λ/-(4-morpholinylcarbonyl)-L-phenylalanylamino]-6-phenylhexanoate.23. The compound of Claim 20 in which R1 is 4-morpholinylcarbonyl, R8 is 2-phenylethyl, R7 is benzyl and R9 is phenylcarbamoyl namely Λ/2-(4-morpholinylcarbonyl)- Λ M3-phenyl-1 S-(2-phenylcarbamoylethyl)propyl]-L-phenylalanιnamide.24. The compound of Claim 20 in which R1 is 4-morpholinylcarbonyl, R8 is 2-phenylethyl, R7 is benzyl and R9 is benzylcarbamoyl namely Λ -4-(morpholinylcarbonyl)- Λ/1-[3-phenyl-1 S-(2-benzylcarbamoylethyl)propyl]-L-phenylalaninamide.n is O to 13;A-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below;Y is -CH(R5)- or -NR5-, wherein R5 is hydrogen or as defined below;Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below;Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below;R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl;R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, amino, alkylamino, dialkylamino, uriedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (Cw)methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); R15 is hydrogen, methyl, fluoro or a group selected from Formulae (a) and (b):(a)wherein each n, A, B, Y, Z and R1 are as defined above and R10 is hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof); and R16 is a group selected from phenyl or (C^heteroaryl (which group is optionally substituted with at least one radical selected from aikylcarbamoyl, dialkylcarbamoyi, alkyloxycarbonyl, alkylsulfinamoyl, dialkylsulfinamoyl, alkylsulfonyl, carboxy, nitro, sulfinamoyl, sulfo, carbamoyi, phosphono, alkyloxyphosphinyl, dialkyloxyphosphinyl, alkanoyl, cyano, alkylsulfinyl, sulfamoyl, alkyisulfamoyl, dialkylsulfamoyi, alkyloxysulfonyl, alkylsulfonimidoyl, aryl, heteroaryl, hydroxy, alkyloxy, optionally halo-substituted alkyl, arylalkyl, halo, -*N(R17)3, wherein each R17 is independently alkyl, aryl or arylalkyl, or -N(R18)2, wherein each R 8 is independently hydrogen, alkyl, aryl or arylalkyl); and the pharmaceutically acceptable salts; individual isomers and mixtures of isomers thereof.26. The compound of Claim 25 in which each n is 0 to 5; each A-B represents a linkage selected from -C(0)NR3-; each Y is -NR5-; each Z is -(CH2)2- or -C(R6)(R7)-; Z1 is -CH(R8)-; each R1 is hydrogen, alkyloxycarbonylalkanoyl of overall 3 to 10 carbon atoms, (C^alkoxycarbonyl, (C2.10)alkanoyl (optionally substituted with a radical selected from carboxy, (C,.9)alkyloxycarbonyl and hetero(C4<)cycloalkyl(C2.10)alkanoylamino), (C4.9)cycloalkylcarbonyl, hetero(C4.β)cycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, (C^alkyl, (C^alkanoyl, (C,.5)alkyloxycarbonyl, (C6-10)aryl(C1.5)alkyloxycarbonyl and hetero(C .e)cycloalkylcarbonyl), (C^oJary CLsJalkyloxycarbonyl, carbamoyi, (C^alkylcarbamoyl, d CL^alkylcarbamoyl, (C^oJarylcarbamoyl, (Ce. ary C^alkylcarbamoyl, (C6.ιo)aryl(C,.s)alkanoyl, (C7..,,)aroyl, (C,.5)alkylsulfonyl, di(C1.5)alkylaminosulfonyl, (C6.,0)arylsulfonyl or hetero(C5^)arylsulfonyl; R8 and R7 are independently (C3.7)cycloalkyl, (C3.7)cycloalkyl(C*.5)alkyl, pyridyl, thienyl, furyl, imidazolyl, indolyl, pyridyl(C,^)alkyl, thienyl(C1-6)alkyl, furyl(C1.β)alkyl, imidazolyKC^alkyl, indolyl(C1-6)alkyl, a group selected from (C,.5)alkyl, (C2^)alkyloxy and (C^sJalkanoyloxy (which group is optionally substituted with a radical selected from mercapto, carboxy, amino, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof), a group selected from phenyl, naphthyl, pheny C^alkyl, naphthyl(C,^)alkyl, (which group is optionally substituted at its aryl ring with one to three radicals selected from amino, hydroxy, chloro, bromo, fluoro, methyl, trifluororπethyl, methoxy and phenyl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3-4)methylene and 1 ,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); R10 is (C,.5)alkyl (optionally substituted with one or two radicals selected from amino, chloro, bromo, fluoro, hydroxy and methoxy or a protected derivative thereof), (C3.7)cycloalkyl, (C3.7)cycloalkyl(C1.5)alkyl, or a group selected from phenyl or phenyl(C,^)alkyl (which group is optionally substituted at its phenyl ring with one to two radicals selected from amino, chloro, bromo, fluoro, hydroxy, methoxy and optionally halo-substituted methyl, or a protected derivative thereof); and R16 is a group selected from 2-furyl, 2-thienyl, 2-pyrrolyl, 2-phosholyl, 2-arsolyl, 3-pyridyl or 3-phosphorinyl (which group is optionally substituted with at least one radical selected from (CLjJalkylcarbamoyl, di(C1.5)alkylcarbamoyl, (C,.5)alkyloxycarbonyl, (C^alkylsulfinamoyl, di(C,.5)alkylsulfinamoyl, (C,.5)alkylsulfonyl, carboxy, nitro, sulfmamoyl, sulfo, carbamoyi, phosphono, (C,.s)alkyloxyphosphinyl, di(C,.5)alkyloxyphosphinyl, (C,.5)alkanoyl, cyano, (C^alkylsulfinyl, sulfamoyl, (C1.5)alkylsulfamoyl, di(C,.5)alkylsulfamoyl, (C1.5)alkyloxysulfonyl, (C,.5)alkylsulfonimidoyl, phenyl, naphthyl, pyridyl, thienyl, furyl, imidazolyl, indolyl, hydroxy, (CLsJalkyloxy, optionally halo-substituted (C-*.5)alkyl, benzyl, halo, -+N(R17)3, wherein each R17 is independently (Chalky!, phenyl or benzyl, or -N(R18)2, wherein each R18 is independently hydrogen, (Chalky!, phenyl or benzyl).27. The compound of Claim 26 in which each n is 0 to 2; Z is -(CH2)2- or -C(R6)(R7)- (with the proviso that when n is 0, Z is not -(CH2)2-); each R1 is hydrogen, (C4.8)alkoxycarbonyl, (C2^)alkanoyl (optionally substituted with a radical selected from carboxy, (C,.5)alkyloxycarbonyl and hetero(C4^,)cycloalkyl(C4^)alkanoylamino), -C(0)NR21R22 wherein R21 and R22 together form aza(C2.6)methylene, oxa(C2^)methylene or (C3.7)methylene, (C^cycloalkylcarbonyl, benzyloxycarbonyl, acetyl, benzoyi or dimethylaminosulfonyl; R8 and R7 are independently (Cjs^cycloalkyl, (Cw)cycloalkylmethyl, 3-pyridyl, 2-thienyl, 2-furyl, 4-imidazolyl, 3-indolyl, 3-pyridylmethyl, 2-thienylmethyl, 2-furylmethyl, 4-imidazolylmethyl, 3-indolylmethyl, methoxy, acetoxy, (C,.5)alkyl (optionally substituted with a radical selected from mercapto, carboxy, amino, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof) a group selected from phenyl, 1-naphthyl, 2-naphthyl, benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, amino, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C3Jl)methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); each R10 is ethyl, (C^Jcycloalkyl, (C5-6)cycloalkylmethyl or a group selected from phenyl and benzyl (which group is optionally substituted at its phenyl ring with one radical selected from amino hydroxy, chloro, bromo or fluoro, or a protected derivative thereof); and R16 is a group selected from 2-furyl, 2-thienyl, 2-pyrrolyl, 2-phosholyl, 2-arsolyl, 2-pyridyl or 3-phosphorinyl (which group is optionally substituted with at least one radical selected from methylcarbamoyl, dimethylcarbamoyi, methyloxycarbonyl, methylsulfinamoyl, dimethylsulfinamoyl, methylsulfonyl, carboxy, nitro, sulfinamoyl, sulfo, carbamoyi, phosphono, methyloxyphosphinyl, dimethyloxyphosphinyl, formyl, cyano, methylsulfinyl, sulfamoyl, methylsulfamoyl, dimethylsulfamoyl, methoxysulfonyl, methylsulfonimidoyl, phenyl, naphthyl, pyridyl, thienyl, furyl, imidazolyl, indolyl, hydroxy, methoxy, methyl, trifluromethyl, benzyl, halo, -*N(R17)3, wherein each R17 is independently methyl, phenyl or benzyl, or -N(R1β)2, wherein each R1β is independently hydrogen, methyl, phenyl or benzyl).28. The compound of Claim 27 in which each n is 0 to 1; Z is -C(R6)(R7)-; each R1 is hydrogen, fert-butoxycarbonyl, benzyloxycarbonyl, acetyl, 3-carboxypropionyl, 3-methoxycarbonylpropionyl, biotinylaminohexanoyl, phenylacetyl, benzoyi, dimethylaminosulfonyl, benzylsulfonyl, 1-piperizinylcarbonyl, 4-methyl-1-piperazinylcarbonyl or 4-morpholinylcarbonyl; R8 is butyl, 2-phenylethyl, 2-methylsulfonylethyl, 2-fert-butoxycarbonylethyl, 2-ferf-butoxycarbonylmethyl, 4-fert-butoxycarbonylaminobutyl, 4-benzoylaminobutyl or benzyloxymethyl; and R7 is 3-pyridylmethyl, 2-thienylmethyl, 2-furylmethyl, 4-imidazolylmethyl, 3-indolylmethyl, (C^alkyl (optionally substituted with a radical selected from mercapto, carboxy, amino, methylthio, methylsulfonyl, carbamoyi, dimethylcarbamoyi, guanidino and hydroxy, or a protected derivative thereof), a group selected from benzyl, 1-naphthylmethyl, 2-naphthylmethyl and 2-phenylethyl (which group is optionally substituted at its aryl ring with one radical selected from hydroxy, amino, chloro, bromo and fluoro, or a protected form thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from (C^)methylene and 1 ,2-pheny lenedimethy lene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo)29 The compound of Claim 28 in which each n is 0, each R3, R5 and R6 are hydrogen, each R1 is hydrogen, fert-butxoycarbonyl, benzyloxycarbonyl, biotinylaminohexanoyl, benzoyi, 1-pιpeπzιnylcarbonyl, 4-methyl-1-pιperazιnylcarbonyl or 4-morpholιnylcarbonyl, R8 is butyl, 2-phenylethyl or 2-methylsulfonylethyl, and R7 is (C, 5)alkyl, 2-methylsulfonylethyl, optionally substituted benzyl, 1-naphthylmethyl, 2-naphthylmethyl, 3-pyπdιnylmethyl or 2-methylsulfonylethyl30 The compound of Claim 29 in which each R1 is 1-pιpeπzιnylcarbonyl, 4-methyl- 1-pιperazιnylcarbonyl or 4-morpholιnylcarbonyl, R8 is 2-phenylethyl, and R7 is optionally substituted benzyl, 1-naphthylmethyl or 2-naphthylmethyl31 The compound of Claim 30 in which R1 is 4-morpholιnylcarbonyl, R8 is 2-phenylethyl, R7 is benzyl, R15 is hydrogen and R 6 is 4-methoxyphenyl, namely L-phenylalaninamide32 The compound of Claim 30 in which R1 is 4-morpholιnylcarbonyl, R8 is 2-phenylethyl, R7 is benzyl, R15 is hydrogen and R16 is 4-amιnophenyl, namely /2-(4-morpholιnylcarbonyl)-V {3-phenyl-1S-[2-(4-amιnophenyl)ethyl]propyl}- L-phenylalanmamide33 A method for inhibiting a cysteine protease comprising reversibly binding a cysteine protease inhibitor to a cysteine protease, wherein said mhibitior comprises the cysteine protease inhibitor of Claim 134 A method for inhibiting a cysteine protease comprising reversibly binding a cysteine protease inhibitor to a cysteine protease, wherein said mhibitior comprises the cysteine protease inhibitor of Claim 235 A method for inhibiting a cysteine protease comprising reversibly binding a cysteine protease inhibitor to a cysteine protease, wherein said mhibitior comprises the cysteine protease inhibitor of Claim 336 A method for inhibiting a cysteine protease comprising reversibly binding a cysteine protease inhibitor to a cysteine protease, wherein said mhibitior comprises the cysteine protease inhibitor of Claim 14.37. A method for inhibiting a cysteine protease comprising reversibly binding a cysteine protease inhibitor to a cysteine protease, wherein said inhibitior comprises the cysteine protease inhibitor of Claim 24.38. A method for treating a condition capable of amelioration by inhibition of a cysteine protease in an animal in need thereof, which method comprises administering to such animal a therapeutically effective amount of the cysteine protease inhibitor of Claim 1.39. A method for treating a condition capable of amelioration by inhibition of a cysteine protease in an animal in need thereof, which method comprises administering to such animal a therapeutically effective amount of the cysteine protease inhibitor of Claim 2.40. A method for treating a condition capable of amelioration by inhibition of a cysteine protease in an animal in need thereof, which method comprises administering to such animal a therapeutically effective amount of the cysteine protease inhibitor of Claim 3.41. A method for treating a condition capable of amelioration by inhibition of a cysteine protease in an animal in need thereof, which method comprises administering to such animal a therapeutically effective amount of the cysteine protease inhibitor of Claim 14.42. A method for treating a condition capable of amelioration by inhibition of a cysteine protease in an animal in need thereof, which method comprises administering to such animal a therapeutically effective amount of the cysteine protease inhibitor of Claim 24.43. A pharmaceutical composition comprising a therapeutically effective amount of the cysteine protease inhibitor of Claim 1 , or of an individual isomer, a mixture of isomers, or the pharmaceutically acceptable salt or salts thereof, in combination with one or more pharmaceutically acceptable excipients.44. A pharmaceutical composition comprising a therapeutically effective amount of the cysteine protease inhibitor of Claim 2, or of an individual isomer, a mixture of isomers, or the pharmaceutically acceptable salt or salts thereof, in combination with one or more pharmaceutically acceptable excipients.45. A pharmaceutical composition comprising a therapeutically effective amount of the cysteine protease inhibitor of Claim 3, or of an individual isomer, a mixture of isomers, or the pharmaceutically acceptable salt or salts thereof, in combination with one or more pharmaceutically acceptable excipients46 A pharmaceutical composition comprising a therapeutically effective amount of the cysteine protease inhibitor of Claim 14, or of an individual isomer, a mixture of isomers, or the pharmaceutically acceptable salt or salts thereof, in combination with one or more pharmaceutically acceptable excipients47 A pharmaceutical composition comprising a therapeutically effective amount of the cysteine protease inhibitor of Claim 24, or of an individual isomer, a mixture of isomers, or the pharmaceutically acceptable salt or salts thereof, in combination with one or more pharmaceutically acceptable excipients48 A process for the preparation of a compound of Formula IVin whichA-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below,Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below,Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below,Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below,R6 is hydrogen or methyl and R7 is as defined below,R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycioalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylammosulfonyl, arylsulfonyl or heteroarylsulfonyl; R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, amino, alkylamino, dialkylamino, uriedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, guanidino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C-^Jmethylene and 1 ,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); andR20 is cyano, -S(0)2R2, -CH2S(0)2R2, -CH2CH(R4)S(0)2R2, -(CH2)2C(0)OR10, -(CH2)2P(O)(OR10)2, -(CH2)2S(O)(NR10)R10, -(CH2)2C(0)R11, -(CH2)2S(0)R11, -(CH2)2C(0)NR12R13, -(CH2)2S(0)2NR 2R13, -(CH2)2C(0)NHR14, -(CH2)2S(0)2NHR14 or -CH2CHR15R16, wherein R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R4 is hydrogen, alkyl or arylalkyl, each R10 is independently hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R 1 is hydrogen, alkyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, perfluoroaryl, perfluoroarylakyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R12 and R 3 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyi, R14 is -C(0)OR1°, in which R10 is as defined above, or a group selected from Formula (a) and (b):(»)wherein each n, A, B, Y, Z, R1 and R10 are as defined above, R15 is hydrogen, methyl, fluoro or a group selected from Formulae (a) and (b) as defined above, and R16 is a group selected from phenyl or (C^heteroaryl (which group is optionally substituted with at least one radical selected from aikylcarbamoyl, dialkylcarbamoyi, alkyloxycarbonyl, alkylsulfinamoyl, dialkylsulfinamoyl, alkylsulfonyl, carboxy, nitro, sulfinamoyl, sulfo, carbamoyi, phosphono, alkyloxyphosphinyl, dialkyloxyphosphinyl, alkanoyl, cyano, alkylsulfinyl, sulfamoyl, alkyisulfamoyl, dialkylsulfamoyi, alkyloxysulfonyl, alkylsulfonimidoyl, aryl, heteroaryl, hydroxy, alkyloxy, optionally halo-substituted alkyl, arylalkyl, halo, -*N(R17)3, wherein each R17 is independently alkyl, aryl or arylalkyl, or -N(R18)2, wherein each R1β is independently hydrogen, alkyl, aryl or arylalkyl); and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof; which process comprises: (A) reacting an amine of Formula V:H,N ' - R "with a compound of Formula VI:VIin which each n, A, B, X, Y, Z, R1, R8 and R20 are as defined above; and(B) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt;(C) optionally further converting a salt form of a compund of Formula IV into non-salt form; and(D) optionally further separating a compound of Formula IV into individual stereoisomers.49. A process for the preparation of a compound of Formula IV:in which: n is O to 12;A-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below;Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below;Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below;Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below;R6 is hydrogen or methyl and R7 is as defined below;R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl;R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, amino, alkylamino, dialkylamino, uriedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, amino, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C-^methylene and 1,2-phenylenedimethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo); and R20 is -S(0)2R2, wherein R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from amino, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof; which process comprises: reacting a compound of Formula VII:VIIwith an aldehyde of the formula R8CHO and a sodium sulfinate of the formula R S(0)ONa, in which each n, A, B, X, Y, Z, R and RB are as defined above;(B) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt; (C) optionally further converting a salt form of a compund of Formula IV into non-salt form, and(D) optionally further separating a compound of Formula IV into individual stereoisomers50 A process for the preparation of a compound of Formula IVin whichA-B represents a linkage selected from -C(0)NR3-, -CH2NR3- -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below,Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below,Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below,Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below,R6 is hydrogen or methyl and R7 is as defined below,R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylammosulfonyl, arylsulfonyl or heteroarylsulfonyl,R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylamino, dialkylammo, uπedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl(which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected deπvative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (Cj methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), andR20 is -S(0)2R2, wherein R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from ammo, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from amino, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof); and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof; which process comprises:(A) (1 ) reacting a compound of the formula NH2P, wherein P is a protective group, with an aldehyde of the formula RβCHO and a sodium sulfinate of the formula R2S(0)ONa and then deprotecting to give a compound of Formula VIII:R"H,N S(0) ,R-in which R2 and R8 are as defined above; and(2) reacting the compound of Formula VIM with a compound of Formula VI:VIin which each n, A, B, X, Y, Z, and R1 are as defined above;(B) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt;(C) optionally further converting a salt form of a compund of Formula IV into non-salt form; and(D) optionally further separating a compound of Formula IV into individual stereoisomers.51. A process for the preparation of a compound of Formula IV:in which: n is 0 to 12;A-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below;Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below;Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below; Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below,R6 is hydrogen or methyl and R7 is as defined below,R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylammosulfonyl, arylsulfonyl or heteroarylsulfonyl,R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylamino, dialkylamino, uπedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl(which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C3-4)methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), andR20 is -CH2S(0)2R2, wherein R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from ammo, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, which process comprises(A) (1) reacting a compound of Formula IXwith a thiolate anion of the formula R2S , in which L is a leaving group and R2 and R8 are as defined above, to give a compound of Formula X,SR'PHN (2) oxidizing the compound of Formula X to give a compound of Formula XI:and(3) reacting the compound of Formula XI with a compound of Formula VI:VIin which each n, A, B. X. Y, Z and R are as defined above;(B) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt;(C) optionally further converting a salt form of a compund of Formula IV into non-salt form; and(D) optionally further separating a compound of Formula IV into individual stereoisomers.52. A process for the preparation of a compound of Formula IV:in which: n is O to 12;A-B represents a linkage selected from -C(0)NR3-, -CH2NR3-, -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below;Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below;Z is -(CH2)2-, -C(Rβ)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below;Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below;R6 is hydrogen or methyl and R7 is as defined below;R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl), arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl,R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylammo, dialkylamino, unedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C^methylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy or a protected derivative thereof, or oxo), and R20 is cyano, -(CH2)2S(0)2R2, -(CH2)2C(0)OR1°, -(CH2)2P(O)(OR10)2, -(CH2)2S(O)(NR10)R10, -(CH2)2C(0)R11, -(CH2)2S(0)R11, -(CH2)2C(0)NR12R13, -(CH2)2S(0)2NR1 R13, -(CH2)2C(0)NHR1 or -(CH2)2S(0)2NHR14 , wherein R2 is hydrogen, alkyl (optionally substituted with one or more radicals selected from ammo, halo hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from am o, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), each R10 is independently hydrogen, alkyl (optionally substituted with one or more radicals selected from ammo, halo, hydroxy, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R11 is hydrogen, alkyl, perfluoroalkyl, cycloalkyl, cycloalkylalkyl, perfluoroaryl, perfluoroarylakyl or a group selected from aryl and arylalkyl (which group is optionally substituted at its aryl ring with one to two radicals selected from ammo, halo, hydroxy, optionally halo-substituted alkyl, alkyloxy, nitro, alkylsulfonyl and arylsulfonyl, or a protected derivative thereof), R12 and R13 are independently hydrogen, alkyl, cycloalkyl, cycloalkylalkyl, aryl or aralkyi and R14 is -C(0)OR °, in which R10 is as defined above, or a group selected from Formula (a) and (b)(a)wherein each n, A, B, Y, Z, R and R10 are as defined above, and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, which process comprises (A) (1) reacting an aldehyde of Formula XII:with a compound selected from Formulae XIII and XIV:XIII XIVin which each R8 and R20 are as defined above, and then deprotecting to give a compound of Formula XV:xv(2) reacting the compound of Formula XV with a compound of Formula VI:VIin which each n, A, B, X, Y, Z and R1 are as defined above, and (3) reducing;(B) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt;(C) optionally further converting a salt form of a compund of Formula IV into non-salt form; and(D) optionally further separating a compound of Formula IV into individual stereoisomers.53. A process for the preparation of a compound of Formula IV:in which: A-B represents a linkage selected from -C(0)NR3-, -CH2NR3- -C(0)CH2- and -NR3C(0)-, wherein R3 is hydrogen or as defined below,Y is -CH(R5)- or -N(R5)-, wherein R5 is hydrogen or as defined below,Z is -(CH2)2-, -C(R6)(R7)- or -N(R7)-, wherein R6 is hydrogen or methyl and R7 is as defined below,Z1 is -(CH2)2-, -C(R6)(R8)- or -N(R8)-, wherein R6 is hydrogen or methyl and R8 is as defined below,R6 is hydrogen or methyl and R7 is as defined below,R1 is hydrogen, alkyloxycarbonylalkanoyl, alkyloxycarbonyl, alkanoyl (optionally substituted with a radical selected from carboxy, alkyloxycarbonyl and heterocycloalkylalkanoylamino), cycloalkylcarbonyl, heterocycloalkylcarbonyl (optionally substituted with a radical selected from hydroxy, alkyl, alkanoyl, alkyloxycarbonyl, arylalkyloxycarbonyl and heterocycloalkylcarbonyl) arylalkyloxycarbonyl, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, arylcarbamoyi, arylaikylcarbamoyl, arylalkanoyl, aroyl, alkylsulfonyl, dialkylaminosulfonyl, arylsulfonyl or heteroarylsulfonyl,R7 and R8 are independently hydrogen, alkyl (optionally substituted with a radical selected from hydroxy, ammo, alkylamino, dialkylamino, uπedo, mercapto, alkylthio, carboxy, carbamoyi, aikylcarbamoyl, dialkylcarbamoyi, alkylsulfonyl and guanidino, or a protected derivative thereof), cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, a group selected from aryl and arylalkyl(which group is optionally substituted at its aryl ring with one to three radicals selected from hydroxy, ammo, halo, optionally halo-substituted alkyl, alkyloxy and aryl, or a protected derivative thereof) or together with an adjacent R3 or R5 forms a divalent radical selected from a divalent radical selected from (C^Jmethylene and 1 ,2-phenylenedιmethylene (which radical is optionally substituted with hydroxy, or a protected derivative thereof, or oxo), andR20 is -CH2CHR15R16, wherein R15 is hydrogen, methyl, fluoro or a group selected fromFormulae (a)and (b)(a)wherein each n, A, B, Y, Z, R1 and R10 are as defined above, and R16 is a group selected from phenyl or (Cs^heteroaryl (which group is optionally substituted with at least one radical selected from aikylcarbamoyl, dialkylcarbamoyi. alkyloxycarbonyl, alkylsulfinamoyl, dialkylsulfinamoyl, alkylsulfonyl, carboxy, nitro, sulfinamoyl, sulfo, carbamoyi, phosphono, alkyloxyphosphinyl, dialkyloxyphosphinyl, alkanoyl, cyano, alkylsulfinyl, sulfamoyl, alkyisulfamoyl, dialkylsulfamoyi, alkyloxysulfonyl, alkylsulfonimidoyl, aryl, heteroaryl, hydroxy, alkyloxy, optionally halo-substituted alkyl, arylalkyl, halo, -*N(R17)3, wherein each R17 is independently alkyl, aryl or arylalkyl, or -N(R18)2, wherein each R18 is independently hydrogen, alkyl, aryl or arylalkyl), and the pharmaceutically acceptable salts, individual isomers and mixtures of isomers thereof, which process comprises (A) (1 ) reacting an aldehyde of Formula XIIR *PHN CHO with compound of Formula XVIXVIin which each R8, R15 and R16 are as defined above, and then deprotecting to give a compound of Formula XVIIXVII(2) reacting the compound of Formula XVII with a compound of Formula VIVIin which each n, A, B, X, Y, Z and R1 are as defined above, and (3) reducing,(B) optionally further converting a non-salt form of a compound of Formula IV into a pharmaceutically acceptable salt,(C) optionally further converting a salt form of a compund of Formula IV into non-salt form, and(D) optionally further separating a compound of Formula IV into individual stereoisomers
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US40999695A | 1995-03-24 | 1995-03-24 | |
US08/409996 | 1995-03-24 | ||
PCT/US1996/003844 WO1996030353A1 (en) | 1995-03-24 | 1996-03-21 | Reversible protease inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
AU5367496A true AU5367496A (en) | 1996-10-16 |
AU713492B2 AU713492B2 (en) | 1999-12-02 |
Family
ID=23622800
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU53674/96A Ceased AU713492B2 (en) | 1995-03-24 | 1996-03-21 | Reversible protease inhibitors |
Country Status (15)
Country | Link |
---|---|
EP (1) | EP0817778A1 (en) |
JP (1) | JPH11503417A (en) |
KR (1) | KR19980703261A (en) |
CN (1) | CN1071751C (en) |
AU (1) | AU713492B2 (en) |
CA (1) | CA2216151A1 (en) |
CZ (1) | CZ298197A3 (en) |
IL (1) | IL117638A0 (en) |
MY (1) | MY113489A (en) |
NO (1) | NO311573B1 (en) |
NZ (1) | NZ305626A (en) |
PL (1) | PL322409A1 (en) |
TW (1) | TW470750B (en) |
WO (1) | WO1996030353A1 (en) |
ZA (1) | ZA962336B (en) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT912601E (en) | 1996-04-22 | 2004-04-30 | Massachusetts Inst Technology | DELETING THE IMUNE RESPONSE FROM CATEPSIN S INHIBITION |
NZ333713A (en) * | 1996-07-30 | 2000-12-22 | Axys Pharm Inc | Compounds for treating diseases associated with tryptase activity |
DE19817461A1 (en) | 1998-04-20 | 1999-10-21 | Basf Ag | New benzamide derivatives useful as cysteine protease inhibitors for treating neurodegenerative diseases, neuronal damage, stroke, cranial trauma, Alzheimer's disease, etc. |
EP1159273A1 (en) | 1999-03-02 | 2001-12-05 | Boehringer Ingelheim Pharmaceuticals Inc. | Compounds useful as reversible inhibitors of cathepsin s |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
ATE244235T1 (en) * | 1999-09-13 | 2003-07-15 | Boehringer Ingelheim Pharma | HETEROCYCLIC COMPOUNDS AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES |
JP2003514524A (en) | 1999-11-18 | 2003-04-22 | コルバス・インターナショナル・インコーポレイテッド | Nucleic acid encoding an endoceliase, endotheliase and uses thereof |
US7700341B2 (en) | 2000-02-03 | 2010-04-20 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
EP1309591B1 (en) | 2000-08-14 | 2007-01-24 | Ortho-McNeil Pharmaceutical, Inc. | Substituted pyrazoles |
MXPA03001420A (en) | 2000-08-14 | 2004-01-26 | Johnson & Johnson | Substituted pyrazoles. |
CZ307185B6 (en) | 2000-08-14 | 2018-03-07 | Ortho Mcneil Pharmaceutical, Inc. | Substituted pyrazole, a pharmaceutical composition containing it and their medical applications |
US7332494B2 (en) | 2000-08-14 | 2008-02-19 | Janssen Pharmaceutica, N.V. | Method for treating allergies using substituted pyrazoles |
CN1642973A (en) | 2000-09-06 | 2005-07-20 | 奥索-麦克尼尔药品公司 | A method for treating allergies |
US20020107266A1 (en) * | 2000-12-12 | 2002-08-08 | Marguerita Lim-Wilby | Compounds, compositions and methods for treatment of parasitic infections |
US7030116B2 (en) | 2000-12-22 | 2006-04-18 | Aventis Pharmaceuticals Inc. | Compounds and compositions as cathepsin inhibitors |
CA2433520A1 (en) | 2000-12-22 | 2002-07-04 | Axys Pharmaceuticals, Inc. | Novel compounds and compositions as cathepsin inhibitors |
US6900237B2 (en) | 2001-09-14 | 2005-05-31 | Axys Pharmaceuticals, Inc. | Sulfonamide compounds as protease inhibitors |
BR0212535A (en) * | 2001-09-14 | 2004-10-19 | Aventis Pharma Inc | Compounds and compositions as cathepsin inhibitors |
RU2004117877A (en) | 2001-11-14 | 2006-01-10 | Авентис Фармасьютикалз Инк. (Us) | OLIGOPEPTIDES AND COMPOSITIONS CONTAINING THEM, AS CATATEPSIN S INHIBITORS |
GB0311406D0 (en) * | 2003-05-17 | 2003-06-25 | Queen Mary & Westfield College | Substituted phosphonate fluorescent sensors,and use thereof |
DK2288615T3 (en) * | 2008-05-21 | 2017-09-04 | Genesis Tech Ltd | SELECTIVE CASPASE INHIBITORS AND APPLICATIONS THEREOF |
WO2010133000A1 (en) | 2009-05-21 | 2010-11-25 | New World Laboratories Inc. | Selective caspase inhibitors and uses thereof |
US8895497B2 (en) | 2009-12-04 | 2014-11-25 | Dcb-Usa, Llc | Cathepsin S inhibitors |
ES2665301T3 (en) | 2011-04-15 | 2018-04-25 | Genesis Technologies Limited | Selective cysteine prorease inhibitors and their uses |
KR101309578B1 (en) * | 2011-05-06 | 2013-09-17 | 연세대학교 산학협력단 | Dityrosine compounds having selectivity for cysteine proteases and method for monitoring cysteine proteases using the same |
KR101385855B1 (en) * | 2012-10-16 | 2014-04-22 | 이동익 | Diaromatic amino acid-based substrate for detecting cathepsins |
WO2019142890A1 (en) * | 2018-01-19 | 2019-07-25 | 株式会社大阪ソーダ | Organosilicon compound and rubber composition including same |
EP3553521A1 (en) * | 2018-04-12 | 2019-10-16 | Koninklijke Philips N.V. | Gingivitis diagnostic methods, uses and kits |
-
1996
- 1996-03-21 CA CA002216151A patent/CA2216151A1/en not_active Abandoned
- 1996-03-21 WO PCT/US1996/003844 patent/WO1996030353A1/en not_active Application Discontinuation
- 1996-03-21 AU AU53674/96A patent/AU713492B2/en not_active Ceased
- 1996-03-21 NZ NZ305626A patent/NZ305626A/en unknown
- 1996-03-21 JP JP8529509A patent/JPH11503417A/en active Pending
- 1996-03-21 PL PL96322409A patent/PL322409A1/en unknown
- 1996-03-21 KR KR1019970706665A patent/KR19980703261A/en not_active Application Discontinuation
- 1996-03-21 CN CN96193951A patent/CN1071751C/en not_active Expired - Fee Related
- 1996-03-21 EP EP96910499A patent/EP0817778A1/en not_active Withdrawn
- 1996-03-21 CZ CZ972981A patent/CZ298197A3/en unknown
- 1996-03-22 MY MYPI96001076A patent/MY113489A/en unknown
- 1996-03-22 ZA ZA962336A patent/ZA962336B/en unknown
- 1996-03-24 IL IL11763896A patent/IL117638A0/en unknown
- 1996-04-12 TW TW085104392A patent/TW470750B/en active
-
1997
- 1997-09-23 NO NO19974403A patent/NO311573B1/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
NO974403D0 (en) | 1997-09-23 |
WO1996030353A1 (en) | 1996-10-03 |
KR19980703261A (en) | 1998-10-15 |
CA2216151A1 (en) | 1996-10-03 |
NO311573B1 (en) | 2001-12-10 |
PL322409A1 (en) | 1998-01-19 |
IL117638A0 (en) | 1996-07-23 |
EP0817778A1 (en) | 1998-01-14 |
NO974403L (en) | 1997-11-17 |
TW470750B (en) | 2002-01-01 |
JPH11503417A (en) | 1999-03-26 |
CZ298197A3 (en) | 1998-03-18 |
ZA962336B (en) | 1996-07-31 |
AU713492B2 (en) | 1999-12-02 |
NZ305626A (en) | 2000-01-28 |
MY113489A (en) | 2002-03-30 |
CN1071751C (en) | 2001-09-26 |
CN1184472A (en) | 1998-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5776718A (en) | Reversible protease inhibitors | |
AU713492B2 (en) | Reversible protease inhibitors | |
US5976858A (en) | Irreversible cysteine protease inhibitors containing vinyl groups conjugated to electron withdrawing groups | |
AU652793B2 (en) | Peptidyl derivatives | |
US4738803A (en) | Amino acid derivatives and their use as antidepressives and hypotensive agents | |
CZ280292A3 (en) | Novel derivatives of 5-amino-4-hydroxyhexanoic acid which derivatives act as therapeutic agents | |
KR19990036271A (en) | C-proteinase inhibitors used to treat diseases associated with collagen overproduction | |
WO1996040737A1 (en) | Reversible cysteine protease inhibitors | |
EP1685142B1 (en) | Phosphinic acid derivatives, beta-secretase inhibitors for the treatment of alzheimer's disease | |
JPH0381256A (en) | Renin blocking agent | |
HUT61032A (en) | Process for producing phosphono-/biaryl-substituted dipeptide derivatives and pharmaceutical compositions comprising same as active ingredient | |
NZ280256A (en) | 5-amino-4-hydroxyacylaminoacetic 2-ethoxy- and (3-propoxy)amide derivatives; pharmaceutical compositions | |
US6344457B1 (en) | Amino acid derivatives inhibiting extracellular matrix metalloproteinase and TNF alpha release | |
CA1322073C (en) | Thiol-carboxylic acid derivatives | |
JPH08301833A (en) | Selective thrombin inhibitor | |
SE452318B (en) | AMINO ACIDS FOR USE AS INTERMEDIATES IN THE PRODUCTION OF BESTATIN | |
RU2181123C2 (en) | Pharmaceutical composition with fungicide activity and derivatives of dipeptide of alpha-amino acid or its derivative and cyclopentane-beta-amino acid or its derivative | |
US6362166B1 (en) | Antipicornaviral compounds and methods for their use and preparation | |
HU201005B (en) | Process for producing new n-substituted mercaptopropaneamide derivatives and pharmaceutical compositions comprising such compounds | |
CZ54194A3 (en) | Derivatives of acylhexanoic acid, process of their preparation, pharmaceutical preparations in which they are comprised and their pharmaceutical use | |
IE921609A1 (en) | Peptidyl derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) | ||
MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |